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ABSTRACT
The Karyopherin a (KPNA) genes encode a family of soluble proteins that 
mediate the transport of macromolecules into the nucleus, a central function of 
eukaryotic cell survival. Due to this important function, dysregulation of these 
proteins has been implicated in a number of human diseases, including schizophrenia 
and cancer, as well as human cytomegalovirus, influenza A and HIV nucleoprotein 
infection. To date, little information is available on the regulation of these proteins, 
especially at the transcriptional level. The proximal promoter region of human 
KPNA3 gene was identified by evolutionary conservation, and putative nuclear 
receptor binding sites identified by in silico analysis. These included one putative 
binding site for the peroxisome proliferator activated receptor (PPAR), plus four 
putative binding sites for the vitamin D receptor (VDR). Subsequent cloning of the 
KPNA3 proximal promoter, plus reporter gene assay, demonstrated a dose-dependent 
inhibition of KPNA3 expression by several PPAR agonists (fibrates and Wy-14643), 
while site directed mutagenesis and electromobility shift assay demonstrated the 
functionality of the identified putative binding site. In contrast, the classical VDR 
agonist la, 25(OH)2D3 elicited both negative and positive regulatory functions on 
human KPNA3 expression in the human hepatoma cell line Huh-7, in a dose- 
dependent manner. Subsequent mutagenesis experiments demonstrated the input of 
each of the four putative VDR binding sites in this response. Finally, the impact of 
over-expression of KPNA3 on VDR sub-cellular localization was studied. KPNA3 
was demonstrated to mediate ligand-independent nuclear accumulation of VDR in 
Huh-7 cells. Taken together, this work is the first direct demonstration of a role for 
PPARa and VDR in regulation of any nuclear import gene, suggesting that 
functionality of these transcription factors may be regulated through a regulatory loop 
involving the mediators of nuclear import, the karyopherin proteins.
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1 INTRODUCTION
One of the defining features of eukaryotic cells is the compartmentalization 
between nucleus and cytoplasm by the nuclear envelope, a double membrane that is 
continuous with the rough endoplasmic reticulum (Fried and Kutay 2003). 
Consequently, there is segregation of DNA replication and RNA transcription, which 
take place in the nucleus, from protein synthesis, occurring in the cytoplasm. This is 
likely to underpin the advantages possessed by eukaryotic cells, which are able to 
handle large amounts of DNA, control gene expression patterns according to 
biological responses of the cells, and produce post-transcriptionally modified RNA 
transcripts (Gorlich and Kutay 1999). Moreover this compartmentalisation allows the 
regulation of several key cellular events in the cell such as signal transduction, and 
cell cycle progression (Macara 2001; Weis 2002; Riddick and Macara 2005). 
However, eukaryotic cells have to accommodate a continuous flow of molecules 
through the nuclear membrane; that is, nuclear proteins have to localize to their site of 
action in the nucleus, whereas RNA transcripts have to be exported to the cytoplasm 
for protein production. Therefore, the highly regulated nucleocytoplasmic transport 
system of macromolecules between the two cellular compartments is a specific 
requirement in eukaryotic cells.
1.1 Nucleocytoplasmic transport in eukaryotic cells
Nucleocytoplasmic transport is a unique cellular transport mechanism that can 
be understood in the terms of facilitated diffusion and signal-mediated transport 
whereby soluble transport receptors recognize and carry specific cargo molecules 
between the cytoplasm and nucleus via nuclear pore complexes (NPC), indirectly 
using metabolic energy to determine directionality and selectivity (Gorlich et al. 1999; 
Macara 2001; Stewart et al. 2001).
1.1.1 The nuclear pore complex (NPC)
Nuclear pore complexes are aqueous channels which comprise of a large 
multi-protein assembly that penetrates the nuclear envelope and connects the 
cytoplasm to the nucleus (Suntharalingam and Wente 2003). While the number of 
NPCs per cell depends on the demands of nuclear transport, cell size, and growth 
activity (Alber et al. 2007), mammalian cells typically contain -3000-5000 NPCs 
(Maul 1977).
High resolution electron microscopic studies have revealed that the nuclear 
pore complex structure is generally conserved throughout eukaryotic evolution (Yang 
et al. 1998; Allen et al. 2008). NPCs have 8 fold rotational symmetry perpendicular 
to the membrane and are asymmetric with regards cytoplasmic and nuclear surfaces. 
The complex can be classified into three substructures: cytoplasmic fibres, a central 8- 
spoke cylindrical core, and a nuclear basket (Figure 1-1). The spoke structures 
collectively encircle the central ring and serve as the channel through which all active 
transport occurs.
Central Region
Cytoplasm ic Filament
Cytoplasm ic Particle \
O u ter N uclear M em brane
C ytoplasm ic Ring
Lumenal Ring
Spoke
Nuclear Ring
inner N uclear M em brane
inner Spoke Ring
Nuclear Basket
Terminal Ring
Figurel-1. Schematic representation of the nuclear pore complex. Adapted from 
the model in Suntharalingam et ai, 2003.
Typically, each NPC has a mass of approximately 125 MDa in vertebrates 
(Reichelt et al. 1990) and 65 MDa in yeast (Rout and Blobel 1993), and is composed 
of 50-100 different proteins, collectively ealled nueleoporins (Nups) (Gorlieh et al. 
1999). Colleetively the Nups earry out two important roles; they provide the 
struetural framework of the NPC and serve as transient docking sites for the 
translocation of nuclear transport reeeptors across the NPC. The majority of the Nups 
eontain at least one domain with phenylalanine-glycine (FG) repeated sequenees; the 
three most common motifs are in the form of glycine-leucine-phenylalanine-glycine 
(GLPG), FG, or phenylalanine-x-phenylalanine-glycine (PxPG) peptide motifs (where 
X is usually serine, glycine or alanine) and their number ranges from 4-45 per domain. 
(Fahrenkrog et al. 2000). Nups with FG-repeats are predicted to function as
3
hydrophobic regions that bind to the eargo-reeeptor complex for aetive transloeation 
through the nuelear pore ehannel (Fried et al. 2003). The NPC, therefore functions as 
a facilitated diffusion ehannel that allows the selective passage of eargo-reeeptor 
eomplexes (Conti and Izaurralde 2001 ; Kuersten et al. 2001 ; Macara 2001).
1.1.2 Nuclear transport receptors
The transport of proteins in and out of the nueleus is a major cellular proeess 
in eukaryotes (Gorlich and Kutay, 1999: Macara 2001). Transport not only localizes 
proteins destined for the nucleus or cytoplasm, but also functions as a key step in 
signal transduction pathways and in the regulation of gene expression (Riddick and 
Macara 2005). As mentioned above, the pathways involved in the transloeation of 
moleeules in and out of the nueleus include both passive diffusion and facilitated 
transport.
Passive diffusion through the ehannel of the NPC is effective for small 
moleeules (<40-60 kDa), including ions and metabolites, which can migrate down 
their concentration gradient. This pathway beeomes very ineffieient as the size of the 
maeromolecule approaches the limit; maeromolecules larger than 40-60 kDa are 
normally transported in an active and carrier-mediated fashion whieh allow transport 
to oceur in a eontrolled manner (Gorlieh and Kutay 1999; Bayliss et al. 2000; 
Fahrenkrog and Aebi 2003).
Faeilitated transport can be elassified by the three types of nuclear transport 
reeeptors whieh have been deseribed to date. First, the best studied type of transport 
receptors are the importin p-like family of proteins (the importins and exportins, also 
known as “karyopherins”) (Xu and Massague 2004), with members of this family 
responsible for the export and import of the majority of nuclear-shuttling proteins.
non-coding cellular RNA transeripts (for example rRNA, snRNA, tRNA, miero RNA) 
as well as eertain types of viral mRNA transcripts (mRNA transcripts of complex 
retrovirus such as HIV-1) (Rosenblum et al. 1997; Seedorf and Silver 1997; Popov et 
al. 1998; Leslie et al. 2004). Second, the small homodimeric nuelear transport factor 
2 (NTF2) imports Ran GDPase into nucleus, where RanGTP is regenerated. Third, 
the TAP/nuclear export factor 1 (NEFl) which participates in the nuclear export of 
eellular mRNA transeripts and certain types of viral mRNA transcripts (mRNA 
transcripts of type-D simple retroviruses) (Weis 2002; Fried et al. 2003). These three 
reeeptor types share a eommon ability to interact directly with the FG repeats within 
the NPC, and to shuttle between the nueleus and the eytoplasm. Although they share 
a common NPC-translocation mechanism, different nuclear receptors are 
charaeterized by different cargo-uptake and transport directionality mechanisms 
(Gorlich et al. 1999; Fried et al. 2003).
Proteins to be imported into the nueleus have specific sequences called nuclear 
loealization signals (NLS’s) whereas proteins to be exported from the nueleus have 
nuclear export signals (NES’s). The first nuelear loealization signal was identified in 
the simian virus 40 (SV40) large T antigen and in the Xenopus nucleoplasmin as a 
monopartite or bipartite, respectively (Kalderon et al. 1984; Dingwall et al. 1988). A 
classieal monopartite NLS consists of a cluster of three to five positively charged 
residues that is often preceded by a proline and followed by a hydrophobic aliphatic 
and acidic residue. Nucleoplasmin, the prototype of a bipartite NLS, has an additional 
smaller cluster of lysine/arginine residues, separated from the monopartite by a linker 
of 10-12 residues as shown in Table 1-1. In both eases, acid residues on the reeeptor 
interact electrostatically with basic residues of NLS on the eargo (Macara 2001). The 
most common NES is comprised of a spacing of four hydrophobic residues.
LxxxLxxLxL where L is often leueine hydrophobic residues and x is any other amino 
aeids (la Cour et al. 2004). Examples of elassical NES’ are shown in Table 1-2.
Table 1-1 Nuclear localisation/export signal
Proteins Signals
SV40 T antigen
Nueleoplasmin
C-myc
Epstein-Barr virus 
HIV virus 
Herpesvirus
Nuclear localization signal (NLS)* 
PKKKRKVE
KRPAATKKAGQAKKKKLD
PAAKRVKLD
KRPRSPSS
KKKYKL
RRPSRPFRKP
p53
HIV Rev
Nuclear export signal (NES)** 
LKKLNDSLELS 
LQLPPLERLTLD
* Basic residues of NLS are marked in bold letters. 
**Hydrophobic residues of NES are marked in bold letters.
1.2 Karyopherins; the importin p-like family of transport receptor
Most of the nuclear transport receptors described to date are members of the 
importin-P like family, also known as p-karyopherin family; in this report I will refer 
to this family as the p-karyopherins. The protein family includes 14 members in 
budding yeast and at least 20 in human (Strom and Weis 2001; Mosammaparast and 
Pemberton 2004; Quan et al. 2008). The members in this family can be divided into 2 
types, depending on whether they direet transport cargoes from or to the nueleus:
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those involved in nuclear import ealled importins whereas exportins are involved in 
nuelear export (Macara 2001). Examples of karyopherin proteins with their cargos 
are shown in Table 1-2.
Importins recognize NLS of a specific cargo and transport it into nucleus. For 
example, karyopherin p transports the transcription factor SREBP, sterol regulatory 
element-binding protein (Nagoshi et al. 1999) whereas Importin 4 is involved in 
nuclear transport of ribosomal protein S3a (Jakel et al. 2002), vitamin D reeeptor 
(Miyauchi et al. 2005), and transition protein 2 of spermatid (Pradeepa et al. 2008). 
Importin 9 and importin 11 are involved in transport of ribosomal proteins S7 (Jakel 
et al. 2002) and L12 (Plafker and Maeara 2000), respectively. Exportins recognize 
the nuclear export signals (NESs) of a specific cargo and transport to cytoplasm. For 
example Crmlp (ehromosomal region maintenance) mediates the export of cargoes 
containing a leucine rich NES, such as cyclin B (Hagting et al. 1998) and the tumour 
suppressor p53 (Freedman and Levine 1998). Cellular apoptosis susceptibility 
protein,CAS is involved in export of all members of the karyopherin a family (see 
section 1.2.1) to the cytoplasm (Kutay et al. 1997) and exportin-t speeifieally exports 
tRNA for use in translation in the cytoplasm (Kutay et al. 1998).
Table 1-2 Characteristics of the karyopherin p superfamily in human
Transport receptor Cargos
(alternative names)
Import receptors (p and a groups)
Karyopherin pi(KPNB) SREBP-2, PTHrP
(Importin p, p97, PTAC97)
KPNB/KPNAs eomplexes Proteins containing cNLS
such as SV40 T antigen, nucleoplasmin
KPNB/snurportinl eomplex snRNP
KPNB/XRIPa eomplex RPA
KPNB/importin 7 Histone HI
Karyopherin p2 hnRNP protein A l, ribosomal proteins
(Importin p2, Transportinl)
Karyopherin p3 Riosomal proteins
(Importin 5, RanBP5)
Export receptors
CRMlp Proteins containing leucine-rich NESs,
(Exportin 1) Snurportin 1
CAS KPNAs
Exportin t tRNA
Abbreviations: cNLS, classical nuclear localization signal; hnRNP, heterogeneous 
nuclear ribonuclear protein; HIV-1; human immunodeficiency virus type 1; NES, 
nuclear export signal; RPA, replieation protein A; PTHrP, parathyrioid hormone 
related protein; snRNP, small nuelear ribonuelear proteins; tRNA; transfer ribonucleie 
acid; SREBP-2, sterol regulatory element-binding protein.
In addition to the ability of nuelear transport proteins to show substrate 
specifieity, they also share a common feature in their ability to bind the FG-rieh 
motifs of the Nups (Kutay et al. 1997; Seedorf et al. 1999; Damelin and Silver 2000). 
The N-terminal and C-terminal portions of karyopherin p have been identified as 
interaction sites for the FG rich regions of Nups. Although the affinity of the C- 
terminal portion is weaker than that of N-terminal site, both of these sites appear to be 
important for karyopherin p funetion and promote its movement through NPC 
(Bayliss et al. 2000; Bednenko et al. 2003). Another common feature is their ability 
to form a eomplex with the GTP-bound state of the Ran GTPase (Gorlich et al. 1997). 
The purpose of these two interaetions is to regulate the binding of cargo to the 
karyopherin and to transport the cargo to its destination.
The most extensively studied member of karyopherin family is perhaps 
karyopherin pi (KPNB). It is the predominant karyopherin that drives import into the 
nucleus and it shows a more complex type of transport meehanism because KPNB 
can bind to its cargo either directly by recognizing the NLS or through an adaptor 
protein. There are several adapter proteins reeognised by KPNB, these include: 
snurportin, which specifically binds to 5'-trimethylguanosine cap structure of snRNPs 
(Huber et al. 1998); XRIPa which is required for the nuclear import of replication 
protein A (Jullien et al. 1999); importin 7 which facilitates histone HI import (Jakel et 
al. 1999); and members of the karyopherin a (KPNA) family whieh mediate nuclear 
import of most nuelear proteins containing nuclear localization signals (Macara 2001; 
Weis 2002). It may be that the use of such adaptor proteins enables the eell to better 
select and regulate cargo in response to particular biological conditions and thereby 
protect against to environmental stress. All adaptor proteins are shown in Table 1-2.
1.2.1 Karyopherin a (KPNA)
KPNA, a family of proteins of approximately 55 kDa, is the best known 
adaptor whieh binds to KPNB to facilitate nuclear transloeation of maeromolecules 
through NPCs, referred to as the classical nuclear import pathway. In addition to 
being an adaptor protein, KPNA alone ean transport ealeium/calmodulin-dependent 
protein kinase type IV (CaMKIV) into the nueleus without utilizing the classieal 
KPNB-dependent transport pathway (Kotera et al. 2005).
1.2.1.1 Structure of KPNA
The crystal structure of KPNA was resolved in 2000 and is shown in Figure 1- 
2. KPNA is essentially eomposed of three functional domains: a basic N-terminal 
importin p binding domain (IBB), whieh binds to KPNB, the eentral ARM domain 
that eonstitutes the cytosolie nuclear localizing signal binding pocket, and a C- 
terminal region, that seems to be important for binding to the export reeeptor CAS 
(Conti and Kuriyan 2000; Gilehrist et al. 2002). The N-terminal IBB domain serves a 
dual role; it not only binds to KPNB but also contains an auto-inhibitory sequence 
which interacts with the NLS binding domain when KPNA is not bound to KPNB. 
(Kobe 1999; Fanara et al. 2000). The NLS-binding domain is made up of 10 
armadillo (ARM) repeats which consist of three a -helices (HI, H2, H3) in a right- 
handed superhelical structure. The H3 helices form the inner eoneave surfaee of NLS 
binding site with conserved tryptophan and asparagines residues. The tryptophan 
residues form hydrophobic interactions with lysine side ehains within the NLS, while 
a series of eonserved asparagines residues aid stability through hydrogen bonding 
(Conti et al. 2006). The NLS binding domain possesses two binding pockets; a major 
one formed by ARM 2 and 4 which is occupied by monopartite NLSs, while a seeond
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pocket formed from ARM 7 to 8 can be occupied by the N-terminal portion of 
bipartite NLS. Thus a bipartite NLS would fit perfeetly between the distance of two 
binding sites (Dingwall and Laskey 1998). The NLS binding domain is very flexible 
such that various NLS containing proteins are able to bind either its N-terminal or C- 
terminal ARM repeat (Melen et al. 2003). Examples of NLS are also show in Table 
1-1. Although the presence of an NLS is a very important indicator for the likelihood 
that a protein is a eargo transported by KPNAs, it is important to note that KPNAs can 
also bind cargoes that contains no recognizable NLS, such as STAT 1 and RanBP3 
(Welch et al. 1999). These results suggest that KPNA family members recognize 
cargoes using both elassical and non-classical NLS’s.
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Figure 1-2 The ribbon structure of KPNA bound to nuelear localization signal of 
nucleoplasmin (red). The 10 different Armadillo (ARM) repeats of KPNA are shown 
in different colours. Two binding pockets are shown: the major binding site spans 
ARM repeats 1-4, whereas the minor site spans ARM repeats 6-8 (Stewart 2007)
1.2.1.2 Molecular mechanism of nuclear protein import
The elassical nuclear import pathway whieh has been described to date refers 
to the KPNB/KPNA pathway, shown in Figure 1-3. In this mechanism, the cargo 
binds to the adaptor, KPNA, rather than directly to carrier, KPNB. The formation of 
the KPNA-cNLS cargo complex in cytoplasm is followed by binding of KPNB, 
which then mediates binding of the ternary complex to FG repeats at the periphery of 
the NPC and transloeation through the NPC (Figure 1-3, step 1). Inside the nucleus
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the ternary complex is dissociated by the binding of the small nuclear GTPase Ran­
GTP which is 24 kDa protein and belongs to the Ras superfamily of small GTPase. 
The guanine nucleotide-binding domain (G domain) of Ran undergoes a 
conformational rearrangement upon switching between GTP- and GDP-bound state, 
and it is this that serves as an important directionality regulator of cargo loading into 
nucleus (Vetter and Wittinghofer 2001). The two regulators of the Ran nucleotide 
binding status are localized at opposite sides of the nuclear envelope. The nucleotide 
exchange factor RanGEF RCCl (regulator of chromosome condensation) generates 
RanGTP by replacing GDP with GTP in the nucleus. By contrast, the GTPase- 
activating protein RanBPl is located in the cytoplasm and depletes RanGTP from the 
cytoplasm by activation of RanGAPl (Bischoff et al. 2002). The combined action of 
these two proteins results in a gradient across the nuclear envelope, with a high 
RanGTP concentration in the nucleus and low concentration in the cytoplasm; 
conversely, there is a higher Ran-GDP concentration in the cytoplasm than in the 
nucleus.
The binding of Ran-GTP to KPNB in the nucleus is a key step in NLS cargo 
import because it triggers the dissociation of the KPNA-KPNB complex (Gorlich et 
al., 1996, Egea et al., 2004). As shown in step 2, the binding of high RanGTP 
concentration to KPNB resulting in release the IBB domain of KPNA. In the absenee 
of KPNB, KPNA is not able to bind to NLS results in dissociation of cargo in to 
nucleus (Kobe 1999). Then free KPNB is thought to return to the cytoplasm rapidly 
in the company of Ran-GTP whereas KPNA is recycling back to the cytoplasm by 
binding to the exportin CAS which is complexed with Ran-GTP. CAS binds 
preferentially to KPNA in the absence of a bound cNLS cargo, which might also
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serve to promote the recycling of cargo-free KPNA to allow binding of another 
import substrate. (Goldfarb et al., 2004).
Finally, in step 3 the export complex is dissembled in the cytoplasm which 
mediated by the hydrolysis of Ran-GTP to Ran-GDP by Ran GAPl (as mentioned 
above), resulting in release of free KPNA to the cytoplasm for other round of 
transport. Ran-GDP and CAS are recycled back to the nucleus by the transporter 
NTF2 for further round of transport. Therefore, this mechanism can effectively 
aecomplish multiple rounds of unidirectional nuclear import. In addition, it has been 
reported that KPNA can migrate into the nucleus in a KPNB and Ran-independent 
manner (Miyamoto et al. 2002), although the mechanism of this transloeation remains 
to be elucidated.
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Figure 1-3 The classical nuclear import pathway through the nuclear pore complex. 
Cargo protein containing NLS is recognized by KPNA (a) (step 1). Then, the 
complex is transported through the nuelear pore complex into nucleus where the cargo 
is dissociated by binding of GTP to KPNA (a) (step 2). Free KPNB ((3) and KPNA 
(a)-CAS eomplex are transported back to cytoplasm where Ran-GTP hydrolysis is 
stimulated by RanGAP and RanBPl (step 3). Adapted from model in (Perry and 
Fainzilber 2009).
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1.2.1.3 The KPNA gene family
There is only one KPNA protein, Srplp, reported in S. Cerevisiae (Enenkel et 
al. 1995), and three proteins in Drosophila melanogaster (Kap-alpha-1, -2/pendulin, - 
3) (Kussel and Frasch 1995; Mason et al. 2002). However, mammals represent a 
more complex eukaryotic model that have multiple members of KPNA subgroups. 
There are five KPNA proteins in mouse (kpna-1, -2, -3, -4, -6) and at least six 
isoforms of KPNA are known in man including KPNAl (Cortes et al. 1994), KPNA2 
(Cuomo et al. 1994), KPNA3 (Nachury et al. 1998), KPNA4 (Seki et al. 1997), 
KPNA5 (Kohler et al. 1997), and KPNA6 (Kohler et al. 1999). This multi-gene 
family are well conserved throughout evolution and can be classified into three 
phylogenetically distinct subgroups according to sequence identity, as shown in Table 
1-3. The sequence identity within the subgroups is >80%, whereas there is 
approximately 50% identity between subgroups (Kohler et al. 1997; Tsuji et al. 1997; 
Nachury et al. 1998). The higher sequence identity between the alpha-P/a2 and 
alpha-Q/a3 subgroup members suggests that these groups were evolutionarily derived 
from a pre alpha-S/a 1 (Mason et al. 2002).
The multiple names that have been given to karyopherin a family member has 
resulted in complications in the literature. In particular, whereas in rats and mice the 
karyopherin and importin nomenclature use corresponding numbers (i.e. importin a l 
and karyopherin a l represent the same gene), in humans this is not the case and, for 
example, impal represents KPNA2. Similarly, it is the human KPNA nomenclature 
that matches that of other species. Since the official gene name (as defined by the 
Human Genome Organisation) for this family is karyopherin a (KPNA) this is the 
terminology used throughout this report; however, a summary of alternative names is 
provided in Table 1-3.
16
Table 1-3 Human KPNA Classification
Subgroups Members (Alternative names)
Alpha-S/Alphal KPNAl (Impa 5, NPI-1, hSRPl)
KPNAS (Impa 6),
KPNA6 (Impa?),
Alpha-P/Alpha2 KPNA2 (Impa 1, Rch 1, hSRP 1 a)
Alpha-Q/ Alphas KPNAS (Impa 4, hHRPy),
KPNA4 (Impa 3, Qip-1)
1.2.1.4 Tissue and substrate specificity
The KPNA isoforms have unique expression patterns in various cells and 
tissues, which might suggest specific requirements for the nuclear import of cargoes 
in different cell types. To date this has been most thoroughly investigated in the fruit 
fly. Drosophila melanogaster, where the three a-karyopherins are selectively 
expressed throughout the development (Yasuharaa et al. 2009). In the early 
embryonic state, all three mRNAs and a-karyopherin proteins are highly expressed 
but decrease to low levels in larvae. The levels are increased again at the pupae and 
adult stages (Kussel et al. 1995; Malik et al. 1997). Interestingly, Kap-alpha 3 plays a 
more central role in development since KPNA3 mutants die between the first and 
second larval phase. Adult D. melanogaster females express Kap-alpha2 and 3 more 
than males and vice versa for Kap-alpha 1 (Giarre et al. 2002). All three a- 
karyopherin genes are expressed in D. melanogaster gonads; Kap-alpha 3 mRNA is 
expressed at similar levels in both ovary and testis, whilst Kap-alpha 1 and Kap-alpha 
2 mRNA are selectively expressed in testis more than ovary (Mason et al. 2002).
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Several studies have reported the tissue and cell type specific expression 
pattern of the KPNA gene family in different mammalian embryonic and adult tissues 
(Tsuji et al. 1997; Kamei et al. 1999; Kohler et al. 2002). The predominant transcripts 
of KPNA2, 3, 4 and 6 appear to be constitutively expressed in several species. 
However, all isoforms except for KPNA5 are expressed within the same tissue. 
Based on in situ hybridization studies, microarray and in silico data, mouse kpnal is 
highly expressed in the spermatocyte and round spermatids, kpna3 is present in 
spermatogonia and spermatocytes, whereas mouse kpna4 is the most abundant in 
spermatocytes and kpna6 is detected in round spermatids only (Hogarth et al. 2006; 
Holt et al. 2007). Moreover, Kpna2 are most prevalent in rat muscle, where as Kpna3 
is expressed at the highest level in rat adipose tissue (Plant et al. 2006). In contrast, 
the study in human tissues has shown that KPNA3 makes up more than 1% of total 
protein in skeletal muscle, but is found to be minimally expressed in liver, kidney, and 
peripheral blood leukocytes, and absent in spleen and heart (Kohler et al. 1997; 
Nachury et al. 1998). Some KPNA are expressed in rat kidney such as Kpna2 was 
expressed in the cytoplasm of distal tubular and peritubular cells, but was not detected 
in glomeruli (Kohler et al. 2001). Rat Kpna6 was expressed highly in tubules, but also 
could be found in glomerular podocytes, endothelial and mesangial cells where as 
Kpnal, which belongs to the same family as Kpna6, was distributed throughout 
normal rat kidneys in glomeruli and tubules (Kohler et al. 2001). These data are in 
accordance with human studies, KPNA6 is expressed in kidney higher than in other 
human tissues, whereas other KPNA mRNA and protein expression in renal tissue is 
relatively low (Kohler et al. 1997; Kohler et al. 1999). Recently, it has been reported 
that kpna2 and kpna3 also show area-specific expression patterns of individual kpna 
subtypes in adult brain of mice whereas kpnal, kpna4, and kpna6 are ubiquitously
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expressed throughout the brain and spinal cords (Hosokawa et al. 2008). This finding 
suggesting that changes in a-karyopherin subtypes expression may be an important in 
transport of specific cargo in neuronal cells according to their need.
In addition to showing differences in cell and tissue specific expression 
patterns, KPNA also show cargo specificity; for instance, KPNA6 imports the 
ribonucleoprotein hnRNP (Miyamoto et al, 1997, Kohler et al., 1999). The 
mammalian tumour suppressor p53 is specifically import by KPNA2 and is inhibited 
from entering the nucleus by a mutation in KPNA2 in breast cancer cell line (Kim et 
al. 2000). It has been suggested that truncated KPNA2 may act as inhibitor of nuclear 
transloeation by competing with wild type KPNA for KPNB binding (Kim et al. 
2000). KPNA2 also interacts with adenosine deaminases acting on RNA3 (ADAR3) 
whereas an alternative splice form of ADR2 interacts with KPNAl and KPN A3 
(Maas and Gommans 2009). Human Ran binding protein 3 (RanBP3) is 
preferentially transported into nucleus by KPNA4 (Welch et al. 1999). DNA helicase 
Q l, tissue transglutaminase, and poly ADP-ribose polymerase-2 (PARP-2) are also 
imported by KPNA4 (Seki et al. 1997; Peng et al. 1999; Haenni et al. 2008). These 
studies indicate that one KPNA molecule is able to use different binding sites for 
various cargos. On the other hand, one cargo is able to bind more than one KPNA, 
for example p27, a CDK inhibitor is preferentially imported by KPNAl and KPNA4 
to control cell cycle progression (Sekimoto et al. 2004). Similarly RCCl is 
transported into nucleus by KPNA3 and KPNA4 (Friedrich et al. 2006). While a lot 
of work has shown specificity in both expression and cargo selection, by contrast, 
relatively little has been done to study the effect of differences in KPNA levels on 
transloeation or the transcriptional regulation of the KPNA genes themselves.
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1.2.1.5 The role of KPNA in gene regulation
The classical nuclear import pathway is one of the efficient mechanisms to 
regulate gene expression in response to physiological and environmental stress by 
strictly controling the access of transcriptional regulators to their target genes. 
However, the regulation of nuclear transport is mainly at the level of transport 
substrate rather than at the level of transport machinery. Several transcription factors 
have been reported to interact with KPNA, such as the glucocorticoid receptor whieh 
is translocated into the nucleus of neuronal cells by KPNA in response to 
corticosterone treatment (Usuku et al. 2005). Human signal transducer and activator 
of transcription-1 and 2 (STAT-1, STAT-2) are transported into the nucleus in 
response to interferon signalling (Melen et al. 2003). NF-A:B, another transcription 
factor cargo for KPNA, is involved in the control of apoptotic, inflammatory, immune 
as well as viral responses. It has been reported that KPNA3 and KPNA4 mediate the 
nuclear import of NF-A:B p50/p65 heterodimers in human hepatoma cell line, Huh-7 
cells (Fagerlund et al. 2005). However, the best characterized example of the 
regulation of transport substrate involves NF-A:B. In unstimulated cells NF-A:B 
interacts with the inhibitory protein Iâ:B, which masks the NLS of NF-A:B, and 
prevents NF-A:B transloeation into nucleus. Pathogens, cytokines, or environmental 
stresses activate signal transduction pathways leading to the phosphorylation of IkBs 
and resulting in its degradation by the proteasome. Therefore, the NLS of NF-A:B is 
unmasked, allowing binding to KPNA and transport into nucleus where they regulate 
the transcription of responsive genes (Baeuerle and Baltimore 1998). In a similar 
manner, it was shown that degradation of heat shock protein (hsp) 90 is essential to 
unmask the NLS of the glucocorticoid receptor, which is then able to interact wi!h
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KPNA allowing GR to be translocated into the nucleus to regulate glucocorticoid 
receptor responsive genes (Galigniana et al. 1999).
1.2.1.6 Additional essential roles of KPNA
It has been reported that KPNA might have additional essential roles distinct 
from the nuclear protein transport such as roles relating to chromosome and nuclear 
segregation, the mitotic onset, and the regulation of the ubiquitin-mediated protein 
degradation pathway (Tabb et al. 2000; Goldfarb et al. 2004). Gruss et al 
demonstrated that KPNA has an inhibitory effect of spindle assembly in mitosis in 
Xenopus egg extracts (Gruss et al. 2001). Furthermore, studies in a Caenorhabdtis 
elegans KPNA2 mutant animal showed abnormality in chromosome segregation and 
spindle formation (Geles et al. 2002). The mechanism of this action has been recently 
elucidated: at the onset of mitosis, KPNA/KPNB complexes are bound by spindle 
assembly factors (SAF) that regulate mitotic spindle formation and the attachment of 
chromosome to the spindle. These complexes are dissociated only in proximity to the 
mitotic chromosome (Schatz et al. 2003). In addition, Caenorhabditis elegans 
embryos lacking KPNA2 protein show the defects in nuclear envelope and NPC 
structure formation, suggesting essential roles for KPNA in post mitotic nuclear 
envelope assembly (Askjaer et al. 2002; Geles et al. 2002).
1.2.1.7 KPNA in human disease
A number of reports have suggested that KPNA may play a role in the 
progression of human disease. Human immunodeficiency virus type 1 (HIV-1) 
causes acquired immunodeficiency syndrome (AIDS), a condition in which the 
immune system in the body fails leading to life threatening infection. VPR, one of the
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gene products of HIV-1, has many functions in infected cells such as the induction of 
cell cycle arrest at the G2 phase and the regulation of apoptosis (Jowett et al. 1995). 
A study in macrophages showed that the nuclear import of VPR is mediated by 
KPNAl, KPNA2, and KPNA 4 in an KPNB-independent manner (Nitahara-Kasahara 
et al. 2007). Moreover, some of the hantaviruses, which cause haemorrhagic fever 
with renal syndrome and hantavirus pulmonary syndrome, act as competitive 
inhibitors of the nuclear transloeation of NF-â:B by binding to KPNA2, KPNAS, and 
KPNA4, thus inhibiting the protective response to pathogen (Taylor et al. 2009). In a 
similar manner, viral protein produced by Ebola virus and severe acute respiratory 
syndrome coronavirus (SARS-CoV) interact with KPNAl and KPNA2 respectively 
and inhibit the nuclear accumulation of STATl (Reid et al. 2006; Frieman et al. 
2007). By contrast the influenza A virus nucleoprotein binds to KPNA4 and is 
transported into nucleus as part of the viral lifecycle (Melen et al. 2003).
In addition to viral interference, alterations in KPNA expression have effects 
in several diseases. KPNA6 is up-regulated in diabetic rat kidney with more minor 
up-regulation of other KPNA isoforms (Kohler et al. 2001). Furthermore, several 
reports show the relationship between KPNA expression and diseases of the nervous 
system: transcriptomic studies on Alzheimer’s disease demonstrated that KPNA3 
transcript levels are up-regulated (Wang et al. 2004), whereas gene disease 
association studies showed that KPAN3 may contribute to schizophrenia (Wei and 
Hemmings 2005). In addition, it has also been reported that KPNA2 protein 
expression showed a significant correlation with tumour stage in invasive breast 
carcinoma and matched peritumoral ductal carcinoma in situ (Dankof et al. 2007) 
These results suggest that KPNA expression is important in the pathogenesis of 
human disease.
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In addition to alterations during disease, expression of the KPNA gene family 
can also be altered by a number of pharmacological agents. KPNAl, KPNA2, and 
KPNA6 showed a marked up-regulation in streptozotocin-treated rat kidneys while 
KPNAl, KPNA4, and KPNA6 are increased in different cultured cells after high 
glucose or mannose administration (Kohler et al. 2001). In the liver, significant 
changes in levels of KPNA mRNAs were observed in response to liver growth agent 
treatment. The peroxisome proliferator Wy-14,643 elicited a significant induction of 
KPNA3 at 48 h and 96 h whereas cyproterone acetate induced KPNAl and KPNA3 
transcripts following 96 h. Dexamethasone administration caused a highly sustained 
significant repression of KPNA3 and KPNAS (Plant et al., 2006). Since these liver 
growth agents are ligands for different nuclear receptors, this evidence suggests that 
the nuclear receptors are likely to be involved in any regulatory mechanism for the 
control of KPNA gene expression.
1.3 Nuclear Receptor Superfamily
Nuclear receptors (NR) are a superfamily of ligand-activated transcription 
factors that are involved in every aspect of mammalian physiology, including cell 
growth and differentiation, embryonic development, metabolic homeostasis, immune 
response, tumour formation, and toxin clearance (Mangelsdorf et al. 1995; Sonoda et 
al. 2008). Genomic sequence alignment shows 48 NR members in humans, which 
can be subdivided into six subfamilies based on their sequence identity (Nuclear 
receptor nomemclature committee 1999). NRs are also subdivided according to their 
mechanism of action and subcellular distribution in the absence of ligand, as shown in 
Table 1-4; this will be discussed in more detail in section 1.3.2. Type I nuclear 
receptors (subfamily 3) are constitutively found in the cytosol and include the
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glucocorticoid receptor (GR), estrogen receptor (ER), and progesterone receptor (PR); 
these NRs are activated by steroid ligands and bind DNA as a homodimer. Type II 
receptors (principally NR subfamily 1) in contrast are retained in the nucleus where 
they are activated by non-steroid ligands and activate gene transcription by 
hetrodimerizing with RXR; this subfamily includes the peroxisome proliferator- 
activated receptors (PPARa, (3 and y), and the retinoic acid receptor (RAR). Type III 
receptors (principally NR subfamily 2) include hepatic nuclear factor 4 (HNF 4) and 
retinoid X receptor (RXR), which bind as homodimers to direct repeats within the 
DNA, whereas type IV bind either as monomers or dimers. Examples of type IV 
receptor are found in most of the NR subfamilies (Mangelsdorf et al. 1995)
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Table 1-4 Nuclear receptor Classification*
Class no. 
(Name)
Members
Class I GR (glucocorticoid receptor)
(homodimers; steroid receptors) AR (androgen receptor)
ER (estrogen receptor)
MR (mineralocorticoid receptor) 
PR (progesterone receptor)
Class II CAR(constitutive androstanedione receptor)
(RXR partners) FXR (famesoid X receptor)
LXR (liver X receptor)
PPAR (peroxisomal proliferator receptor) 
PXR (pregnane X receptor)
RAR (retinoic acid receptor)
TR (thyroid hormone)
VDR (vitamin D receptor)
Class III RXR (retinoid X receptor)
(Orphans: homodimers) HNF4 (hepatocyte nuclear factor 4)
Class IV LRHl (liver receptor homologue 1)
Others SHP (small heterodimer partner)
* This table shows some examples of nuclear receptor members in each class. For 
a more complete list see (Olefsky 2001)
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1.3.1 Structure and Function
The essential structures of the nuclear receptor superfamily members usually 
consists of four modular domains separated by a hinge as shown in Figure 1-4A.
A. Nuclear receptor structure
A/B
NH2_T
Activation 
Function 1
F
AF1 I DNA I Hinge I LIGAND
DNA-
binding
Domain
 coo-
Ligand-binding Activation 
Domain Function 2
B. DNA-binding elements
Direct repeat (DR)
Inverted repeat (IR) 
Everted repeat (ER)
AGGTCAnAGGTCA
TCCAGA n TCCAGT
AGGTCA n TGACCT
TCCAGA n TCCAGA
TGACCT n AGGTCA
ACTGGA n TGACCT
n = spacing between hexamers, 0-8 nt
Figure 1-4: Structural organization of a prototypical nuclear receptors (A) and DNA- 
binding elements (B)
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All nuclear receptors share basic structural domains that are essential for 
receptor function. A highly variable N-terminal domain (A/B region) domain 
interacts with cofactors and other transcription factors and also with its own C- 
terminal domain (Germain et al. 2006). Some nuclear receptors harbour an activation 
function (AF-1) in A/B region, which is cell and promoter specific, important for gene 
regulation and recruitment of the transcription complex. The highly conserved DNA 
binding domain (DBD; region C) consisting of two zinc-finger motifs is required for 
the specific recognition of the hormone response element (HRE) within DNA 
sequences and is also involved in NR dimerization. A flexible hinge domain links the 
DBD and LBD, allowing a structural flexibility in the receptor dimer to enable 
interactions with multiple HRE sequences without creating a steric hindrance. The C- 
terminal ligand binding domain (LBD, region E) interacts with ligands, chaperones, 
and co-regulators; it consists of a hydrophobic ligand-binding pocket (LBP) and a co­
activator binding groove. In the presence of agonist within the LBP, the LBD 
undergoes a conformation change which makes the groove accessible for co-activator 
binding to induce transcription regulation (Germain et al. 2006; Bain et al. 2007). 
Finally, some nuclear receptors also contain an activation function (AF-2; region F in 
Figure 1-4A) which is the last helix of LBD.
Figure 1-4B shows the classification of NR DNA response elements (Nuclear 
receptor nomemclature committee 1999). The prototypically NR DNA response 
element is composed of 6 base pair sequences separated by 0-8 nucleotides and can be 
divided into 3 groups as follow; direct repeat (DR), inverted repeat (IR), and everted 
repeat (ER). For example DR4 and DR5 binding elements are referred to a direct 
repeat hexamer binding motifs separated by 4 and 5 nucleotides, respectively. In 
addition to prototypically AGGTCA hexamer motifs, some nuclear receptors may
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bind to other elements; for example LRH-1 binds as a monomer to an extended half­
site sequence whereas others such as SHP have no DNA-binding capability. 
Therefore, in addition to the presence of a DNA recognition sequence in a promoter, 
other factors such as the presence of co-regulator or co-repressor, heterodimerization 
efficiency and competition between agonist and antagonist also influence the process 
of gene regulation (Karpen 2002).
1.3.2 Intracellular localisation of nuclear receptors
As outlined previously, the subcellular localisation of nuclear receptors varies 
and is one distinguishing feature of the different classes. Thus whereas GR and AR 
are localized in the cytoplasm in absence of ligand, the mineralocorticoid receptor 
(MR) is evenly distributed in both nucleus and cytoplasm; upon ligand binding all 
three receptors are localised in the nucleus (Kumar et al. 2006). By contrast, ER and 
PR are localized in the nucleus in both the presence and absence of ligand. The 
cellular distribution of non-steroid binding NRs also differs; TR, RXR, RAR, CAR, 
PPARa and LXR are localized in the nucleus both in the absence and presence of 
ligand (Zelko et al. 2001; Maruvada et al. 2003; Dong et al. 2004) whereas CAR is 
retained in the cytoplasm by forming a complex with CCRP (CAR cytoplasmic 
retention protein) and heat shock protein 90. The receptor translocates to nucleus 
upon agonist activation (Yoshinari et al. 2003; Hosseinpour et al. 2006). 
Interestingly, VDR exhibits cell type-specific pattern of distribution; in most cell 
types localisation is mainly in the cytoplasm in the absence of VDR ligand; however, 
in HL-60 promyelocytic leukemia cells (Boos et al. 2007), ROS 17/2.8 cells (Klopot 
et al. 2007), and COS-7 cells (Racz and Barsony 1999) it is predominantly localised 
in the nucleus; finally, nuclear localisation has also been reported in the majority of
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cells within the human brain (Eyles et al. 2005). Recently, Klopot et al (2007) 
reported that VDR is evenly distributed within the cytoplasm and the nucleus in Caco- 
2 cells and translocated to the nucleus after ligand induction. It is currently not clear 
if this differential localisation is dependent upon cell-type or the technology used to 
assay localisation, or if differential localisation, if a true biological fact, has any 
functional consequence.
The intracellular distribution of some NRs also shows species specificity, for 
instance human PXR is consistently localized in the nucleus in the absence of ligand 
whereas mouse PXR was found to be localized in the cytoplasm and translocated to 
the nucleus only upon addition of PCN or other agonists (Kawana et al. 2003; Squires 
et al. 2004). Again, whether such differences are biological or technological in origin 
is unclear
For some nuclear receptors the mechanism mediating the nuclear translocation 
has been reported. For example VDR is imported into the nucleus by importin 4 in a 
ligand-independent mechanism (Miyauchi et al. 2005), which also requires nuclear 
localization signals within its heterodimeric partner, RXR (Prufer and Barsony 2002; 
Miyauchi et al. 2005). Furthermore, it has been reported that the vitamin D3 induced 
nuclear import of the VDR-RXR heterodimer involves interactions between KPNA 
and VDR (Yasmin et al. 2005). In mice, cytoplasmic PXR within hepatic cells is 
translocated into the nucleus after administration of pregnenolone 16a-carbonitrile by 
the binding of a typically bipartite nuclear localization signal to KPNAl, KPNA2, and 
KPNA4 in the presence of KPNB (Kawana et al. 2003). In contrast to PXR, the 
transport of CAR into nucleus is either mediated by a leucine rich region in its ligand 
binding domain or by a passive diffusion mechanism; the latter is possible because of 
its low molecular mass (approximately 40 kDa) and is an important mechanism due to
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the weak nuclear localization signal contained within the CAR (Zelko et al. 2001). 
Recently, additional features of CAR nuclear translocation have been reported where 
phénobarbital induced nuclear accumulation of CAR in mouse (Koike et al. 2005). 
Moreover, PPARa ligands, Wy-14643 and ciprofibrate also induced nuclear 
translocation of CAR in liver cells without any effects on CAR target gene induction 
(Guo et al. 2007). However, the mechanism remains to be elucidated.
Taken together, these and other studies suggest that nucleo-cytoplasmic 
shuttling of nuclear receptors is an essential component of their transcriptional 
function and in many cases there is evidence to suggest that this step is highly 
regulated.
1.3.3 Nuclear receptor action and biological implications
NRs play a central role in transcription regulation of many gene batteries 
which exhibit physiological roles throughout the body. Hepatic nuclear factor4a, for 
instance, is a key regulator of hepatic gene expression which in turn activates the 
expression of a large number of liver-specific genes, including those involved in 
glucose, cholesterol, and fatty acid metabolism (Gupta and Kaestner 2004). PXR and 
CAR have been identified as the master regulators of the expression of CYP3A4, 
which metabolizes more than 60% of human drugs, and CYP2B (Honkakoski et al. 
1998), respectively. These families are of great clinical importance in xenobiotic 
metabolism in humans, protecting the body from a variety of foreign chemicals. VDR 
is ubiquitously expressed in almost all cells at variable concentrations and posses 
multiple actions in the human body. In addition to playing a central role in calcium 
homeostasis, VDR also plays a role in immune system function, bile acid and 
xenobiotic metabolism, and differentiation and growth of a number of malignant cells.
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PPARa is predominantly expressed in the liver, the kidney, and intestine (Bookout et 
al. 2006) where it is variously involved in lipid metabolism, bile and cholesterol 
metabolism (Francis et al. 2003).
Transcriptional regulation by NRs is a multistep process involving the 
association of NRs with regulatory sites in the genome, the ligand-dependent 
recruitment of co-regulators, the regulation of DNA polymerase II binding resulting in 
activation (or repression) of the target promoter, and finally the termination of NR- 
dependent signalling (Metivier et al. 2006; Kininis and Kraus 2008). Nuclear 
receptors that are nuclear in the absence of ligand may be constitutively bound to a 
HRE, forming a repressive complex with a co-repressors such as histone deacetylase 
complexes (Yang et al. 2007) . Binding of ligand in the ligand-binding pocket 
induces conformational changes in the AF-2, which facilitates the release of co­
repressor and the recruitment of co-activators including histone acetyl-transferase and 
chromatin remodelling complexes which open chromatin and interact with general 
transcription factors and initiate transcription (Sonoda et al. 2008). Table 1-5 shows 
some of the most important nuclear receptors within human liver, their ligands and 
example target genes.
Altogether, NRs are capable of regulating the expression of complex gene 
networks. Many genes have been reported to be regulated by NRs as shown in Table
1-5. However, the transcription regulation of nuclear transport genes, which plays an 
essential role in enabling the nuclear translocation of various macromolecules 
including the NRs in the cell, still needs to be elucidated.
31
<u
I
I
13e
C3Kl
13
I
S
Ioa
B
I
uI
i
in
«
H
3
I
IC3
’E,
I
CA-aa&
I
bX)
I
I
a
I
Ia
> PQ
o
P h
Ü
.13 00
03 VO
O
C m(U Tf
x>
P h I f
c/T
o CA
.2 2 13
X <u ‘o 3
o % o3 03<3
X XX o s *Ph
12
0
1
S 2 2
Q Q Q
s
i
•I
E
1
P^  .ti
Q
.S
I ‘i
r" ojX >
2w
VO
PChW
(N -rf m
2 P^ P<
Q Q Q
2 2 2 2
Q Q Q Q
rp Ph
«
m
&&
<o
<
I
10
1 
*
o><o
0 
<
1
I
u
u
<
I
i
•sI
o
bû
P^
Q
I
s 
I
1  . .
I
S'
c3a,
c
s
HÔ
I
t:o
<NCO
I5 oI
1
&<u
I
'o
■ |&
A
Î
13
■|
<D
A
13
I0
g
%
<ù
1
I
I
A
O
Ü
oo
VO
2  -3 - a
S  ^
II§I
I
H
I
13
1
§zn
I
I
i
I
H00
Ü
.1
I
I1-
S J
oIT)If
I
iCO
§
i
I
I0
■g
1 
Iro
I
1.4 Hypothesis and Aims
Although several studies have reported the tissue and cell type specific 
expression pattern of the KPNA gene family in different mammalian cells (Nachury et 
al. 1998; Kohler et al. 2002; Plant et al. 2006), there is currently little information 
regarding the transcriptional control of KPNA protein expression. Therefore, this 
research was initiated to address this deficit, and in particular to characterize the role 
of nuclear receptors on the regulation of the KPNA3 gene.
Hypothesis
Chemical substances alter the expression of KPNAs at the transcriptional level 
which then alters the capacity of the specific KPNA to transport molecules across the 
nuclear envelope.
Aims
To examine the molecular mechanisms of nuclear receptor-dependent 
transcriptional regulation of human KPNA3 and to assess the consequences of such 
alterations on nuclear transport.
1.5 Objectives
1. To identify the proximal regulatory region of human KPNA3 gene and
putative nuclear factor binding sites.
2. To clone the human KPNA3 putative promoter into a secretory alkaline
phosphatase (SEAP) reporter vector.
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3. To determine the effect of nuclear receptor ligands on human KPNA3 
expression by using the SEAP reporter gene assay.
4. To confirm the precise position of nuclear receptor-dependent regulatory 
elements using promoter deletion and site directed mutagenesis.
5. To characterize the protein-DNA interactions of nuclear receptors binding to 
human KPNA3 promoter region
6. To assess the effect of altering KPNA3 levels on the subcellular distribution of 
putative KPNA3 cargoes.
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2. MATERIALS AND METHODS 
2.1 Materials
2.1.1 Reagents and antibodies
General chemicals were obtained from Fisher Scientific (Leicestershire, UK) 
OR Sigma Aldrich Chemical (Dorset, UK) and were of molecular biology grade. 
Dulbecco’s Modified Eagle Medium (DMEM, 4.5 g/L glucose, L-glutamine and 
without sodium pyruvate), fetal bovine serum (FBS), nonessential amino acids 
(NEAA), and penicillin/streptomycin were obtained from Invitrogen GIB CO (Paisley, 
UK). Superscript II reverse transcriptase was obtained from Invitrogen (Paisley, UK). 
DNA ligase was purchased from Promega, (Southampton, UK). Prime STAR DNA 
polymerase was obtained from Takara Bio Inc (Wokingham, UK). FuGENE 6 
transfection reagent, protease inhibitor tablets, and LDH assay kit were from Roche 
Diagnostics (Lewes, UK). Restriction enzymes were purchased from Promega 
(Hampshire, UK) and New England Biolabs (Herts, UK). DNA purification kits (gel 
extraction, PCR purification, cleanup, plasmid mini/midi preps) were purchased from 
Qiagen (Epsom, UK). Tropic® Phospha-Light™ System-Chemiluminescent was 
~ obtained from Applied Biosystems (Warrington, UK). A TNT® T7 Quick Coupled 
Transcription/Translation reactions kit was obtained from Promega (Hampshire, UK). 
Oligonucleotide and biotin labelled primers were purchased from Eurofins MWG 
Operon (Ebersberg, Germany). Donkey anti-goat immunoglobulin IgG conjugate to 
peroxidise was obtained from Santa Cruz Biotechnology (Heidelberg, Germany). 
Goat polyclonal to KPNAS and rabbit polyclonal antibody to KPNAS were obtained 
from Abeam (Cambrigde,UK). Goat-anti rabbit Alexa fluor 350 was obtained from 
Invitrogen (Paisley, UK). Polyvinylidene Fluoride (PVDF) membranes vere
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purchased from Millipore (Watford, UK). Novex® Sharp molecular weight standard 
was purchased from Invitrogen (Paisley, UK). Enhanced Chemiluninescence plus 
Western Blotting detection reagents was form GE Healthcare (Amersham, UK). 
Biodyne Precut Nylon Membranes and LightShift Chemiluminescent EMSA kit were 
obtained from Pierce (Lancashire, UK). Vectashield® mounting medium was from 
Vector Laboratories (Peterborough, UK).
2.1.2 Cells
The human hepatocellular carcinoma cells (Huh-7) were a kind gift from Dr. 
Steve Hood (GlaxoSmithKline, Ware, UK). DH5a E. coli competent bacterial cells 
were prepared by Mrs Jenny Spinks, University of Surrey.
2.1.3 Plasmids
The pSEAP2-basic plasmid was purchased from BD Biosciences (Oxford, 
UK). Several nuclear receptor expression plasmids have been used in this work and 
were cloned by previous members of the group; pCR3-PPARa, pCR3-CAR, pEF6/vs- 
His VDR, and pEF6/vs-His HNF4a. Human KPNA3 expression plasmid, pTriEx 1.1- 
hKPNA3, was a kind gift from Dr. Kate Plant (University of Surrey). pEGFP-hVDR 
was a kind gift of Ellen Weidemann (University of Surrey).
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2.2 Methods
2.2.1 In silico Analysis
20 kb immediately upstream of the first exon of the human, rat and mouse 
KPNAS gene was extracted from the National Centre for Biotechnology Information 
nucleotide database and compared by alignment using the Vista software 
('http://genome.lbl.gov/vista/index.shtmn to reveal the conserved region predicted to 
include the KPNAS promoter. Matlnspector software (http://www.genomatix.de) was 
used to identify the putative nuclear receptor binding site in the well conserved region 
up to 2 kb immediately upstream of the first exon of human KPNAS. The DNA 
binding profile for transcription factors was selected with the matrix similarity at 
>0.70 (the quality of a match between the matrix and input sequence) and core 
similarity (the quality of a match between the core sequence of the matrix and the 
input sequence) at > 0.80 to minimize the identification of false positives.
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2.2.2 Generation of human KPNAS promoter clones
2.2.2.1 Polymerase Chain Reaction (PCR)
Various fragments of the region upstream of the human KPNAS transcription 
start site were amplified by polymerase chain reaction and cloned into the pSEAP2- 
basic reporter vector.
2.2.2.1.1 Primer design
The hKPNAS proximal promoter sequence was obtained from the NCBI 
(National Centre for Biotechnology Information) database. Primers were designed to 
amplify the various fragments of the region upstream of hKPNAS transcription start 
site using Vector NTI 10 (Invitrogen, Paisley). Parameters for primer design were set 
as the following; 20-25 nucleotides in length, 40-60% GC content, Tm 55 °C to 65 °C 
and no more than 4 °C difference between the two primers. The mismatches were 
introduced at least 10 nucleotides from S' end and at least 6 nucleotides from 5' end to 
produce restriction site. Primers were resuspended in 0.1% Tris-EDTA (TE) buffer to 
a stock concentration of 100 pmol/pl and stored at -20 °C.
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2.2.2.1.2 Amplification of -2 kb hKPNAS promoter
The putative KPNAS promoter region was amplified from human genomic 
DNA (100 ng) using the high fidelity DNA polymerase Prime STAR which is a very 
accurate proof-reading enzyme to minimise the number of mutation caused by PCR. 
Volumes used in the PCR reaction are shown in Table 2-1.
Table 2-1 Volumes of reagents used in PCR reaction
Reagent Volume (pi) Working concentration
Water 26
Prime STAR'" buffer (5x) 10 Ix
dNTPs(lOmM) 4 0.8 mM
Primers (10 pmol/pl) 1.5 (1:1 primer pair mix) 0.3 pmol/pl
Genomic DNA (25 ng/pl) 8
Prime STAR Polymerase 0.5 0.06 U/pl
The PCR reaction was performed with the following profile: 35 cycles of 10 
seconds dénaturation at 95°C, 30 seconds annealing at primer-specific temperature 55 
°C and 130 seconds elongation at 72°C. PCR primers were proximal KPNAS 
promoter region. A single mismatch mutation was introduced in the forward primer 
at -1963 pb (G -Kf) and in the reverse primer at 84 bp (A -►C) to produce an Acc65 I 
and Bgl II restriction sites, respectively.
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Table 2-2 Primers used for amplification of -2 kb hKPNAS proximal promoter
Position in sequence Primers Sequence*
hKPNA3 -1963 Forward 5'- CAAACTGGGTACCTGATATTCTG-3 '
hKPNA3 84 Reverse 5'- TGCAAGAGATCTCCACAACC-3 '
*The restriction sites are underlined and the mutated base is shown in bold.
2.2.2.1.3 Amplification of four serial deletion -2 kb human KPNAS 
fragments
The hKPNAS promoter was also cloned as a serial deletion series into 
pSEAP2-basic vector. The pSEAP2-hKPNA3 promoter construct containing -2 kb of 
hKPNAS promoter was used as a template for PCR using specific primer according to 
Table 2-3. Five serial deletion fragments were amplified by PCR using forward 
primers containing mutations to generate the Acc65I restriction site as shown in Table 
2-3. Reverse primers were designed against the pSEAP2 vector so that following 
amplification the Bglll site previously introduced (see above) could be used in 
cloning. The PCR profiles for amplification of -PPAR, -VDR 237, -VDR 739 and - 
VDR 1300 fragments were 98°C for 10 s, 56.4°C for 5 s, and 72°C for 2 min (35 
cycles) while for fragment VDR 1402 the annealing temperature was 57.4°C. The 
series of DNA fragments with different 5' ends were then extracted from 1% crystal 
violet gel electrophoresis.
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Table 2-3 Oligonucleotide primers used to generate serial deletion fragments
Fragment name Forward primer (5’-3’)* Reverse primer (5’-3’)
-PPRE agcttseeTaccaaauucttcte tttgtgccagaaatggagcc
-VDRE 1402 gatccaggtaCctcgacctccaa tttgtgccagaaatggagccgg
-VDRE 1300 attaasstaCcagcaaateaagccc atcgcccaggaagatgatga
-VDRE 739 tgggctggtAcctgaaggctaag tttgtgccagaaatggagcc
-VDRE 237 ggaagGgtaccggcattctcc cagggagagctgtagcctca
*The restriction sites are underlined and a mutated base is shown in uppercase.
2.2.2.1.4 Site directed mutagenesis of putative nuclear receptor
binding sites
A PCR-based method was employed to mutate putative nuclear receptor 
binding sites (PPRE and 4 VDRE sites). Briefly, one PCR reaction amplifies the 
distal region using a 5' primer which hybridises upstream of the multiple cloning site 
(MCS) of pSEAP2-basic with a reverse primer containing mutations which 
simultaneously destroys the nuclear receptor binding site and introduces a unique 
restriction site. The second PCR amplifies the proximal region using a forward 
primer (reading from 5 -3 ) which contains the mutations of the nuclear receptor 
binding site plus a reverse primer which hybridises downstream of MCS (reading 
from 3 -5 . Following isolation and restriction digestion the two fragments are ligated 
together and the entire fragment is then amplified using nested primers which are 
internal to the two upstream and downstream primers of the MCS (Figure 4-1). Core 
sequence binding sites were changed using mutant primers as shown in Table 2-4 and
2-5. The PCR amplification profiles for four VDREs (1402, 1300, 739, 237 ) 
upstream and downstream fragments were as following: 10 s at 98°C, 5 s at 56.4°C,
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and 2 min at 72 (35 cycles). However, the annealing conditions of upstream and 
downstream PPRE fragments were 58°C for 5 s and 60°C for 5 s, respectively. These 
upstream and downstream PCR products, which overlap at mutation region, were 
digested with Xhol. After they were ligated together with DNA ligase and used as 
templates for the final PCR reaction. Primers used to amplify the PPRE recombinant 
fragments were forward 5-TCCCCAGTGCAAGTGCAGGT-3 and reverse 5- 
TTCTTGGCGGCTGTCTGTGCAG-3'. Primers used to amplify the four VDRE 
recombinant fragments were forward 5 -TCCCCAGTGCAAGTGCAGGT-3 and 
backward 5 -TGCAGGCTGCAGCTTCTTGG-3. The PCR profile for amplification 
was 98°C for 10 s, 56.4°C for 5 s, and 72°C for 2 min (35 cycles). The DNA 
fragments were then separated by 1% crystal violet gel electrophoresis for the next 
step of cloning.
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Figure 2-1 A diagram illustrating the method of nested PCR for site directed 
mutagenesis of putative nuclear receptor binding sites.
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Table 2-4 Oligonucleotide primers used for producing mutation in proximal
region.
Fragment name Forward primer (5 -3 ) Reverse primer (5 -3 )
-PPREs teascTCTCsAGcagtateaccag cagggagagctgtagcctcaggcc
-VDRE1402 acctcctCTCgAGgrgatccacc tgcaggctgcagcttcttgg
-VDRE1300 cctttCtCGAGtcttcatggtatag agatgatgaggttcttggcg
-VDRE739 tsctacacCTCsAGGtctscgeac ttcttggcggctgtctgtgcag
-VDRE237 aggcccaCTCgAgTcctcctgatag ttcttggcggctgtctgtgcag
*The restriction sites are underlined and the mutated bases are shown in uppercase.
Table 2-5 Oligonucleotide primers used for producing mutation in distal region.
Fragment name Forward primer (5 -3 ) Reverse primer (5 -3 )
-PPREs ttcacgtagtgggccatcgc atactsCT cGaGGgcccagtgttg
-VDRE1402 cgcccgctcctttcgctttctt tcacaACTCgAGgaggtcgagacc
-VDRE1300 ctcctttcgctttcttccct eaagaCTCGaGaaaggacaatc
-VDRE739 tttcccattcgccattcagg gcasacCtCGAGTtgtagcactcc
-VDRE237 tccccagtgcaagtgcaggt gaggaaCTCgAGAggccttcctgg
* The restriction sites are underlined and the mutated bases are shown in uppercase.
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2.2.2.2 Agarose gel electrophoresis of DNA
The PCR products were analysed by electrophoresis through 1% (w/v) agarose 
gel supplemented with 0.05 pg/ml ethidium bromide in IxTAE (40 mM Tris base, 40 
mM acetic acid, ImM EDTA). The DNA was mixed with 5x Orange G loading dye 
(0.25% Orange G, 50% glycerol) in a 5:1 ratio DNA:Orange G and loaded onto the 
gel. Bands were photographed under UV light using the Gene Snap gel 
documentation software (Frederick, USA).
2.2.2.3 PCR fragment isolation and gel extraction-Qiagen method
The PCR product was isolated by running onto a crystal violet gel (1% 
agarose gel containing 10 pg/ml crystal violet). The band was excised with a scalpel, 
weighted and placed in a 1.5 ml Eppendorf tube. Three volumes of QG buffer were 
added to 1 volume of a gel and incubated at 50 °C for 10 min or until the gel 
completely dissolved (vortexing the tube every 2-3 min during incubation). After that 
one volume of isopropanol was added and mixed by inverting the tube several times. 
The sample was applied into a MinElute column and spun for 1 min at 10000 g in a 
bench top centrifuge. The PCR product binded to the silica-gel in the column. This 
was washed to remove contaminants and eluted in EB buffer (10 mM Tris-HCl, pH 
8.5). The purified PCR product was stored at -20 °C.
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2.2.2.4 Plasmid constructs
2.2.2.4.1 Restriction endonuclease digestion of PCR fragment and
vector
The purified PCR products were subcloned into the respective site of 
pSEAP2- basic cloning vector. 10 pg of each PCR product, containing restriction 
sites for Acc65I in the 3 oligonucleotide and BgRI in the 5 oligonucleotide, and 
pSEAP2-vectors (Ipg) were cut with Acc65l and Bglll to produce compatible ends 
for ligation. Volumes used in digestion reaction are shown in Table 2-6. The reaction 
mix was incubated at 37 °C overnight for the PCR product while the vector was 
digested at 37 °C for 2 hours.
Table 2-6 Volumes of reagents used in digestion reaction
Reagent Reaction mix (pi)
PCR fragment Vector
Water 22 15
Buffer (lOx) 5 2
DNA 18 1
Restriction enzyme 
(20000 unit/ml)
5 2
Total volume (pi) 50 20
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To minimize religation of the vector after restriction enzyme digestion, the 
vector was dephosphorylased to remove the 5' phosphates. As a result, neither strand 
of the duplex can form a phosphodiester bond, preventing self-ligation. However, a 
foreign DNA segment with 5'-terminal phosphates can be ligated efficiently to the 
dephosphorylated plasmid DNAs. For dephosphorylation of the vector digest, 5 pi of 
lOx phophatase buffer (ImM ZnCl, 1 mM MgCl, 10 mM Tris pH 8.3) and 1 pi 
phosphatase were added to an end volume of 50 pi water and incubated at 30 °C for 
30 minutes. An additional batch of enzyme (1 pi) was added and incubated for 
further 30 minutes.
The dephosphorylization vector and the digested PCR fragement were cleaned 
up with the Qiagen kit (as below) and run on a gel to check purity and concentration.
2.2.2.4.2 Ligation
The dephosphorylization vector and the digested PCR fragments were 
incubated together with the ligation enzyme. Therefore the ends of the PCR products 
and pSEAP2 plasmid molecules were hybridized and then sealed into the 
phosphodiester linkage using the enzyme DNA ligase. Two reactions were set up for 
ligation process, one control (without insert) and one ligation (with insert). For 
ligation, a 3:1 ratio of insert to dephosphorylized vector was added to an equal 
volume of DNA Mighty Mix, a T4 DNA ligase while a vector control was set up 
where water replaced the insert. The samples were incubated at 16 °C for 30 minutes 
before being stored at minus 20 °C.
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2.2.2.S Transformation of Bacteria
In order to produce large quantities of the plasmid DNA, the recombinant 
plasmid was transformed into competent E. coli DH5a cells (prepared by Jenny 
Spinks, University of Surrey). These cells are suitable for transformation of plasmid 
DNA because they contain mutations, which reduce the occurrence of unwanted 
recombination in the cloned DNA and eliminate non-specific digestion by 
endonuclease therefore allowing clean preparations of DNA.
Recombinant plasmids (approximately 10-50 ng) or empty plasmids (control) 
were introduced into 50 pi of competent E. coli DH5a cells and incubated for 30 min 
on ice and then heat shocked at 42 °C in water bath for 45 seconds to allow DNA to 
enter cell. Then the transformed bacteria were incubated in 450 pi of LB broth (0.17 
M NaCl, 0.5% yeast extract, and 1% tryptone) for an hour at 37 ®C. The cells were 
spun at 7000 rpm in a bench top centrifuge for 1 minute and resuspended in 100 pi of 
LB broth (with ampicillin 50 pg/ml) before plating onto LB agar (LB broth plus 1.5% 
bactoagar) supplemented with ampicillin (50 pg/ml). A plate was incubated at 37°C 
overnight. The transformed cells which contained the plasmid with ampicillin 
resistant gene could grow and multiply in LB agar. Colonies that were well separated 
from the others on the plate were taken and put into a sterile/capped universal tube in 
solution containing 5 mL LB broth and ampicillin (50 pg/mL). The cells were 
incubated with shaking overnight at 37°C.
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2.2.2.6 DNA preparation methods
2.2.2.6.1 Mini preparation of plasmid DNA-AIkaline lysis method
Plasmid DNA was isolated from bacterial cultures using the alkaline lysis 
method to allow rapid screening for the presence of inserts. 1.5 ml of bacterial culture 
was centrifuged at 10000 g for 5 minutes in a bench top centrifuge and the pellet was 
resuspeded in 100 pi buffer 1 (50 mM glucose, 25 mM Tris-HCl pH 8, 10 mM 
EDTA). Then, 250 pi of buffer 2 (0.2 M NaOH, 1% SDS) was added and gently 
inverted until the solution became viscous and slightly clear. To this 350 pi of buffer 
3 (3 M KO Ac in glacial acetic acid) were added and the mixture was centrifuged at 
10000 g for 10 minutes at 4 °C. The aqueous layer was removed and 800 pi ethanol 
added. This was centrifuged at 10000 g for 5 minutes to remove ethanol. The pellet 
was washed with 70% ethanol and spun down for 2 minutes at 10000 g. The pellet 
was air dried and resuspened in 50 pi in Ix TE.
2.2.2.6.2 Endotoxin-free preparation of plasmid DNA-Qiagen 
method
Large quantities of endotoxin free plasmid were subsequently prepared for 
transfection studies. The highly purified DNA was isolated using endotoxin-free 
Qiagen Midi-prep or Maxi-prep kit. 100 ml (midi) or 200 ml (Maxi) of LB broth 
containing ampicillin 50 pg/ml were inoculated with 50 pi of the mini-preparation 
culture and incubated in a shaker, 300 cycles per min at 37 °C overnight. The plasmid 
was purified following the protocol of the kit. Briefly, cells were harvested by 
centrifuging at 6000 g for 15 minutes at 4 °C. The supernatant was removed. A pellet 
was lysed and the lysate was added to a Midiprep or Maxiprep column in a high-salt 
buffer, causing the plasmid to bind to silica gel membrane. Then, a medium-salt
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buffer was used to remove RNA, proteins and low-molecular impurities. Finally, the 
plasmid DNA was eluted in a low-salt TE buffer. Another restriction digest was 
repeated at this stage to ensure the correct clone.
2.2.2.6.3 Diagnostic restriction digest
The fragment was confirmed and screened by restriction analysis using the 
enzyme that cuts both the vector and insert asymmetrically. The master mix was 
prepared using the appropriate lOx buffer and 10 units of each enzyme. Then one 
microgram of DNA was added to the mixture to a final volume 15 pi. This reaction 
mix was incubated at 37 °C for 1-2 hours. The products were checked in the 1% 
agarose gel containing ethidium bromide to identify the right clone. Fragment size 
was determined by comparison to molecular weight marker, and compared to the 
predicted digest given by Vector NTI 10.
12.1.1 Measurement of nucleic acid content and purity
The amount and purity of construct plasmid was determined by absorbance at 
260 nm and the 260/280 ratio using a Nanodrop spectrophotometer (Nanodrop ND- 
1000 spectrophotometer V.3.0.1). The integrity of all plasmid constructs was 
confirmed by further sequencing (performed by GATC Biotech AG; Konstanz, 
Germany) to verify the successful cloning.
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2.2.3 Analysis of hKPNA3 promoter activity in Huh-7 Cells
2.2.3.1 Routine cell culture
The Huh-7 human hepatocellular carcinoma cells were cultured in DMEM 
(4.5 g/L glucose, L-glutamine and without sodium pyruvate) with phenol red, 
supplemented with 10% FBS, 1% NEAA, and 100 U/mL penicillin/ 100 pg/mL 
streptomycin in 75-cm^ vented tissue culture flasks which were then incubated in 5% 
CO2 at 37°C. Cells were allowed to grow to about 80% confluene, and then passaged 
by trypsinization. Briefly, the medium was removed via aspiration and the cells were 
washed with 10 ml phosphate buffer saline (PBS). After aspiration, the cells were 
incubated with 3 ml of Ix trypsin-EDTA (PET) for 5 minutes at 37 °C. In order to 
inactivate and neutralise the trypsin-EDTA, 10 ml of complete media were added and 
split into new 75-cm^ vented tissue culture flasks. The exact ratio of splitting was 
dependent on experimental requirement, and varied between 1:2 to 1:6. The cells 
were routinely split until passage 20 to minimise the morphological changes that can 
occur following prolonged periods of culture.
A new cell batch was resuscitated from liquid nitrogen storages. Huh-7 cells 
were kept in liquid nitrogen in freezing medium (91% FBS and 9% DMSO) at a 
concentration 1x10^ cells/ml. Cells were resuscitated by quick thawing at 37 °C in 
water bath. After that 10 ml of warm medium was added to the cells, centrifuged at 
1000 g for 5 minutes, and resuspended in 10 ml warm medium. The cell suspension 
was transferred to a new 25-cm^ vented tissue culture flasks and incubated at 37 °C 
with 5% CO2 . The fresh medium was replaced after 24 hours incubation to remove 
DMSO and any non-adherent cells.
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2.2.5.2 Plasmid Transfection of Huh-7 Ceils
Cells were seeded the day before transfection into 96-well at a concentration 
2x10"^  cells/well and incubated at 37°C for 24 hours in a humidified container to 
prevent evaporation of cell culture medium. The container was incubated at 37 °C, 
5% CO] overnight for attachment of the cells to the plate surface. After that, 
transfection with the pSEAP2-human KPNA3 expression plasmid was carried out 
using FuGENE 6 transfection reagent, a multicomponent lipid-based transfection 
reagent which forms a complex with the DNA. In order to transport plasmid DNA 
into cell, the positive charge of cationic lipid must exceed the negative charge of 
DNA, thus a 3:1 ratio of FuGENE 6 to DNA were used for all transfection 
experiments. FuGENE 6 was added to DMEM containing no FBS according to 
manufacturer’s instructions. For co-transfection experiments, the 25 ng/well of the 
expression plasmids was added and equilibrated for 30 minutes before DMEM 
containing 10% charcoal stripped FBS was added. Medium was aspirated from each 
well and replaced with the stripped serum medium containing the FuGENE:DNA 
complexes. Then, the plate was returned to incubator in a humidified container and 
incubated at 37°C with 5% CO] for 24 hours
2.2.3.3 Treatment of Transfected Cells
After transfection the cells were cultured in stripped serum medium overnight. 
The medium was then removed and stored at -20°C as pre-dose for later secretory 
alkaline phosphatase (SEAP) assay. After that the cells were treated for 48 hours with 
following reagents as shown in Table 2-7. Stock solutions of compounds were 
prepared at 100 mM in corresponding solvent. Working solutions were prepared by 
diluting stock solutions 1:1000 in DMEM containing 10% (v/v) stripped serum FBS.
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Thus, the concentration of vehicle in the treatment was 0.1%, which had previously 
been shown to have minimal impact on cellular function for all vehicles used in this 
study. The cells were kept in a humidified container and incubated at 37°C with 5% 
CO2 for 48 hours. Then, the post-dose medium were removed and stored at -20°C for 
later SEAP activity measurement.
Table 2-7 Reagents used in treatment of transfected cells.
Reagent Solvent The range of concentration (jtiM)
Bezafibrate DMSO 0.01 -200
Clofibrate Ethanol 0.01-200
Fenofibrate DMSO 0.01-200
Lithocolic acid Ethanol 50
Palmitoyl Co A Water 50
Palmitate Ethanol 50
la, 25(0H)2D3 Ethanol 0.0001-0.3
a-tocopherol Ethanol 1-300
ascorbic acid Water 1-300
Hydrogen peroxide Water 0.1-100
Wy-14643 DMSO 0.01-200
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2.2.S.4 SEAP Reporter Activity Assay
The pSEAP2-basic vector contains a reporter gene for secreted alkaline 
phophatase (SEAP). When a regulatory region is cloned into the vector, SEAP 
expression is directly proportional to the activity of the cloned regulatory region. 
SEAP activity was measured using the Tropic® Phospha-Light™ System- 
Chemiluminescent reporter gene assay kit. Aliquots of cell culture medium were 
transferred to 96-well optiplates. Endogenous alkaline phosphatase activity was 
deactivated by heat treatment of the medium with buffer at 65°C for 30 min followed 
by rapid cooling on ice for 2 minutes. Assay buffer was then add to each well and 
incubated at room temperature for 5 minutes. The chemiluminescenct substrate was 
added and incubated for 20 minutes at room temperature. Chemiluminescent output 
was measured using a LumiCount automated plate reader (Packard Instrument Co. 
Inc., Ramsey, MN, USA) and was analysed using Plate Reader version 2.10 software. 
SEAP activity following 48 h culture was normalised with respect to pre-dose level 
(transfection control) and calculated as % of the expression of the vehicle control. 
The equation is shown below.
% SEAP activity of vehicle =_ Post-dose reading ^ 100
Pre-dose reading Mean normalized dose
reading of vehicle
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2.2.4 Lactate Dehydrogenase Assay
Cytotoxicity was identified by measurement the activity of enzyme lactate 
dehyrogenase (LDH) released due to plasma membrane damage by using an LDH 
assay kit (Roche). Cell supernatant 100 pL was taken and then transferred to a 96- 
well ELISA plate. This was then mixed with 100 pL reaction solution containing the 
LDH substrate and incubated, protected from light, at room temperature for 30 
minutes. After that the LDH activity was measured at 490 nm in an ELISA plate 
reader (BioTEK ELxSOO). Results were expressed as percentage of cell viability and 
compared to a vehicle control group.
2.2.5 Ceil culture and preparation of nuclear extracts
Huh-7 cells were seeded on 6-well plates (3x10^ cells/well) one day before 
transfection. 60 ng of pEF6/vs-VDR and pSG5-PPAR were transfected into cells 
using FuGENE 6 reagent. A 3:1 ratio of FuGENEiDNA was used in this study. After 
48 hr incubation, the cells were harvested and used for preparation of nuclear extracts 
according to the method of Dignam et al (1985). All steps were carried out at 4°C. 
The monolayer cell cultures were washed with 10 ml chilled PBS and trypsinised with 
5 ml PET. After 5 min incubation in the cell incubator, the cells were harvested, 
scraped, and collected in conical tubes. The cell lysates were then centrifuged for 5 
min at 1300 g and the supernatant was aspirated. The cell pellets were resuspended 
gently in 10 ml cold PBS and centrifuge for 5 min at 1300 g at 4°C. The hypotonic 
buffer A (10 mM HEPES-KOH pH 7.9, 1.5 mM MgCb, 10 mM KCl, and 0.5 mM 
DTT) was added to the cell pellets and the cells were allowed to swell on ice for 10 
min before the swollen cells were homogenized by 10 strokes in a Dounce 
homogenizer. The supernatant was aspirated after 15 min centrifugation at 2000 g at
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4°C. The pelleted nuclei were resuspened in 0.5 packed nuclear volume low-salt 
buffer C (20 mM Hepes/NaOH pH 7.9, 1.5 mM MgCli, 0.2 mM EDTA, 0.5 mM 
DTT, 25% glycerol, 20 mM NaCl and 1 mM PMSF). Clumps of nuclei were 
resuspended with one or two strokes in a Dounce homogenizer. Subsequently, 0.5 
volume high-salt buffer C (buffer containing 1.2 M NaCl) was added drop-wise with 
swirling. The suspensions were homogenized by 10 strokes and then centrifuged at 
16000xg for 30 min at 4°C, divided into aliquots, and stored at -80°C. The protein 
concentration was determined by the Lowry method (Lowry et al, 1951) using BSA as 
a standard.
2.2.6 Transcription and translation reaction (TnT reaction)
TnT reaction was employed to produce purified protein as a positive control in 
the electromobility shift assay (EMSA). A TNT® T7 Quick Coupled 
Transcription/Translation reactions kit for plasmid DNA was used. Briefly, 1 pg of 
plasmid DNA template, pSG5-PPARa were added to a mixture of 40 pi of TNT® 
Quick master mix and 1 pi of 1 mM methionine. Finally, nuclease-free water was 
added to a final volume of 50 pi. The reaction was incubated at 30 °C for 90 minutes 
before being stored at -  80 °C.
2.2.7 Electromobility shift assay (EMSA)
2.2.7.1 Annealing primers
The oligonucleotide probes containing wild type and mutated sites for PPRE, 
VDRE 1402, VDRE 1300, VDRE 739, and VDRE 237 are shown in Table 2-8. 
These probes were unlabelled or labelled with biotin at the 3 end. The mutant probes 
had nucleotide exchange within the core region of each binding site. For each site, a
55
duplex probe was formed by annealing two complementary oligonucleotides which 
one strand was labelled with biotin at the 3' end and that unlabelled duplexes were 
also generated for use as a competitor. The oligonucleotides were resuspended in Ix 
annealing buffer solution (10 mM Tris-HCl, 1 M NaCl, 10 mM EDTA). 1 nM each 
of a pair of complementary oligonucleotides were mixed together in 1.5 ml tube and 
placed in standard heat block at 90-95°C. After 5 min, the heat block was switched 
off and allowed to cool down to room temperature for 45-60 min. The annealed 
probes were removed, and stored at -20°C until use.
Table 2-8 Oligonucleotides used for EMSA.
Fragment name Wild type sequences (5 -3 ) Mutant sequence (5 -3 )
-PPRE caacactgggccacagtccagtatg caacactgggcTCTCAGcagtatg
-VDRE1402 tcacaaggtcaggaggtcgagacca tcacCTCgAGaggaTgtcgagacca
-VDRE1300 tgaagagatcaaaaaggacaatctt tgaagaCTCGaGaaaggacaatctt
-VDRE739 gtgggagtgctacacaggagagtct gtgggagtgctacacCTCGAagtct
-VDRE237 tatcaggaggaagagggcgggcctt tatcaggaggaCTCgAgTgggcctt
hoc-VDRE wt geeteactcaccgggt2 aac2 se 2 ctacatt
hAco-PPRE wt cttagaactagaaggtcactggtcaagcagccatttg
** Core sequences of putative nuclear receptor binding sites are underlined. 
The mutation sites are in capital letter.
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1.2.12 Gel electrophoresis of protein-DNA complexes
The DNA-protein interactions were carried out by using the Thermo Scientific 
Lightshift Chemiluminescent EMSA kit. Each biotin end-labelled DNA was 
incubated with 10 ng of nuclear protein or in vitro translated proteins for 20 min in a 
total volume of 25 ul binding buffer (100 mM Tris, 500 mM KCl, 10 mM DDT, 1 M 
KCl, 100 mM MgCl], 1 pg/pl poly (dl-dC) pH 7.5, 50% glycerol, and 1% NP-40). 
Osteocacin VDRE (hOC-VDRE) and acyl-coA oxidase PPRE binding sequences 
(hAco-PPRE) (Table 2-8) were used as positive control. The reaction mixtures were 
then loaded on to native 6% non-denaturing polyacrylamide gels (1 ml of 5x TBE, 1.5 
ml of 40% acrylamide, 0.8 ml of 2% bis-acrylamide, 250 pi of 100% glycerol, 150 pi 
of 10% ammonium persulfate, 10 pi of N,N,N’,N’-tetramethylethylenediamine, 
TEMED, and 6.3 ml of water). Protein species were separated at 100 v for 60 min in 
0.5 TBE (45 mM Tris, 45 mM boric acid, and 1 mM EDTA).
2.2.7.3 Identification of protein-DNA complexes
After that the protein-DNA complexes were transferred to the nylon 
membranes. Briefly, the gel and nylon membrane were sandwiched in electrophoretic 
transfer unit filled with cooled 0.5 TBE. Transfer was carried out at 300 mA for 120 
minutes. Then the membrane was placed with the bromophenol blue side up on a dry 
paper towel to allow buffer on the membrane surface absorbed into the membrane for 
1 minute. Next, transfer DNA was fixed to the membrane by cross-linking at 120 
mJ/cm^ using UV-light cross-linker instrument equipped with 254 nm bulbs for 60 
second. The membrane was blocked in 20 ml of blocking buffer and incubated for 15 
minutes with gentle shaking. The blocking buffer was replaced by adding 20 ml 
conjugate/blocking buffer solution (1:300 of Stabilized Streptavidin-Horseradish
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Peroxidase Conjugate to blocking buffer) and incubated for 15 minutes with gentle 
shaking. The membrane was washed four times for 5 minutes each in 20 ml Ix wash 
solution with gentle shaking. The biotin end labled DNA was detected using the 
chemiluminescent substrate working solution (1:1 of Luminol/Enhancer solution to 
Stable Peroxide solution. The membrane was incubated in the substrate solution for 5 
minutes with protecting from light. Finally, the membranes were analysed on X-ray 
film for 2-5 minutes. For the competition experiments, the pre-incubation reactions 
were performed in the present of unlabeled competitor DNA fragment at 0, 10, 30, 50, 
100, and 200 fold molar excess.
2.2.8 Total protein extraction
Huh-7 cells were seeded into 6-well plates at a concentration 3x10^ cells/well. 
After 24 hr, the cells were transfected with pTriEx 1.1 -hKPNA3 as following amount: 
50, 100, 500, and 1000 ng per well. As a control, cells were transfected with 
pTriExl.l vector. Total protein extraction from the transfected cells was performed 
after 48 hr incubation. The cell culture medium was removed and the transfected cell 
were washed twice with ice cold PBS. 2 ml of ice cold lysis buffer (IxPBS, 10% 
SDS, Igepal CA-630, 1 M DTT, and protease inhibitor cocktail) were added to the 
cells and incubated for 30 min on ice. Cell lysates were harvested by scraping, 
vigorously mixed and then passed through a 21G needle, washing down the flask 
while doing so. This was continued until no intact cells were visible under the 
microscope. The lysate was centrifuged for 10 min at 2000 rpm to remove large 
debris. The supernatants were collected and stored at -80°C until use for western blot.
58
2.2.9 Determination of protein concentration
This assay was performed according to Lowry (1951). The method is based 
on Biuret reaction, where the peptide bonds of proteins react with copper sulphate 
under alkaline conditions producing Cu^, which react with folin reagent. 150 pi of 
freshly mixed complex-forming reagent (2% NazCOg, 2% C4H4KNa0 6 , 1% 
CUSO4 5 H2O2 in the proportion 100:1:1, V:V:V) was mixed with 30 pi protein 
samples diluted with 0.5 M NaOH. After 10 min incubation, 15 pi of Ix Folin- 
Ciocalteau reagent were added, mixed immediately and incubated for 1 hr. The 
Folin-Ciocalteau reaction phosphomolylbdotungstate is reduced to heteropoly­
molybdenum blue by the copper catalyzed oxidation of aromatic amino acid. 
Absorption was measured at 490 nm.
2.2.10 Western blot analysis
2.2.10.1 Separation of protein by SDS-PAGE
Total protein samples (50 pg) were separated on 12.5% resolving gel (12.5% 
acrylamide, 0.3% bis-acrylamide, 0.375 M Tris-HCl pH 8.8, 0.1% SDS, 0.1% 
ammonium persulphate, and 0.01% TEMED) and 6% stacking SDS-polyacrylamide 
gel (6% acrylamide, 0.16% bis-acrylamide, 0.125 M Tris-HCl pH 6.8, 0.1% SDS, 
0.1% ammonium persulphate, and 0.02% TEMED) were used to separate protein 
samples. Before loading into the gel, protein samples were mixed with equal volume 
of loading dye (0.5 M Tris-HCl pH 6.8, 10% SDS, 10% glycerol, 0.7 M 
mercaptoehanol, and 0.05% pyronin Y) and denatured by heating at 98 °C for 5 
minutes followed by placing on ice for 2 minutes. Ten pi of Novex® Sharp 
molecular weight standard were run alongside the sample and used to compare the
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mass of the separated protein. The electrophoresis gel was carried out at 120 
milliamps for 60 minutes.
2.2.10.2 Detection of protein
The gels were transferred on to PVDF membranes at 300 milliamps for 120 
minutes in transfer buffer (25 mM Tris base, 0.2 M glycine, and 10% methanol; pH 
8.5. Subsequently, the membranes were blocked overnight with 10 ml of 10% semi­
skimmed milk in TEST buffer (137 mM NaCl, 20 mM Tris, pH 7.6, 0.1% Tween 20) 
and incubated for 1 h at room temperature with 10 ml of primary goat anti-KPNA3 
(1:1000 dilution, catalog no ab6038. Abeam ) antibody in 10% semi-skimmed milk 
TEST. After that the membranes were washed three times with TEST and then 
incubated with 10 ml of horseradish peroxidise-conjugated anti-goat IgG (1:10000 
dilution) in 10% semi-skimmed milk TEST. Finally, protein bands were visualized 
using enhanced chemiluminescence (ECL) western blotting detection reagent for 5 
minutes before being developed on film. Each experimental condition was repeated 
at least twice.
2.2.11 Immunofluorescence
Huh-7 cells were seeded on coverslips in 6 well plates at concentration 3x10^
cells/well for 24 hr. 500 and 1000 ng of pTriExl. 1-KPNA3 was cotransfected with
100 ng of fluorescent protein plasmids (pGFP-VDR, pGFP-PPARa) using FuGENE 6
as a transfection reagent (ratio 3:1 of FuGENE 6 to DNA). After 48 hr incubation, the
cells were washed three times with PBS and fixed with 4% formaldehyde in PBS at
room temperature for 1 hr. After that the cells were permeabilized using 0.25% Tritox-
XIOO in PBS for 10 min at room temperature. Coverslips were washed in PBS and non
specific sites were blocked with 2% skimmed milk in PBS overnight before the
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coverslips were incubated with anti-hKPNA3 rabbit polyclonal antibodies (1:500, 
catalog no. ab84706. Abeam). Subsequently, the cells were labelled with Alexa fluor 
350 goat anti-rabbit secondary antibodies (1:10000) for 3 hr. The cells were then 
washed five times with PBS. Finally, the cells were stained with propidium iodide (PI) 
for 10 min at room temperature. Three additional washes with PBS were performed 
and the coverslips were mounted onto slides using Vectashield® mounting medium for 
nucleus stained with PI solution.
2.2.12 Data Analysis and Statistics
All values are expressed as the mean + standard error of the mean (SEM). 
Statistical significance between groups was determined using one-way ANOVA with 
Bonferronipost-hoc analysis (GraphPad Prism Software version 5.0, San Diego, CA, 
USA). The number of biological repeats is indicated in each figure and each 
experiment was performed on at least two independent occasions.
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3. IN  SILICO PROMOTER ANALYSIS AND REGULATION OF HUMAN 
KPNA 3 EXPRESSION BY NUCLEAR RECEPTOR ACTIVATORS IN 
Huh-7 CELLS
3.1. Introduction
KPNA3 genes encode a soluble protein that mediates the transport of 
macromolecules into the nucleus, a central function of eukaryotic cell regulation. In 
addition, these proteins have been implicated in a number of human diseases, 
including schizophrenia, alzheimer’s disease, and cancer, as well as some of the 
hantaviruses, influenza A and HIV nucleoprotein infection (Wang et al. 2004). To 
date, no information is available on human KPNA3 gene regulation, especially at the 
transcriptional level. Therefore, this research was initiated to understand 
transcriptional control of human KPNA3 gene expression which is central for 
understanding its function, mechanism of disease and therapeutic approaches.
Transcriptional regulation of the human KPNA3 gene was investigated using 
in silico promoter analysis. These methods have been employed in many biological 
studies (El-Sankary et al. 2000; Parent et al. 2002; Holt et al. 2007) and are highly 
efficient, consuming relatively little time and representing an inexpensive method to 
initially identify regulatory regions of specific genes. The likely regulatory region of 
the human KPNA3 promoter was firstly determined by looking for conservation 
upstream of the KPNA3 transcription start site. Following this, putative transcription 
factor binding sites were indentified based on their sequence (section 3.3). The human 
KPNA3 proximal promoter region was then cloned into a reporter gene plasmid, 
expressed in a human hepatoma cell line (Huh-7), and reporter activity measured
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following exposure to ligands for the nuclear receptors predicted to bind to the human 
KPNA3 promoter.
3.2 KPNA3 promoter conservation between mammals
A promoter is a sequence that initiates and regulates the gene transcription and 
is typically located upstream the gene it regulates. In order to understand KPNA3 
gene regulation, the 20 kb upstream of the human KPNA 3 gene was extracted from 
the National Center for Biotechnology Information database 
thttp://www.ncbi.nlm.nih.gov/nuccore/NW 925473.1 ?&from=31063620&to=311572 
12&report=genbank&strand=truel and aligned with orthologues from rat and mouse 
using Vista analysis tool (http://genome.lbl.gov/vista/mvista/submit.shtml). This 
computational tool is based on alignment strategies and graph visualization techniques 
for rapid identification of conserved sequences among species (Frazer et al. 2004; 
Dubchak and Ryaboy 2006); the rational in this case being that important regulatory 
regions are likely to be more highly conserved than the surrounding DNA.
As shown in Figure 3-1, the highest identity regions which respect to upstream 
of transcription start site are between 18 kb to 20 kb (>50% identity) which are 
defined as conserved non-coding sequences (pink regions). These regions were 
therefore identified as being most likely to contain the KPNA3 regulatory elements. 
Only this conserved sequence was then used in the binding site search.
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Figure 3.1 The regulation region of KPN A3 was identified by Vista alignment of 
human, rat, and mouse using human as the reference sequence to reveal the 
evolutionary conserved region among species. Y-axis represents percent of identity 
among species. X-axis represents base pair position of 20 kb immediately upstream 
of the first exon of KPNA3 gene. The colourings above the plot show the annotation 
of the region: green boxes are short interspersed sequence elements (SINEs), maroon 
boxes are LINE repeats, magenta boxes are long terminal repeats (LTR), yellow 
boxes indicate location of tandem repeats. The pink regions in the peak graph are 
conserved non-coding sequences (CNS).
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3.3. Putative transcription factors binding sites in the human KPNA3 
proximal promoter.
The 2 kb immediately 5' to the putative transcription start site of hKPNAS 
gene (region 18-20 kb on the VISTA plot) was identified from the National Centre for 
Biotechnology Information database. Next, the Matlnspector library (Matrix family 
library version 6.3) was used as the to examine the human KPNA3 promoter analysis 
(http://www.genomatix.de/matinspector.html). This technique was used to predict 
transcriptional factor binding sites by using a large library of weight matrix, the DNA 
binding profile of transcriptional factor (Cartharius et al. 2005). This program 
categorizes transcription factor binding sites into matrix families and has the largest 
library available for public search when compared to other programs such as Match, 
TRANSFAC 8.4, and ConSite.
Putative nuclear receptor binding sites were determined by using two 
parameters; matrix similarity, which is the quality of a match between all bases in the 
matrix, and the input sequences and core similarity, which is the quality of a match 
between the core sequences of the matrix and the input sequences. A high match 
between matrix and input sequence that was considered by using a matrix and core 
similarity score greater than 0.70 and 0.80, respectively. This strategy minimises the 
false positives and therefore, putative transcription factor binding sites have a high 
probability of representing functional sites.
Initially, a total of 304 putative transcription factor binding sites were 
identified in -2 kb human KPNA3 proximal promoter. Based on the introduction of 
high similarity to both core and matrix thresholds combined with transcription factors 
known to be nuclear receptors reduced the number of total matches to 32 (10%). The
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remaining 32 matches were subsequently refined to 7 binding sites for nuclear 
receptors known to be expressed in the liver. These putative nuclear receptor binding 
sites are shown in Table 3-1.
Table 3-1 Searching nuclear receptor binding sites in the human KPNA3 
promoter
NR Core
Similarity
Matrix
Similarity
Sequence*
PPARa, DRl 0.807 0.783 caacactgggccACAGtccagta
HNF4a, DRl (F837 0.916 aacactgggcCACAgtccagtatga
VDR1402, DR3 1.000 0.801 tcacaaGGTCaggaggtcgagacca
VDR1300, DR3 0.821 0.862 tgaagaG AT Caaaaaggacaatctt
VDR739, DR5 0.937 0.753 gtgggagtgctacacAGGAgagtct
CAR, DR4 0.805 0.770 ttgggGGGCatgtaaatacagggac
VDR237, DR3 1.000 0.876 tatcaggaggaaGAGGgcgggcctt
*Upper case letters in the sequence represent core element of binding site.
Figure 6 shows a representation of potential nuclear receptor binding sites
within the 2000 base pairs fragment of the human KPNA3 proximal promoter
upstream of transcription start site. Each box represents approximate positions of
identified putative DNA/protein interaction sites which include PPARa recognition
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site at nucleotide position -1875 to -1853; HNF4a site at position -1867 to -1843; four 
VDR sites at positions -1426 to -1402, -1324 to -1300, -763 to -739, -237 to -261; 
and recognition site for CAR at nucleotide position -667 to -643. These nuclear 
receptor binding sites are likely candidates for regulating KPNA3 gene expression in 
human liver.
VDR VDR 
1102 13R0
VDRVDR
Figure 3-2. Schematic of putative nuclear factor binding sites. Human KPNA3 
proximal promoter (-2 kb) was analyzed for putative transcription factor binding sites 
by running Matlnspector search engine. The putative transcription factor binding site 
is shown as box and their locations are indicated in number.
3.4 Cloning of hKPNA3 proximal promoter into pSEAP2-basic reporter 
gene
Identification of putative nuclear factor binding sites by in silico analysis in 
the previous chapter provides the basis for an investigative hypothesis. However, it 
does not form the basis for proven molecular mechanism of action. Therefore, the -2
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kb proximal promoter of human KPNA3 gene regulation was cloned into a reporter 
gene plasmid (pSEAP2-basic) and investigated by in vitro analysis.
The human KPNA3 promoter region was amplified from genomic DNA using 
a proof-reading DNA polymerase enzyme and primers that contained Acc651 and Bg/ 
II restriction sites (5’ and 3’ primers respectively). The polymerase chain reaction 
selectively and rapidly amplified the promoter sequence to large amount. 
Subsequently, the PCR products were separated on 1% agarose gel electrophoresis. A 
2 kb fragment probably corresponding to the human KPNA3 proximal promoter was 
identified by comparing the size of the amplified band to a molecular weight standard 
(Figure 3-3A).
A) B)
2.3
800
Figure 3-3. Gel electrophoresis of 2 kb hKPNA3 proximal promoter. A) PCR 
products were separated on 1% agarose gel. The correct 2 kb bands are seen in each 
lane (1-4) which represent four samples from the same condition indicated in 
Methods. B) 2 kb fragment was isolated and extracted from other PCR products 
using a crystal violet gel. M=molecular weight markers (values are size of bands in 
kilobases)
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The 2 kb fragment was isolated (Figure 3-3B), and cloned into the pSEAP2- 
basic reporter vector. pSEAP2-basic contains several important elements (Figure 3- 
4): the first one is a multiple cloning site immediately upstream of the Secretory 
Alkaline Phosphatase (SEAP) reporter gene into which putative promoters can be 
inserted. A drug resistant gene destroys antibiotics, in this case ampicillin, to allow 
selective growth of the host bacterial cell during cloning while the replication origin 
to allow the plasmids to replicate in bacteria.
SEAPS'a
SEAPS'b \  MCS
W /
5' seq primer' 
Transcription blocker
SEAP reporter gene
pSEAP2-Basic
4677 bp
ampicillin.
SV40 polyA
Figure 3-4. pSEAP2-basic vector map. pSEAP2-basie contains three important 
elements; the multiple cloning site (MCS) where the foreign DNA fragment can be 
inserted, a ampicillin resistant gene destroys antibiotics, and the replication origin to 
allow the plasmids to replicate in host cell.
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In order to insert -2 kb KPNA3 proximal promoter into vectors, firstly, the 
PCR products and the vectors were digested with Acc65 I and Bgl II. The digested 
PCR products were ligated into pSEAP2-basic vector and the resulting recombinant 
plasmids were transformed into DH5a E.coli cells. Plasmids were isolated and 
purified using the Qiagen Miniprep kit and the correct plasmid was confirmed and 
screened by three restriction enzymes, EcoR I, Nco I and Bgl I, which cut both the 
vector and insert asymmetrically. The products were checked in the agarose gel 
(Figure 3-5B). Fragment size was determined by comparison to a molecular weight 
marker, and compared to the predicted digest of pSEAP2-hKPNA3 plasmid given by 
Vector NTI 10 (Figure 3-5A). Finally, the recombinant plasmids were further 
confirmed by sequencing to ensure that no mutation had been incorporated during the 
cloning process.
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A)
SEAPS'a 
SEAPS'b' 
S' seq  primer 
Transcription b iocker_
ampiciilin
Bfffl(5l 46)
EcdRl (.246)
pSEAP2-hKPNA3 2kb
6690 bp
BgR(.944)
hKPNAS promoter
W ed (10 67)
SV40 polyA
Boil {1982}
BccR I(208 i )
W ed (2353)
SEAP reporter gene
W ed (30 92)
B)
Figure 3-5. Diagnostic restriction digest of pSEAP2-human KPNA3 plasmids. A) 
Plasmid map of pSEAP2-basic reporter vector containing the -2 kb human KPNA3 
proximal promoter insertion with restriction sites marked on it. B) The plasmids were 
digested with ECoR 1 (lane 1, predicted fragment sizes 4.9 kb and 1.8 kb), Nco I (lane 
2, predicted fragment sizes 4.7 kb, 1.3 kb, and 739), and Bgl I (lane 3, predieted 
fragment sizes 3.2 kb, 1.26 kb, 1.22 and 1.1 kb). M=molecular weight markers 
(values are size of bands in kilobases)
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3.5 The effect o f nuclear receptor activators on human KPNA3 expression 
in Huh-7 cells transfected with pSEAP2-human KPNA3 plasmids.
The liver is the largest organ in the human body and has many functions, 
including both endogenous metabolic pathways and the detoxification of drugs and 
xenobiotics. Therefore, a vast variety of macromolecules, drugs, and toxins go 
through and reside in the hepatocytes. In order to control and provide self-protection 
in hepatocytes, the nuclear receptor superfamily plays a major role in this mechanism 
(Karpen 2002). The regulation of nuclear receptors is controlled by the action of 
nuclear receptor ligands. Previous work from this laboratory demonstrated that 
KPNA expression levels are significantly changed by liver growth agents that 
function as nuclear receptor ligands (Plant et al. 2006). Based on this rationale, liver 
cells were selected for examining KPNA3 gene regulation by nuclear receptor 
ligands.
In vitro cultured cell lines are regularly used to investigate gene regulation 
because they provide a relatively stable and uniform population. A human hepatoma 
cell line (Huh-7) maintains many of the differentiated function of liver cells in vivo. 
Furthermore, the gene expression profile is rather stable under culture conditions, thus 
they providing a good model to study the regulatory mechanisms of gene expression 
(Nakabayashi et al. 1982). Huh-7 cells have been used with reporter gene technology 
to assess the regulatory mechanism of many genes sueh as CYP3A4, PXR, hepcidin, 
and glucokinase (El-Sankary et al. 2000; Aouabdi et al. 2006; Swagell et al. 2007; 
Matak et al. 2009). Huh-7 cells express low levels of some nuclear receptors such as 
CAR, and PXR, however over-expression of individual nuclear receptors is a 
common method for delaminating the transcription regulation (Phillips et al. 2005).
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Furthermore, basal expression of HNF4a and the heterodimeric partner RXR shows 
high correlation with in vivo expression (Phillips et al. 2005).
In the following experiments the pSEAP2-human KPNA3 plasmid was 
transiently co-transfected with corresponding nuclear receptors plasmids into Huh7 
cells and treated with specific ligands in order to determine the effect on KPNA3 
expression.
3.5.1 Regulation of human KPNA3 expression by CAR activator
Phénobarbital (PB) is a classical activator of the CAR pathway (Honkakoski et 
al. 1998; Kawamoto et al. 1999). To examine whether PB-mediated CAR 
transcriptional regulation of human KPNA3 proximal promoter, the human KPNA3 
reporter gene constructs were co-transfected into Huh-7 cells with an expression 
plasmid for CAR. The results demonstrated that PB had no significant effect on 
SEAP activity in Huh-7 cells when compared to vehicle control (Figure 3-6). This 
result suggests that CAR had no effect on the transcriptional activity of human 
KPNA3 expression by PB.
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Figure 3-6. The effect of CAR activator on human KPNA3 expression. pSEAP2- 
human KPNA3 reporter gene constructs (25 ng) were co-transfected with 25 ng 
pCR3-CAR expression plasmid into Huh-7 cells. After 24 hours, the pre-dose media 
was collected and the cells were treated with 0.1% water (vehicle control) or 50 pM 
phénobarbital. The post-dose media was collected after 48 hours later. The level of 
expression was evaluated by measuring the luminescence from SEAP reporter gene 
products. Data was normalized with the pre-dose and expressed as % of control. 
Data were analyzed by unpaired t-test and represent as average + SEM (error bars), 
N=5. Administration of PB resulted in no effect of human KPNA3 expression when 
compared to vehicle control.
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3.5.2 Regulation of human KPNA3 expression by HNF4a activators
HNF4« is a tissue-specific transcription factor known to regulate a large 
number of genes in hepatocytes (Lucas et al. 2005). The proposed HNF4« ligands, 
acyl CoA thioesters, have been identified (Bogan et al. 2000). Moreover, saturated 
fatty acids such as palmitate have previously been showed to activate HNF4a (Roth et 
al. 2002). In the present study, pamitoyl CoA (50 pM) used in biosynthesis of cell 
membrane lipid and palmitate (50 pM) the major component of palm oil and the first 
product of lipogenesis, were used to assess ligand-dependent regulation of human 
KPNA3 expression by HNF4a.
Huh-7 cells were transiently co-transfected with an expression plasmid for 
HNF4« along with SEAP reporter construct containing regions of the human KPN A3 
proximal promoter (-2 kb), and assayed for SEAP reporter gene assay. As shown in 
Figure 3-7, the level of human KPNA3 expression was not significantly altered by 
pamitoyl CoA and palmitate administration when compare to vehicle control. This 
suggests that the putative HNF4a element in human KPNA3 proximal promoter 
construct may not a functional site for human KPNA3 regulation by palmitoyl CoA 
and palmitate.
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Figure 3-7. The effect of HNF4a activators on human KPNA3 expression. pSEAP2- 
hKPNA3 reporter gene constructs (25 ng) were co-transfected with pEF6vs-His 
HNF4a expression plasmid (25 ng) into Huh-7 cells. After 24 hours, the pre-dose 
media was collected and the cells were treated with 0.1% water or ethanol (vehicle 
control) or 50 pM palmitoyl CoA or 50 pM palmitate. The post-dose media was 
collected after 48 hours later. The level of expression was evaluated by measuring the 
luminescence from SEAP reporter gene products. Data was normalized with the pre­
dose and expressed as % of control. Data were analyzed by one-way ANOVA with 
Bonferroni post-hoc test and represent as average + SEM (error bars), N=5. 
Administration of palmitoyl CoA and palmitate resulted in no effeet of human 
KPNA3 expression when compared to vehicle control.
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3.5.3 Regulation of human KPNA3 expression by PPARa activators
PPARa is highly expressed in liver, heart, and muscles where it regulates gene 
expression (Sonoda et al. 2008). PPARa agonists were identified including, the 
fibrate-class of anti-hyperlipidemic drug and peroxisome proliferators (Lefebvre et al. 
2006). In order to determine the effect of PPARa on human KPNA3 expression, Wy-
14,643 (a peroxisome proliferator), fenofibrate, bezafibrate and clofibrate (fibrate- 
drug) were used as ligands for PPARa. SEAP assays were performed after 48 h 
dosing with each individual agonist or solvent control in Huh-7 cells.
As shown in Figure 3-8, Wy-14,643, bezafibrate, and fenofibrate significantly 
decrease the expression of human KPNA3 reporter constructs, reducing expression to 
approximately 68%, 54%, and 59% of vehicle control levels respectively (P<0.0001). 
In contrast, no significant difference was detected upon exposure to clofibrate. These 
results suggested that Wy-14,643, bezafibrate, and fenofibrate might play a role in 
human KPNA3 transcription regulation through PPARa binding sites.
To ensure that the observed decrease was due to a transcriptional effect, and 
not decreased cell number through toxicity, the effect of Wy-14,643, fenofibrate, and 
bezafibrate on cell death was also measured using lactate dehydrogenase assay as a 
marker of cell death. LDH was not significantly increased after administration of 
Wy-14,643, fenofibrate, and bezafibrate when compared to vehicle control (Figure 3- 
9) , demonstrating that the inhibition observed was mediated via the KPNA3 promoter 
rather than being a consequence of cell death.
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Figure 3-8. The effect of PPARa activators on human KPNA3 expression. pSEAP2- 
hKPNAS reporter gene constructs (25 ng) were co-transfeeted with pCR3-PPARa 
expression plasmid (25 ng) into Huh-7 cells. After 24 hours, the pre-dose media was 
collected and the cells were treated with 0.1% DMSO or ethanol (vehicle control) or 
50 pM of PPARa activators. The post-dose media was collected after 48 hours later. 
The level of expression was evaluated by measuring the luminescence from SEAP 
reporter gene products. Data was normalized with the pre-dose and expressed as % of 
control. Data were analyzed by one-way ANOVA with Bonferroni post-hoe test and 
represent as average + SEM (error bars), ***P<0.0001, N=5.
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Figure 3-9. The effect of Wy-14,643 on cell viability. pSEAP2-hKPNA3 reporter 
gene constructs (25 ng) were co-transfected with pCR3-PPARa expression plasmid 
(25 ng) into Huh-7 cells. After 24 hours, the cells were treated with 0.1% DMSO or 
ethanol (vehicle control) or 50 pM of PPARa activators. The media was collected 
after 48 hours later to perform LDH assay. Data was subtracted with assay medium 
(background control) and expressed as percentage of cell viability. All results 
represent the means + SEM (N=5). Data were analyzed by one-way ANOVA with 
Bonferroni post-hoe test and represent as average + SEM (error bars), N=5.
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To further examine the inhibition profile of the human KPNA3 reporter gene 
construct by Wy-14643, fenofibrate, and bezafibrate, Huh-7 cells were co-transfeeted 
with pSEAP2-hKPNA3 reporter gene constructs and pCR3-PPARa. Then the cells 
were treated with 0.01-200 pM Wy-14643, fenofibrate, and bezafibrate. The 
promoter activity was determined 48 h later by assessing the concentration of SEAP 
reporter gene assay (Figure 3-10). In all cases, down-regulation of human KPNA3 
expression was observed in dose dependent manner. The half maximum inhibitory 
concentration, IC50, for Wy-14643, fenofibrate, and bezafibrate were 0.9 + 2.12 pM, 
37.6 + 2.20 pM, and 48.8 ±1 .7  pM, respectively. The half maximum inhibition of 
Wy-14643 is lower than fenofibrate and bezafibrate, respectively, indicating that Wy- 
14643 is the most potent inhibitor for human KPNA3 expression than that of 
fenofibrate and bezafibrate, respectively. These suggest that the PPARa element in 
human KPNA3 proximal promoter construct may be involved in human KPNA3 
regulation by Wy-14643, fenofibrate, and bezafibrate with different efficiencies.
Once again, the effect of Wy-14,643, fenofibrate, and bezafibrate on cell death 
was also measured using lactate dehydrogenase assay as a marker of cell death. LDH 
was not significantly increased after administration of Wy-14,643, fenofibrate, and 
bezafibrate when compared to vehicle control (Figure 3-11), which demonstrates that 
the inhibition observed was mediated via the KPNA3 promoter rather than being a 
consequence of cell death.
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Figure 3-10. Dose-response 
curve of hKPNA3 expression 
by Wy-14,643 (A), fenofibrate 
(B), and bezafibrate (C). Huh- 
7 cells transfected with human 
KPNA3 reporter constructs 
were exposed to 0.01-200 pM 
of PPARa agonist or 0.1% 
DMSO as vehicle eontrol. The 
level of inhibition was 
measured by SEAP reporter 
gene assay and is expressed as 
% of control. The data were 
analysed using non-linear 
regression. All results 
represent the means + SEM 
(N=5). The IC50 for Wy- 
14643, fenofibrate, and 
bezafibrate were 0.9 + 2.12 
pM, 37.6 + 2.20 pM, and 48.8 
+ 1.7 pM, respeetively.
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Figure 3-11. The effect of Wy-
14,643 (A), fenofibrate (B), and 
bezafibrate (C) on cell viability. 
Huh-7 cells transfeeted with 
human KPNA3 reporter 
constructs were exposed to 
0.01-200 pM of PPARa agonist 
or 0.1% DMSO as vehiele 
control. The media was 
eolleeted after 48 hours later to 
perform LDH assay. Data was 
subtraeted with assay medium 
(baekground eontrol) and 
expressed as percentage of eell 
viability. All results represent 
the means + SEM (N=5). Data 
were analyzed by one-way 
ANOVA with Bonferroni post­
hoe test and represent as 
average + SEM (error bars), 
N=5.
B ezafibrate (uM )
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3.5.4 Regulation of human KPNA3 expression by VDR activators
VDR is principally involved in calcium mineral metabolism, although the 
receptor regulates a variety of other metabolic pathways, such as those involved in the 
immune response and cancer. The most biologically active vitamin D3 metabolite, 
la,25(OH)2D3, mediates its genomic effects via the VDR with high affinity (7Q=10 
nM) (Carlberg and Scuter 2007). VDR also functions as a receptor for the secondary 
bile acid lithocholic acid. In order to determine the effect of VDR ligands on human 
KPNA3 expression, both la,25(OH)2D3 and lithocholic acid were used to treat Huh-7 
cells co-transfeeted with the pSEAP2-hKPNA3 plasmid and a VDR expression 
plasmid (pEF6 /vs-VDR). SEAP assays were performed 48 h after la , 25(OH)2D3 (50 
pM) or lithoeholie acid (50 pM) administration.
It was found that lithocholic acid showed no significant different when 
compared to the vehicle control. This might be due to lithocholic acid is hydrophilic 
bile acid which may be in poorly absorbed into the Huh-7 eell (Makishima et al. 
2002). However, la , 25(OH)2D3, which is more potent than lithocholic acid 
(Makishima et al. 2002; Nehring et al. 2007), strongly depressed the expression of 
human KPNA3 reporter gene construct about 94% when compared to the vehiele 
control (P<0.001) (Figure 3-12) without any effect on eell death (Figure 3-13). This 
result suggest that the inhibition of human KPNA3 expression here was due to an 
effect of la, 25(OH)2D3 rather than an effect of cell death.
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Figure 3-12. The effect of VDR activators on human KPNA3 expression. pSEAP2- 
hKPNA3 reporter gene constructs (25 ng) were co-transfeeted with pEF6/vs-His VDR 
expression plasmid (25 ng) into Huh-7 cells. After 24 hours, the pre-dose media was 
eolleeted and the cells were treated with 0.1% ethanol (vehicle eontrol) or 50 pM of 
la , 25(0H)2D3 or lithocholic acid. The post-dose media was collected after 48 hours 
later. The level of expression was evaluated by measuring the luminescence from 
SEAP reporter gene products. Post- dose data was normalized with the pre-dose and 
expressed as % of control. Data were analyzed by one-way ANOVA with Bonferroni 
post-hoc test and are represented as average ± SEM (error bars), ***f <0.0001, N=5.
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Figure 3-13. The effect of la , 25(OH)2D3 on viability. pSEAP2-hKPNA3 reporter 
gene constructs (25 ng) were co-transfected with pEF6/vs-His VDR expression 
plasmid (25 ng) into Huh-7 cells. After 24 hours, the cells were treated with 0.1% 
ethanol (vehicle control) or 50 pM of la , 25(OH)2D3. The media was collected after 
48 hours later to perform LDH assay. Data was subtraeted with assay medium 
(baekground control) and expressed as percentage of eell viability. All results 
represent the means + SEM (N=5). Data were analyzed by pared t-test and are 
represented as average + SEM (error bars), N=5.
85
Based on the previous results, which used a very high dose of la , 25(OH)2D3, 
a lower dose-response eurve for la , 25(OH)2D3 was generated (0.1-300 nM). The 
SEAP reporter gene assays were performed after 48 h post treatment (Figure 3-14A, 
3-14B). Interestingly, KPNA3 expression levels were increased in a dose-dependent 
manner at low doses (0.1, 0.3, 1, 3, 10 nM) with an EC50 of 3.14 + 1.97 nM (Figure 3- 
14A), whereas higher dose treatments 20, 30, 50, 70, 100, 300 nM resulted in an 
inhibition of human KPNA3 expression in a dose dependent manner with an of EC50
48.2 + 1.20 nM (Figure 3-14B). These suggest that VDR-mediated control of human 
KPNA3 gene expression is complex, demonstrating both positive and negative 
aspects.
No eell death was observed in all la , 25(OH)2D3 treated cells suggesting that 
the SEAP reporter gene expression was due to up and down regulation of the KPNA3 
promoter rather than due to cytotoxicity (Figure 3-15).
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Figure 3-14. Dose-response 
curve of hKPNA3 expression 
by a low dose of la , 
25(0H)2D3 (A) and a high 
dose of la , 25(OH)2Ds (B). All 
data points are shown in (C). 
Huh-7 cells transfeeted with 
human KPNA3 reporter 
constructs were exposed to a 
low dose of la , 25(OH)2D3 0.1, 
0.3, 1,3, 10 nM (A) and a high 
dose of la , 25(OH)2D3 20, 30, 
50, 70, 100, 300 nM (B) or 
0.1% ethanol as vehicle 
control. The level of inhibition 
was measured by SEAP 
reporter gene assay and is 
expressed as % of control. The 
data were analysed using non­
linear regression. All results 
represent the means + SEM 
(N=5). The ECso for a low 
dose and high dose were 3.14 + 
1.97 nM and 48.2 + 1.20 nM, 
respectively.
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Figure 3-15. The effect of la , 25(OH)2Ü3 on cell viability. pSEAP2-hKPNA3 
reporter gene constructs (50 ng) were transfeeted into Huh-7 cells. After 24 hours, the 
pre-dose media was eolleeted and the cells were treated with 0.1% ethanol (vehicle 
eontrol) or 0.01-300 nM of la , 25(OH)2D3. The media was eolleeted after 48 hours 
later to perform LDH assay. Data was subtraeted with assay medium (background 
control) and expressed as percentage of eell viability. All results represent the means 
+ SEM (N=5). Data were analyzed by one-way ANOVA with Bonferroni post-hoe 
test and are represented as average + SEM (error bars), N=5.
3.6 Discussion
Even though many studies have reported the cell and tissue specific 
expression of KPNA genes (Plant et al. 2006; Umegaki et al. 2007), little information 
has been described to date upon how the KPNA genes themselves are regulated. Holt 
et al (2007) did in silico promoter analysis of KPNA gene in the mouse testis and 
found that putative transcription factor binding sites of different KPNA genes showed 
tissue specific expression patterns. However they were interested only the 
transcription factors that are involved in spermatogenesis but not nuclear receptors, 
therefore this is the first report to study the putative nuclear receptor binding sites 
within the human KPNA3 proximal promoter.
3.6.1 In silico promoter analysis of human KPNA3 proximal promoter
According to the in silico promoter analysis, the 2 kb immediately upstream of 
the putative transcription start site was identified as a conserved region between 
human, rat, and mouse (Figure 3-1). Analysis of this region identified multiple 
putative nuclear factor binding sites include PPARa, HNF4a, CAR, and VDR (Figure 
3-2). In this report, I will focus on transcription regulation by CAR, HNF4 a, PPARa, 
and VDR as the putative transcription factors binding sites found in KPNA3 proximal 
promoter.
3.6.1.1 The role of CAR in gene regulation
The constitutive androstane receptor (CAR) is the nuclear receptor subfamily 
I, group I, member 3 (NRH3). It plays an important role in transcription activation of 
multiple xenobiobite and endobiotie (steroid and thyroid hormones, bilirubin, and bile 
acids) metabolizing enzymes and transporters in the liver. CAR up-regulates a set of 
genes in phase I and 11 drug-metabolism enzymes including, CYP2B, 2C, and 3A, and
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uridine 5'di-phosphate (UDP)-glucuronosyltransferase lA l and eytosolic 
sulfotransferase 2A1, and glutathione S-transferase in response to phénobarbital 
(Ferguson et al. 2002; Goodwin et al. 2002; Ueda et al. 2002). In addition to these 
metabolizing enzymes, CAR also up-regulates drug transporters such as Mrp2 and 
Mrp 4 (Huang et al. 2003; Assem et al. 2004).
Prior to its exposure to ligand, CAR is retained in the cytoplasm as a complex 
with heat shock protein 90 and the cytoplasmic CAR retention protein (Kawamoto et 
al. 1999; Kobayashi et al. 2003). Following treatment with phénobarbital, CAR is 
activated by dephosphorylation of the C-terminal region and is translocated into the 
nucleus (Zelko et al. 2001). CAR forms a heterodimer with retinoid X receptor in 
nucleus and binds to the PB-responsive enhancer module (PBREM), a DR4 type 
element located in the promoters of CAR target genes such as CYP3A, CYP2C, and 
UDP-bilirubin glueuronosyltransferase (UGTlAl) (Swales and Negishi 2004). Two 
co-aetivators, the steroid receptor co-activator 1 (SRC-1) and the peroxisome 
proliferator-activated receptor y co-aetivator-la enhance the transcription of CAR 
target genes (Min et al. 2002).
The inverse agonists of CAR include the testosterone metabolites 5a-androst- 
16-en-3a-ol (androstanol) and 5a-androst-16-en-3a-ol (androstenol) (Forman et al.
1998). These compounds suppress the constitutive activity of CAR in vitro by 
interfering with the interaction between CAR and SRC-1. The direct agonists of CAR 
show speeies-specifieity for example 4-bis[2-(3,5 dichloropyridyloxy)]benzene 
(TCPOBOP) is a direct agonist of mouse CAR (Tzameli et al. 2000) whereas 6-(4- 
chlorophenyl)imidazo[2,1 -6][l,3]thiazole-5-carbaldehydeO-(3,4- 
diehlorobenzyl)oxime (CITCO) is a selective ligand for human CAR (Maglich et al. 
2003). The mechanism of CAR activation can be divided into two different
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pathways, the direct ligand-dependent and the ligand-independent pathway (Li and 
Wang 2010). Nevertheless, the majority of CAR activators, such as phénobarbital, 
efavirenz, phenytoin, and carbamazepine, do not bind directly to CAR, resulting in 
target gene activation via the ligand-independent pathway (Kodama and Negishi 
2006). Recently, two CAR antagonists, clozapine (CLZ) and PK11195, a 
mitochondrial benzodiazepine receptor ligand have been reported (Moore et al. 2000; 
Li et al. 2008). CLZ exhibits high binding affinity to human CAR in vitro however 
this effect is yet to be verified in vivo. PKl 195 has been identified as a selective and 
potent inhibitor of human CAR. It inhibits the activity of human CAR by 85% in 
HepG2 cell whereas CLZ inhibits by 50% in CV-1 and HepG2 cell.
3.6.1.2 The role of HNF4a in gene regulation
The hepatic nuclear factor 4 alpha HNF4a (nuclear receptor subfamily 2, 
group A, member 1; NR2A1), plays an important role in liver development. HNF4a 
is also present in pancreatic islets, kidney, intestine, and stomach (Nakhei et al. 1998). 
Like other steroid/thyroid hormone receptors, HNF4a binds DNA as homodimer but 
binds predominantly to DRl elements (Tirona et al. 2003). Endogenous ligands for 
HNF4a are fatty acids and related molecules (Dhe-Paganon et al. 2002) however, the 
mechanism of nuclear transloeation of HNF4a and its ligands has remained almost 
unknown. Recently, Deblois et al used chromatin immunoprécipitation (ChlP)-based 
approaches to identify a large number of HNF4a binding sites in genes that are 
actively transcribed in human liver and pancreatic islets (Odoms et al. 2004; Deblois 
and Giguere 2008); these results correlate with the central role of HNF4a in these 
organs. For example, HNF4a is involved in glucose homeostasis, especially in 
gluconeogenesis (Rhee et al. 2003), and disruption of the HNF4a gene in pancreatic
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p-cells leads to impaired insulin secretion (Gupta et al. 2004), as reported for HNF4a- 
assoeiated non-insulin-dependent diabetes mellitus MODYl in humans (Yamagata et 
al. 1996; Taghavi et al. 2009). Extra-panereatie abnormalities have been reported in 
maturity-onset of diabetes of the young type 1 (MODYl) patients showing low 
plasmatic triglyceride, apoAIl and apoCIII levels, most probably due to hepatoeyte 
defects (Lausen et al. 2000). Moreover, HNF4a is required for embryogenesis and 
organogenesis such that absence of HNF4a is embryonic lethal (Parviz et al. 2003). 
HNF4ot is necessary for metabolic functions in liver and for proper insulin secretion in 
the pancreas.
In addition to its role in carbohydrate and lipid metabolism, HNF4a has been 
associated with drug metabolizing enzyme expression by direct activation of CYP 
promoters or regulating expression of other nuclear receptors which in turn regulate 
CYP gene expression (Plant and Aouabdi 2009). For example, HNF4a activates PXR 
and CAR mediated transcriptional activation of CYP3A4 (Tirona et al. 2003). In this 
case, HNF4a binds to a regulatory element within the CYP3A4 promoter and induces 
PXR and CAR mediated transcription of CYP3A4. Furthermore, HNF4a also 
regulates expression of other nuclear receptor such as HNFla, PXR, and CAR 
(Kamiya et al. 2003; Odom et al. 2004; Ding et al. 2006). These interactions indicate 
the master role of HNF4a in nuclear receptor regulatory network.
3.6.1.3 The role of PPARa in gene regulation
The peroxisome proliferator activator receptor (PPARa) is nuclear receptor 
subfamily 1, group C, (NRICI). Three PPAR isoforms exist in higher species; 
PPARa, PPARp/5, and PPARy, which are encoded by separate genes and have unique 
tissue distribution patterns (Cullingford et al. 1998; Nuclear receptor nomemclature
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committee 1999). However, this report will focus on PPARa which play an important 
roles in hepatic lipid metabolism (Francis et al. 2003). PPARa is predominantly 
expressed in liver, but it is found to be significantly expressed in adipose tissue, 
intestine, kidney, skeletal muscle, and heart (Mukherjee et al. 1994). PPARa shows 
significant species differences in tissue distribution; human livers contain lower 
PPARa nuclear binding activity than in mouse livers. In order to activate gene 
expression, PPARa binds to RXR and the heterodimer binds to PPAR response 
elements (PPREs), preferentially at DRl or DR2 in the regulatory regions of genes 
(Kliewer et al. 1992). PPARa resides predominantly in the nucleus; in the absence of 
ligand binding, PPARa-RXR heterodimers are bound to co-repressor proteins such as 
histone deaeytylases (HDACs) and nuclear co-repressor (N-CoRs) that maintain the 
chromatin in the condensed state and inhibit transcription. Upon ligand binding, 
PPARa-RXR dissociates the co-repressor proteins and then forms complex with eo- 
aetivator proteins such as p300 leading to transcription regulation of target gene 
promoters (reviewed in reference (Miehalik et al. 2006).
PPARa can be activated either by natural ligands such as eicosanoids, mono- 
and polyunsaturated fatty acids, and long-ehain fatty aeyl-CoenzymcA or by synthetic 
ligands such as phthalates, and hypolipidaemie fibrate drugs which lower triglyceride 
and cholesterol levels (Francis et al. 2003). In addition to fibrates, high affinity 
PPARa ligands include 4-ehloro-6-(2,3-xylidino)-2-pyrimidinylthio acetic acid (Wy- 
14643) and GW-7643 as human PPARa agonists. Interestingly, the peroxisome 
proliferators show species-specific activation of PPARa, causing increased cell 
proliferation and liver tumours in rodents but not humans (Holden and Tugwood
1999). The mechanisms of action that have been proposed to date include oxidative 
stress, activation of NF-A:B and production of tumour necrotic factor- a, alteration in
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cell proliferation and a decrease in apoptosis (Peters et al. 2000). However, these 
species differences might be due to the lower levels of PPARa in humans compared 
to rodents, where human PPARa activation increases fatty acid oxidation but not 
peroxisome proliferation (Plant et al. 2009).
A large number of PPARa target genes have been identified many of which 
are involved in lipid metabolism and bile acid synthesis (Qi et al. 2000). The lipid 
oxidizing genes include AeylCoA oxidase (ACO-OX), acyl CoA synthase, HMG 
CoA synthase, medium chain aeyl CoA dehydrogenase and genes involved in 
oxidation of triglyceride such as lipoprotein lipase are positively regulated by PPARa. 
In addition, genes involved in hepatic lipogenesis and phospholipid transport (MDR2, 
ABCB4) are also activated by PPARa (Karpen 2002). In contrast, a number of genes 
are inhibited by PPARa; these include apoprotein AI, apoprotein C3, and CYP7AI, 
the first step in bile acid synthesis (Hertz et al. 1995; Vu-Dac et al. 1998; Gbaguidi 
and Agellon 2004).
Taken together, PPARa regulates genes which play a major role in lipid 
metabolism; therefore mediating the effects of fibrates in increasing high density 
lipoprotein synthesis, fatty acid uptake, decreased triglyceride, and fatty acid 
synthesis (Karpen 2002). However, the regulation of PPARa in other genes such as 
nuclear transport genes in response to PPARa ligands has not been established.
3.6.1.4 The role of VDR in gene regulation
The vitamin D receptor (VDR) is nuclear receptor subfamily I, group I, 
member I (NRHl). In addition to playing a major role in calcium homeostasis, VDR 
also exhibits important roles in epidermal differentiation, differentiation and growth 
of a number of malignant cells, immune system function, the cardiovascular system.
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muscle, brain, reproduction, adipocytes function, bile acid, and xenobiotie metabolism 
( reviewed in Bouillon et al. 2008). It has been reported that VDR is expressed in 
nearly all cells or tissues at variable concentration however, red blood cell, mature 
striated muscle and some highly differentiated brain cells {e.g. Purkinje cells of the 
cerebellum) have low or absent VDR expression (Eyles et al. 2005). As described in 
the introduction, VDR exhibits cell- and tissue-speeifie intracellular localization being 
mainly localized in the cytoplasm in absence of VDR ligand in the HL-60 
promyeloeytic leukemia cells, ROS 17/2.8 cells (Klopot et al. 2007), COS-7 cells 
(Raez et al. 1999) but predominantly in the nucleus of human brain (Eyles et al. 
2005).
The most biological active ligand of VDR is I a,25-dihydroxyvitamin D3 
[Ia,25(OH2)D3]. However, it has also been reported that VDR also responds with 
bile acids especially lithocholic acid by direct binding and activated gene expression 
(Adaehi et al. 2005). Even though, VDR can either form homodimers or heterodimers 
with RXR, the VDR-RXR heterodimers are more physiological important (Gocek et 
al. 2007). Upon Ia,25(OH2)D3 binding, VDR-RXR heterodimers bind to vitamin D 
response element (VDRE), which comprised of two hexanucleotide half-sides 
separated by a short space (DR3, DR5) located within two kilobases upstream of the 
transcriptional start site (Kim et al. 2006). In silico analysis of -2 kb human KPNA3 
promoter in this study also found three putative DR3 and one DR5 element. The 
presence of multiple VDRE sites has also been reported in many genes such as the 
human RANKL and cyclin C genes that contain up to five VDREs with equivalent 
behaviour (Sinkkonen et al 2005, Kim et al 2006) and three distal VDREs were 
identified in the VDR gene (Deblois et al 2008). The chromatin immunoprécipitation 
analysis shows that the VDR-RXR complex binds to different VDREs in cyclic waves
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(Meyer et al. 2006). However, it is important to note that the regulation of gene 
expression by VDR is not directly binding to VDREs elements. Rather, the VDR- 
RXR heterodimer recruits eo-regulatory protein complexes that are essential to alter 
gene transcription (Pike et al. 2007).
VDR not only activates gene expression but also inhibits the transcription of 
some target genes. The genes that are up-regulated by VDR in the presence of ligands 
such as la,25(OH2)D3 include RANKL and osteocalcin gene in osteoblastic cells, and 
the genes involved transcellular calcium transport such as transient receptor potential 
vanilloid type 6 (TRPV6), and the calcium binding protein, ealbindin-D9k,(Kemer et 
al. 1989; Song et al. 2003; Christakos et al. 2007). Down-regulated genes include 
parathyroid hormone (PTH), parathyroid hormone related peptide (PTHrP), interlukin 
2, interlukin 17, and interferon y (Alroy et al. 1995; Koszewski et al. 2004; Bouillon 
et al. 2008; Margolis and Christakos 2010). Taken together this demonstrates that 
la,25(OH2)D3 and VDR appear to be involved in a variety of cellular functions 
including growth regulation, membrane transport, metabolism, apoptosis, and 
oxidative stress.
In summary, in silico promoter analysis was the crucial first step in 
understanding human KPNA3 gene regulation. However, these predicted nuclear 
receptor binding sites may not actually be functional in a biological cell context. 
Further investigations were performed in the next experiments to biologically validate 
the functional significance of the nuclear receptor binding sites within human KPNA3 
promoter in the liver.
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3.6.2 Regulation of human KPNA3 expression in response to nuclear
receptor activators
Putative NR binding elements CAR, HNF4a, PPARa, and four VDR sites 
were identified by in silico analysis and it was hypothesized that they were involved 
in hKPNA gene regulation. Therefore, these experiments were designed to test the 
hypothesis using in vitro activation assays. All putative response elements found in -2 
kb hKPNAS proximal promoter were cloned into SEAP reporter gene construct. 
Activating ligands NRs were chosen according to the effects that have been shown to 
be mediated by these nuclear receptors. The activation assay was used to test the 
functional potency of a compound to activate putative NR binding sites. The assay 
measured the expression of a reporter gene which is driven by a promoter responsive 
to the specific binding of the transcription factor. In this ease CAR, HNF4a, PPARa, 
and VDR are ligand dependent transcription factors, so molecules that bind to these 
NRs would activate the expression of the reporter gene.
3.6.2.1 The effect of human KPNA3 expression by phénobarbital
The observation from the in vitro study showed that the expression of human 
KPNA3 was not altered by phénobarbital which is believed to be a CAR activator 
(Figure 3-6). However, CAR remains to be established as a true signal mediating 
phénobarbital induction (Honkakoski et al. 1998; Kawamoto et al. 1999; Sueyoshi et 
al. 1999). Previous studies showed that 50 pM phénobarbital induced expression of 
various genes such as CYP2B6, CYP2BI0 mediated by CAR. In contrast, this study 
demonstrated that 50 pM phénobarbital had no effect on KPNA3 gene expression. 
This would suggest that the putative CAR response element is not a functional site in 
the regulation of hKPNA3 gene expression.
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3.6.2.2 The effect of human KPNA3 expression by palmitoyl CoA, and 
palmitate
In addition to phénobarbital, palmitoyl CoA and palmitate, HNF4a ligands, 
failed to significantly alter hKPNAB gene expression. This might be due to a 
proposed traditional ligand, fatty aeyl CoA thioesters may not a good candidate for 
HNF4a since it binds poorly to HNF4a (Bogan et al. 2000). However, palmitate 
which has previously been showed to regulate many genes such as hepatic 
glueokinase, L-pyruvate kinase mediated by HNF4a activity (Roth et al. 2002) also 
failed to alter hKPNAS gene expression. This result correlated with the study from 
Swagell et al (2005) who investigated the change in gene expression after 48 hr 
treated with palmitate in Huh-7 cells and observed no change in KPNA3 gene 
expression using microarray analysis. Thus, this might suggest that the putative 
HNF4a element in the hKPNAS promoter is not functional site.
3.6.2.3 The effect of hKPNA3 expression by Wy-14643, fenofibrate, 
bezafibrate and clofibrate
The fibrate-elass of anti-hyperlipidemic drugs or peroxisome proliferators 
show most potent PPARa activation. Wy-14643 is selective PPARa ligand that has 
been used extensively as an experimental tool (Kliewer et al. 1999; Willson et al. 
2000; Carroll and Severson 2001). In this study the fibrate drugs fenofibrate, 
bezafibrate, and clofibrate were also used as PPARa ligands for comparison with Wy- 
14643. Significant down-regulation of human KPN A3 expression was observed after 
48 h treatment with Wy-14,643; however, this result differed from previous study by 
Plant et al (2006) that Wy-14,643 showed a significant induction of KPNA3 in 
isolated primary hepatoeytes. This might be due to difference in the experimental
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technique sinee the current study used transfected Huh-7 cells where as previous work 
was carried out in rat liver and isolated primary hepatoeytes. However the present 
study might also suggests the speeies specific expression of KPNA3 by xenobiotics.
In addition to Wy-14,643, human KPNA3 expression was also inhibited by 
fenofibrate, and bezafibrate (Figure 3-8). However, the structurally and 
pharmacologically similar compounds, clofibrate showed no effect in the reporter 
gene assay (Figure 3-9). The reason for this is unclear. It could be due to the dose 
was not high enough or due to different gene regulation by different drugs. It is 
possible that when different ligands bind to PPARa they induce slightly different 
changes in conformation, which attracts a different set of regulator proteins, and 
alters the target gene set transcribed. For example bezafibrate significantly 
suppressed SREBP-IC gene expression in mice, whereas neither fenofibrate nor 
clofibrate had the same effect (Nakajima et al. 2009). In contrast, fenofibrate alone 
induced hepatic transaminase gene expression in rats (Kobayashi et al. 2009). 
Therefore, it could be possible that bezafibrate, clofibrate, and fenofibrate activate 
transcription of different transcription factors and thereby have different effects on the 
reporter genes.
The dose-response curves of Wy-14643, fenofibrate, and bezafibrate were also 
characterised, and it has been found that the human KPNA3 expression was 
significantly inhibited by these ligands in the dose-dependent manner without any 
effect on eell death (Figure 3-11). The IC50 for Wy-14643, fenofibrate, and 
bezafibrate were 0.9 + 2.12 pM, 37.6 + 2.20 pM, and 48.8 + 1.7 pM, respeetively. 
The IC50 values observed in this study are in general agreement with previous 
estimates of the affinity of hPPARa for these three compounds: the EC50 for Wy-
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1463, fenofibrate, and bezafibrate were 0.3-1 pM, 30 pM, and 50 pM (Willson et al. 
2000; Winegar et al. 2001; Shipley et al. 2004). This result indicates that Wy-14643 
is more potent activator PPARa when compared to fenofibrate and bezafibrate which 
are low-affinity ligands for PPARa. The observation that Wy-14643, fenofibrate, and 
bezafibrate had an inhibition effect on hKPNA3 gene expression suggests that the 
putative PPARa element in pSEAP-hKPNA3 gene construct plays a major role for 
KPNA3 gene regulation by these ligands. Further study is required to elucidate this 
mechanism of action and will be described in chapter 4.
3.6.2.4 hKPNA3 expression by la , 25(OH)2D3 and lithocholic acid
Human KPNA3 expression was also drastically inhibited by 50 pM la, 
25(0H)2Ü3 treatment in Huh-7 cells (Figure 3-12) without any apparent effect on cell 
death (Figure 3-13). However the dose used in this pilot study was very high; sinee 
la, 25(0H)2D3 has a high affinity for VDR (Xd=10 nM) (Carlberg et al. 2007), such a 
concentration would be supersaturating at the receptor, and may elicit non-specific 
effects. Thus, lower doses (0.1-300 nM) were also tested in Huh-7 cells. It was found 
that at 0.1-10 nM la , 25(OH)2D3 induced hKPNA3 gene expression in a dose 
dependent manner (Figure 3-13A), whereas treatment dose above its Kd (20-300 nM) 
of la , 25(0H)2D3 strongly depressed hKPNA3 gene expression in a dose dependent 
manner (Figure 3-13B). Further study is required to elucidate this mechanism of 
action and will be described in chapter 5. Taken together, this study suggests that the 
putative VDR binding elements in pSEAP2-hKPNA3 promoter construct play an 
important role in KPNA3 gene regulation by la , 25(OH)2D3.
Interestingly, different ligands for the same nuclear receptor show different 
effects on KPNA3 gene expression. For example PPARa ligands, Wy-14,643 inhibits 
human KPNA3 gene expression but no significant effect was observed in elofibrate-
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treated Huh-7 cells. In addition, la , 25(OH)2Ds represses human KPNA3 gene 
transcript whereas the expression is not altered by lithocholic acid which is also VDR 
ligand. This might not only indicate the xenobiotics specificity of KPNA gene 
expression, but also suggests that individual properties of the compounds have an 
effect on gene expression such as the hydrophilic characteristic of lithocholic acid 
which prevents its transport into the eell and then no effect is observed (Makishima et 
al. 2002).
3.7 Summary
The regulatory region 2 kb upstream of transcription start site of human 
KPNA3 and putative nuclear receptor response elements (CAR, HNF4a, PPARa, and 
four VDRs) were identified by in silico analysis. The functional sites were further 
confirmed by in vitro experiments. These data have suggested the presence of one 
PPARa and four VDR binding sites in human KPNA3 proximal promoter that are 
likely to be involved in regulation of KPNA3 gene expression; these present a 
potential underlying control mechanism for many biological processes through the 
control of KPNA cargo proteins into nucleus, hence altering their biological activity 
in eell.
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4. REGULATION OF hKPNA3 EXPRESSION BY PPARa AND  
OXIDATIVE STRESS INDUCER
4.1 Introduction
The previous chapter identified of a number of putative nuclear receptors 
binding sites in hKPNA3 proximal promoter. These assignments were investigated in 
vitro using a hKPNA3 proximal promoter reporter gene construct exposed to classical 
ligands for those nuclear receptors. In particular, treatment with a variety of PPARa 
ligands resulted in the repression of hKPNA3 reporter gene expression and provided 
evidence that the PPARa may contribute to hKPNA3 gene regulation. Therefore, the 
work described in this chapter sets out to further confirm the functionality of putative 
PPARa binding sites in hKPNA3 proximal promoter region. This was investigated by 
generating a promoter deletion series, site directed mutagenesis, and electromobility 
shift assay in order to identify functional elements that contribute to regulation of 
hKPNA3 gene expression by PPARa ligands.
My approach to ablating the putative PPRE element was two-fold: firstly I 
used PCR and restriction enzymes to delete sequences upstream of and including the 
putative PPRE from the hKPNA3 promoter. Secondly, I introduced point mutations 
into the PPRE binding site within the -2 kb hKPNA3 proximal promoter. In addition, 
the putative PPRE site was further confirmed by characterization of a direct protein 
DNA interaction between a nuclear protein extract from Huh-7 cells and the PPRE 
response element.
In addition to examining the role of the PPRE in regulating the human KPNA3 
gene, I also investigated the potential for regulation by oxidative stress. It has been
102
reported that activation of PPARa by peroxisome proliferators induces oxidative 
stress in cells, and that this may be important in hepatocellular carcinomas observed 
in rats and mice (Peters et al. 1997). The mechanisms by which peroxisome 
proliferators produce change in oxidative stress include: the induction of lipid 
oxidation, oxidative DNA damage, and changes in the expression of genes such as 
fatty acyl coA oxidase and cytochrome P450 4A enzyme that finally produce 
hydrogen peroxide and superoxide anion, respectively (O'Brien et al. 2005; Glauert et 
al. 2008). Although there is little clear evidence for high levels of peroxisome 
proliferation or hepatomegaly in humans, I was interested to examine whether other 
oxidative stress inducing agents could also affect hKPNA3 gene regulation, which 
could represent a novel cellular mechanism in response to oxidative stress.
4.2 The effect of PPRE deletion on hKPNA3 expression
4.2.1 Generation of PPRE promoter deletion construct
Figure 4-1A illustrates schematic diagrams of a deletion construct in which 
located its deletion PPRE in the pSEAP-basic vector backbone. The sizes of the 
deletion fragments and important putative nuclear receptor binding sites which are 
present are also shown in the diagrams. The plasmid generated was confirmed as 
containing the proximal 1.7 kb of the human KPNA3 gene, thereby excluding the 
putative PPRE. It is important to note that the overlap between HNF4a and PPARa 
regulatory sequences which meant it was impossible to delete independently from the 
promoter, thus both sites were removed in order to investigate the functional PPRE 
binding site.
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The putative PPRE element was removed from the -2 kb full length hKPNA3 
proximal promoter by PCR using forward primer which hybridized to the region 
immediately downstream of the PPRE in combination with the reverse primer 
previously used to generate the -2 kb promoter fragment. Subsequently, the resulting 
PCR products were separated on 1% agarose gel electrophoresis and the correct PCR 
product of 1.7 kb was identified by comparing the size of the amplified band to a 
molecular weight standard as shown in Figure 4-IB.
The PPRE promoter deletion fragment was subsequently digested and inserted 
into the pSEAP2-basic vector. The correct plasmid was confirmed and screened by 
diagnostic digest using restriction enzymes that cut both the vector and insert 
asymmetrically (Figure 4-1C). Finally, the recombinant plasmids were further 
confirmed by sequencing to ensure that no mutation had been incorporated during the 
cloning process.
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Figure 4-1. A) The PPRE deletion construct of hKPNA3 proximal promoter. The -
1.7 kb deletion fragment was cloned into pSEAP-basic reporter vector. As a result, 
the deletion construct differs in size because of the lack of the putative PPRE binding 
element. Each box represents putative nuclear receptor binding site with its name 
located above. B) Gel electrophoresis of the PPRE deletion fragment. The correct
1.7 kb band is seen in lane 1. C) Diagnostic digest of 1.7 kb deletion plasmid 
constructs. The 1.7 kb plasmid was digested with Bgl U/Sph 1 (lane 1; predicted 
fragment sizes 5.3 kb, and 1.1 kb), Nco 1 (lane 2; predicted fragment sizes 4.34 kb, 1.3 
kb, and 760 bp), Bgl UIHph 1 (lane 3; predicted fragment sizes 4.65 kb and 1.75 kb) 
and Acc65 VBgl 11 (lane 4; predicted fragment sizes 4.7 kb and 1.7 kb ). 
M=molecular weight markers (values are size of bands in kilobases)
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4.2.2 Reporter gene analysis of the PPRE deletion construct in response to 
Wy-14643, fenofibrate, and bezafibrate in Huh-7 cells.
Reporter gene analysis in the previous chapter demonstrated that full length (- 
2 kb) hKPNAS proximal promoter is down regulated by PPARa ligands namely Wy- 
14643, fenofibrate and bezafibrate, in a dose-dependent manner with IC50 values of 
0.9 + 2.12 pM, 37.6 + 2.20 pM, and 48.8 ±1.7 pM, respectively. This study aimed to 
test whether the inhibition of hKPNA3 expression by Wy-14,643, bezafibrate, and 
fenofibrate is mediated through the putative PPARa binding element at position -1875 
to -1843. The PPRE deletion construct was transiently transfected into Huh-7 cells 
for 24 hr after which the cells were treated with 1 pM Wy-14643 and 50 pM of 
bezafibrate and fenofibrate, approximating the the IC50 value for each compound.
After 48 hr exposure, Wy-14643, fenofibrate, and bezafibrate significantly 
inhibited full length reporter gene constructs (-2 kb) by approximately 50% as 
previously demonstrated (Figure 4-2). In contrast, no inhibition of reporter gene 
activity was observed after Wy-14643, fenofibrate, and bezafibrate administration in 
Huh-7 cell transfected with the -1.7 kb PPRE deletion construct (Figure 4-2). These 
results are consistent with the putative PPRE element in the -2 kb full length construct 
being important for the regulation of hKPNA3 gene expression by Wy-14643, 
fenofibrate, and bezafibrate.
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Figure 4-2. Promoter activity of the hKPNAS 1.7 kb deletion construct in response to 
Wy-14643, fenofibrate and bezafibrate. pSEAP2-hKPNA3 deletion constructs (25 
ng) were co-transfected with pCR3-PPARa expression plasmid (25 ng) into Huh-7 
cells. After 24 hours, the pre-dose media was collected and the cells were treated 
with 0.1% DMSO (vehicle control) or 1 pM Wy-14643, 50 pM fenofibrate, 50 pM 
bezafibrate. The post-dose media was collected after 48 hours later. The level of 
expression was evaluated by measuring the luminescence from SEAP reporter gene 
products. Data was normalized with the pre-dose and expressed as % of the vehicle 
control for each plasmid. Data were analyzed by two-way ANOVA with Bonferroni 
post-hoc test and represent as average + SEM (error bars), *P<0.05, N=5.
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4.3 The effect o f site directed mutagenesis of the PPRE element on
hKPNAS expression
4.3.1 Generation of putative PPRE mutant construct
While the experiments described above are suggestive that the putative PPRE 
at position -1875 to -1843 in the human KPNA3 promoter mediates the repression 
observed in response to PPARa ligands, this result is not unequivocal because a 
number of other putative binding sites were also deleted in this construct. In order to 
further define the precise position of the PPARa responsive element, site specific 
mutation of the PPRE binding sequences was accomplished by PCR-based method as 
described in Materials and methods. The wild type PPRE response element 
(caacactgggccACAGtccagta) was mutated by site directed mutagenesis to change the 
most highly conserved (uppercase) and neighbouring bases (cACAtc) which finally 
produce the mutated PPRE recognition sequence (caacactgggctÇTÇGagcagta; bold 
indicates mutated bases). In addition, this mutation introduced a Xho I restriction site 
(underlined) which is unique within the hKPNA3 promoter, and can be used for 
selection of mutated sub-clones.
Using a forward primer which hybridises upstream of the multiple cloning site 
of pSEAP2-basic in combination with a reverse primer which hybridises to and 
mutates the PPRE as described above the distal region of the human KPNA3 
promoter was amplified from my original -2 kb construct. In a similar way the 
proximal region was amplified using a mutagenic forward primer hybridising to the 
putative PPRE and a reverse primer downstream of the multiple cloning site. These 
two PCR products therefore overlap at mutation region and were identified in 1% 
agarose gel electrophoresis as shown in Figure 4-3B. Thereafter, the two PCR
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fragments were digested with Xho I and ligated together before the ligation product 
was used as a template for a second round of PCR using nested primer. The resulting 
-2 kb proximal promoter fragment containing a mutated PPRE was separated on 1% 
gel electrophoresis as shown in Figure 4-3C.
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Figure 4-3. A diagram illustrating the method of PCR is shown in A. Gel 
electrophoresis of PPRE mutagenesis in hKPNAS proximal promoter region. The 
correct proximal (lanes 1 and 2; expected size 2.01 kb) and distal PCR products (lane 
3; expected size 669 bp) are shown in B. The correct 2 kb full length band containing 
mutant PPRE site was digested with restriction enzyme, Acc65 I and Bgl II and 
separated in 1% gel electrophoresis is shown in C. M=moleciiiar weight markers 
(values are size of bands in kilobases)
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The full length PCR products containing the mutated PPRE were digested 
with enzymes Acc65 1 and Bgl II, ligated into pSEAP2-basic vector cut with the same 
enzymes and transformed into DH5a E.coli cells. Recombinants were screened by 
diagnostic digests using restriction enzymes that cut both the vector and insert 
asymmetrically (Figure 4-4). Finally, the recombinant plasmids were further 
confirmed by sequencing to assure that the required mutation had been incorporated 
and no unwanted mutation during the cloning process.
Figure 4-4. Diagnostic digest of PPRE mutation plasmid constructs. The PPRE 
mutant plasmids were digested with EcoR 1 (lane 1 ; predicted fragment sizes 4.9 kb 
and 1.8 kb), ATzo MScal 1 (lane 2; predicted fragment sizes 3.6 kb and 3.1 bp), and Kpn 
MHpa 1 (lane 3; predicted fragment sizes 3.7 kb and 3 kb). M=molecular weight 
markers (values are size of bands in kilobase).
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4.3.2 Reporter gene analysis of PPRE site directed mutagenesis plasmid 
constructs in response to Wy-14643, fenofibrate, and bezafibrate in Huh-7 cells
The PPRE mutant construct generated as described above was transiently 
transfected into Huh-7 cells for 24 hr after which the cells were treated with PPARa 
ligands at the doses used previously. As can be seen in Figure 4-5, Wy-14643, 
fenofibrate, and bezafibrate significantly inhibited the expression of hKPNA3 in -2 kb 
wild type proximal promoter; however, these effects were no longer seen in PPRE 
mutant construct. These finding further confirm that PPARa binding site is indeed 
central to the ability of Wy-14643, fenofibrate, and bezafibrate to suppress hKPNA3 
expression.
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Figure 4-5 Promoter activity of PPRE mutant constructs in response to Wy-14643, 
fenofibrate and bezafibrate. pSEAP2-hKPNA3 deletion constructs (25 ng) were co­
transfected with pCR3-PPARa expression plasmid (25 ng) into Huh-7 cells. After 24 
hours, the pre-dose media was collected and the cells were treated with 0.1% DMSO 
(vehicle control) or 1 pM Wy-14643, 50 pM fenofibrate, 50 pM bezafibrate. The 
post-dose media was collected after 48 hours later. The level of expression was 
evaluated by measuring the luminescence from SEAP reporter gene products. Data 
was normalized with the pre-dose and expressed as % of the vehicle control for each 
plasmid. Data were analyzed by two-way ANOVA with Bonferroni post-hoc test and 
represent as average + SEM (error bars), *P<0.05, N=5.
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4.4 Characterization of protein-DNA interactions of the human KPNA3 
putative PPRE
The results of my promoter deletion and site directed mutagenesis experiments 
demonstrate the obligate role of the PPRE within the human KPNA3 promoter 
mediate the repression in expression by Wy-14643, fenofibrate, and bezafibrate. To 
further support this finding, I characterized protein-DNA interactions at the hKPNA3- 
PPRE site using electrophoretic mobility shift assay (EMSA) to further confirm that 
this PPRE is a functional site that is able to form a complex with PPARa protein. 
Double stranded oligonucleotides corresponding to putative PPRE (wt-PPRE) within 
human KPNA3 proximal promoter, a mutant PPRE with six base pairs change 
corresponding to those introduced in the site directed mutagenesis experiment 
described above (mt-PPRE), and a control oligonucleotide corresponding to the 
previously described PPRE of acyl CoA oxidase (Aco-PPRE) (Rodriguez et al. 2000) 
were used for these studies. These oligonucleotides were labelled with biotin at the 3' 
end of the sense strand and used as probes to look for evidence of protein binding.
Nuclear protein extracted from naive Huh7 cells, or cells transfected with a 
PPARa expression plasmid (pGS5-PPARa), were incubated with labelled wt-PPRE 
oligonucleotide probe. Three protein-DNA complexes were evident by the presence 
of a shift band compared with free probe alone (Figure 4-6A, compare lanes 2 and 3 
to lane 1). The specificity of the binding reaction was evaluated by competition with 
a 100 molar excess of unlabelled wt-PPRE; the intensity of the higher molecular 
weight (X) band complex was abolished while the lower molecular weight (Y) 
complex was reduced substantially by presence of unlabelled wt-PPRE probe in the
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binding reaction (lane 4). However, only a single band with the same apparent 
molecular weight as the Y complex was formed after incubation of in vitro 
synthesized PPARa (generated by TNT reaction) with human KPNA3 PPRE 
sequence (compare lanes 6 and lane 2). These results suggest that complex Y may 
represent the specific binding between PPARa and PPRE of hKPNA3 proximal 
promote whereas the X complex may represent binding of another endogenous 
nuclear protein to this PPRE region. The human Aco-PPRE, which is known to bind 
PPARa (Rodriguez et al. 2000) was used as positive control probe to compare the 
mobility of the complexes (Figure 4-6 lane 5; Aco-PPRE). The PPARa containing 
complex of the hKPNA3 gene demonstrated slower mobility than the respective 
complex of the Aco gene PPARa. This might be due to the difference in 
transcriptional complex composition such as co-activator or co-suppresser.
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Figure 4-6. PPARa binding to the hKPNAS PPRE. EMSA was performed using 
nuclear protein extracted from naive Huh-7 cells or from Huh-7 cells transfected with 
a PPARa expression plasmid (pCR3-PPARa) or with PPARa synthesized in vitro by 
TNT reaction. The wild type hKPNAS PPRE (wt-PPRE) was incubated in the 
absence (lane 1) or presence (lanes 2-4 and 6) of protein while the acyl CoA PPRE 
(Aco-PPRE, lane 5) provided a positive control. In lane 4 unlabelled oligonucleotide 
competitor (wt-PPRE) was also added to the binding reaction at a concentration equal 
to 100 fold molar excess that of probe. The protein-DNA complexes were resolved 
on a 6% non-denaturing polyacylamide gel: two protein-DNA complexes (X and Y) 
are indicated as well as the free probe. The presence of a band at the top of the gel 
was not taken into account because it was not completed out by unlabelled wt-PPRE 
(lane 4).
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In contrast to the result shown for wt-PPRE probe, no specific band shift was 
observed after incubation of nuclear protein extract from Huh-7 cells or in vitro 
translated PPARa with the mutant human KPNA3 PPRE oligonucleotide probe 
(Figure 4-7). This further demonstrates the specificity of binding as well as proving 
that the mutations introduced into the human KPNA3 PPRE were sufficient to 
completely ablate PPARa binding and thereby supporting the results of the analysis of 
the PPRE site directed mutant clone set out in section 4.3.2.
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Figure 4-7. Ablation of the hKPNAS PPRE site abolished PPARa binding. EMSA 
was performed using nuclear protein extracted from naive Huh-7 cells or from Huh-7 
cells transfected with a PPARa expression plasmid (pCR3-PPARa) or with PPARa 
synthesized in vitro by TNT reaction. The mutant human KPN A3 PPRE (mt-PPRE) 
was incubated in the absence (lane 1) or presence (lanes 2-4) of protein while an 
unlabelled oligonucleotide competitor (mt-PPRE) was also added to the binding 
reaction at a concentration equal to 100 fold molar excess that of probe. The protein- 
DNA complexes were resolved on a 6% non-denaturing polyacylamide gehand the 
free probe is indicated. No specific protein-DNA interaction observes at a mutant 
PPRE response element (lane 2-4).
Taken together, these results demonstrate that inhibition of the human KPN A3 
gene in response to treatment with Wy-14643, fenofibrate, and bezafibrate occurs 
through a direct mechanism involving binding of the PPARa to the PPRE DRl 
response element present within the -2 kb proximal promoter region of human 
KPN A 3 gene.
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4.5 The effect of oxidative stress inducing agents on human KPNA3 gene
regulation
As mentioned earlier, peroxisome proliferators such as Wy-14,643, clofibrate 
and bezafibrate are known to significantly induce hydrogen peroxide formation and 
cause oxidative stress to the cell (Soliman et al. 1997; Qu et al. 2001). By re­
examining the in silico analysis for regulatory elements, I identified one nuclear factor 
erythroid 2-related factor 2 (Nrf2), anti-oxidant responsive element within the -2 kb 
proximal promoter region of hKPNA3 gene: ccgcgcgCGCGCgggtcccgg (the capital 
letters represent the core sequence) located at position -50 to -30 bp. A matrix and 
core similarity score were 0.904 and 1.000, respectively. As this could provide an 
indirect mechanism by which the peroxisome proliferators might repress KPNA3 
expression, in parallel to the experiments described above. I also examined the effect 
of other oxidative stress inducing agents on the regulation of human KPNA3.
Hydrogen peroxide (H2O2) is widely used as a classical oxidative stress 
inducing agent and was used in the current study along with the anti-oxidants vitamin 
C and vitamin E to assess the role of oxidative stress in regulating the pSEAP2 - 
hKPNA3 proximal promoter reporter gene construct. Furthermore, site directed 
mutagenesis was performed to ascertain the functionality of the putative Nrf2 
response element.
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4.5.1 Mutation of the Nrf2 responsive element in the pSEAP-2kb 
hKPNAS construct
Site specific mutation of the NrfZ binding sequences was accomplished using 
the PCR-based method described for the generation of PPRE mutants. The most 
highly conserved bases of wild type NrfZ (wt NrfZ-RE) core element, CGCGC were 
mutated to TCGAG which simultaneously generated the Xho I  restriction site that was 
used to ligate the distal and proximal first round PCR products together prior to re- 
amplification of the promoter containing the mutated NrfZ response element (mt 
NrfZ-RE). The sequences of the PCR primers are shown in table 4-1 while figure 4-8 
shows the products of the first and second round of PCR.
Table 4-1 Primers used for amplification of the mutated Nr£2-binding site in -2 
kb human KPNA3 proximal promoter
Primer names Primers Sequence*
Proximal primers Forward 5-CCAGTGCAAGTGCAGGTGCCAGAA-3'
Reverse 5-GGACCACTCGAGGCGCGGCTCTTT-3'
Distal primers Forward 5-CGCGCCTCGAGGTCCCAGCATTCTC-3
Reverse 5-TGTTGCACTGGTTAAAGCGGGCGGCT-3'
Nested primers Forward 5-TCCCCAGTGCAAGTGCAGGT-3'
Reverse 5-TTCTTGGCGGCTGTCTGTGCAG-3'
*The restriction sites are underlined and the mutated bases are in bold.
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Figure 4-8. Gel electrophoresis of mt NrfZ-RE in -2 kb hKPNAS proximal promoter 
region. The correct upstream (lane 1 and 2, expected size 1.924 kb) and downstream 
PCR products (lane 3, expected size 641 bp) are seen in A) while the correct -2 kb full 
length promoter fragment containing the mutant PPRE site was digested with 
restriction enzymes, Acc65 1 and Bgl 11 and separated in 1% gel electrophoresis (B). 
M=molecular weight markers (values are size of bands in kilobases)
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PCR products containing the full length hKPNAS promoter with the mutated 
NrfZ were cloned into the pSEAPZ-basic vector using Acc65 I and Bgl II restriction 
sites. The resulting recombinant plasmids were screened by diagnostic digest using 
restriction enzymes that cut both the vector and insert asymmetrically as shown in 
Figure 4-9. Finally, the recombinant plasmids were further confirmed by sequencing 
to assure that the required mutation had been incorporated and no unwanted mutation 
during the cloning process.
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Figure 4-9. Diagnostic digest of mt NrfZ-RE plasmid constructs. The NrfZ mutant 
plasmids were digested with EcoR 1 (lane 1, predicted sizes 4.9 kb and 1.8 kb), Xho 
llXba 1 (lane 2, predicted sizes 3.6 kb and 3.1 bp), Kpn MHpa 1 (lane 3, predicted sizes
3.7 kb and 3 kb), and Acc65 MBgl 11 (lane 4, predicted sizes 4.7 kb and 2 kb). All 
fragments show the right bands. M=molecular weight markers (values are size of 
bands in kilobase).
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4.5.2 Reporter gene analysis of human KPNA3 promoter in response to
H2O2 and anti-oxidants
The Huh-7 cells were transiently transfected with -2 kb wt or mt Nrf2-RE 
pSEAP2-hKPNA3 plasmid constructs. Cells were exposed to various doses of H2O2 , 
ascorbic acid (vitamin C), or a-tocopherol (vitamin E) along with an appropriate 
vehicle control. After 24 hr the post-dose medium was removed for SEAP activity 
measurement. These experiments used a shorter incubation than previous 
experiments, as pilot data demonstrated significant cellular toxicity following 48 hour 
H2O2 treatment but not 24 hours.
4.5.2.1 Dose-response of hKPNA3 expression by H2O2
After transfection with -2 kb wt or mt Nrf2-RE pSEAP2-hKPNA3 plasmid 
constructs, the Huh-7 cells were treated with 0-100 pM H2O2 . As H2O2 is a known 
cytotoxic agent, cell viability was initially determined.
Figure 4-10 demonstrates the effect of H2O2 on cell viability using lactate 
dehydrogenase assay as a marker of cell death. Cell viability was not significantly 
affected by H2O2 at concentrations <1 pM, while at 10 pM and greater H2O2 
significantly increased cell death when compared to the vehicle control group (by 
37%, 41%, 58%, and 20% at 10, 20, 50, and 100 pM H2O2 respectively in wt Nrf2- 
RE construct after 24 hr). This effect was not significantly different when compared 
to the mt NrfZ-RE construct. In order to eliminate the effect of cell death on hKPNA3 
regulation, all values in the dose-response curve shown in Figure 4-11 were adjusted 
with % cell viability.
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Figure 4-10. The effect of H2O2 on cell viability: Huh-7 cells transfected with wt or 
mt Nrf2-RE reporter constructs were exposed to 0.1, 0.5, 1,10, 20, 50, 100 pM of 
H2O2 or 0.1% milHQ water as vehicle control. Media samples were taken after 24 h 
treatment with H2O2 in order to perform the LDH assay. Data was subtracted with 
assay medium (background control) and expressed as percentage of cell viability. All 
results represent the means + SEM (N=5). Data were analyzed by two-way ANOVA 
with Bonferroni post-hoc test and represent as average + SEM (error bars), N=5; a 
and b significant difference compared to control of wt Nrf2-RE and mt Nrf2-RE, 
respectively, P<0.05.
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In the case of the wild type -2 kb hKPNAS proximal promoter construct this 
resulted in down-regulation of SEAP reporter gene activity in dose dependent manner 
(Figure 4-10). The calculated IC50 value from the response curve was 1.3 + 1.28 pM 
with maximum inhibition of about 90% observed at concentration 10 pM H2 O2 . It is 
important to note that this IC50 is within the region where no significant cellular 
toxicity was observed. Furthermore, the inhibition of hKPNAS expression still 
occurred in the mt NrfZ-RE reporter construct at concentrations of 1 pM H2O2 and 
greater. However, these effects were substantially reduced when compared to the 
wild type hKPNAS reporter plasmid (about 40-50% at dose 10 pM with no further 
decrease in expression at higher doses), and lie within the region where significant 
cellular toxicity occurs. An IC50 of H2O2 for the mutant NrfZ construct could not be 
determined since the inhibition curve was nearly linear and it was not possible to fit a 
dose-response curve. These data demonstrate hKPNAS proximal promoter can be 
down regulated by H2O2 in NrfZ dependent manner. However because mutation of 
the NrfZ binding site did not totally abolish the hKPNAS expression, other factors 
might be involved in H2O2 mediated hKPNAS down regulation.
125
150n
100 -
50-
■2 1 0 1 2 3
T  Wt Nrf2-RE construct 
•  mt Nrf2-RE construct
Log dose (uM)
Figure 4-11. Dose-response curve of hKPNAS expression by H2O2 . Huh-7 cells 
transfected with wt or mt Nrf2-RE reporter constructs were exposed to 0.1, 0.5, 1,10, 
20, 50, 100 pM of H2O2 or 0.1% milliQ water as vehicle control. The post-dose level 
of expression was measured by SEAP reporter gene assay after 24 hr and normalised 
to the pre-dose reading. All values were corrected for cell viability before being 
expressed as a % of the (untreated) control. Each data point represent the mean + 
SEM (N=5). The data were analysed using non-linear regression: the IC50 of H2O2 in 
wild type construct was 1.3 ± 1.28 pM whereas an IC50 could not be calculated for the 
mt Nrf2-RE construct.
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4.S.2.2 The effect of vitamin C and vitamin E on hKPNAS expression
Given the apparent regulation of hKPNAS gene expression by pro-oxidants, I 
decided to determine the effect of antioxidants on hKPNAS gene regulation. 
Vitamins C and E were tested for activation of the -2 kb hKPNAS proximal promoter 
and mt Nrf2-RE reporter construct over a range of concentration. After transfection 
with wt or mt Nrf2-RE constructs, the Huh-7 cells were treated with vitamins C and E 
at concentration 1-SOO pM for 24 hr. As shown in Figure 4-12, vitamins C (A) and E 
(B) elicited no effect on hKPNAS expression in either the wild type or mutant Nrf2 
constructs. Moreover, no significant effect on cell death was observed by vitamin C 
and E administration (data not shown).
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Figure 4-12. The effect of vitamin C (A) and E (B) on hKPNAS expression. Huh-7 
cells transfected with wt or mt Nrf2-RE reporter constructs were exposed to 1-300 
pM of tested chemicals or 0.1% vehicle control. The post-dose level of expression 
was measured by SEA? reporter gene assay after 24 hr and normalised to the pre-dose 
reading. All values were corrected for cell viability before being expressed as a % of 
the (untreated) control. Data were analyzed by two-way ANOVA with Bonferroni 
post-hoc test and each data point represent the mean + SEM (N=5). No significant 
different was observed in all treated groups.
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In order to determine whether anti-oxidants can attenuate H2 O2 induced 
suppression of human KPNA3 gene expression, Huh? cells were transfected with 
pSEAP-2 kb hKPNAS construct for 24 hr and then pre-treated with vitamins C or E at 
concentration 10 pM for 24 hr before being treated with various doses of H2O2 .
As shown in Figure 4-1 SA pre-treatment with vitamins C and E actually 
increased the repression of human KPNAS expression by low doses of hydrogen 
peroxide (significant at concentration 0.1 pM and 0.5 pM when compared to 
corresponding H2O2 treated group in the absence of vitamins). However, the 
maximum repression observed at higher doses of H2O2 was reduced in the presence of 
these vitamins (36% - 58% repression by 10 pM and 20 pM H2 O2 in the presence of 
vitamins C and E compared to about 90% repression in their absence). This latter 
effect is probably explained by the observation that pre-treatment with vitamins C and 
E protected the cells from cytotoxicity at high doses of H2 O2 ; cell death was 
significantly reduced at 10 pM and 20 pM H2 O2 (Figure 4-lSB). These results 
suggest that vitamins C and E prevent cell death caused by high doses of H2O2 , hence 
increase hKPNAS expression when compared to H2 O2 treated group.
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Figure 4-13. The effect of vitamins C and E pre-treatment on human KPNAS 
expression (A) and cell viability (B). Huh-7 cells were transfected with pSEAP-2 kb 
human KPNAS reporter construct for 24 hr then pre-treated with 10 pM of vitamins 
C, E or 0.1% vehicle control. After 24 hr pre-treatment, the cells were exposed to 0.1, 
0.5, 1, 10, and 20 pM of H2O2 . The SEAP reporter gene and LDH assay were 
performed 24 hr later. The post-dose level of expression was measured by SEAP 
reporter gene assay after 24 hr and normalised to the pre-dose reading. All values 
were corrected for cell viability before being expressed as a % of the (untreated) 
control. Data were analyzed by two-way ANOVA with Bonferroni post-hoc test and 
each data point represent the mean + SEM (N=5), * P<0.05, ** P<0.01, ***P<0.001.
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4.6 Discussion
As mentioned earlier, the regulation of KPNA is poorly studied in human, thus 
this is the first report describing the transcription regulation of human KPNAS gene. 
In silico analysis identified several putative nuclear receptor binding sites including 
HNF4a, CAR, VDRs, PPARa. Initial data from in vitro reporter gene assays 
demonstrated the promoter was responsive to ligands for VDR and PPARa binding 
sites. Therefore this chapter aimed to further confirm the functional potency of the 
putative PPRE in response to PPARa ligands using promoter deletions, site directed 
mutagenesis, and electromobility shift assay.
PPARa is ligand activated-transcription factor which is highly expressed in 
the liver and exerts a dominant role in lipid and energy metabolism (Bookout et al. 
2006; Rakhshandehroo et al. 2007). Importantly, PPARa serves as xenobiotic sensor 
in response to the hypolipidemic fibrate class of drugs that reduce plasma 
triglycerides and increase plasma high density lipoprotein levels (Pyper et al. 2010). 
It has been reported that PPARa regulates many genes in the liver relating to fatty 
acid metabolism and mitochondrial oxidative phosphorylation, which are involved in 
the therapeutic effect of fibrates (Cariello et al. 2005). However, little information is 
known about the effect of fibrates on the regulation of nuclear protein transport. This 
study specifically identified a PPARa response element within the hKPNAS promoter 
and set out to examine its role in KPNAS gene regulation in response to PPARa 
synthetic ligands Wy-1464S, fenofibrate, and bezafibrate.
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4.6.1 PPRE-dependent hKPNAS regulation by Wy-14643, fenofibrate, 
and bezafibrate
Functional analysis of the hKPNAS proximal promoter reporter construct 
revealed PPRE dependent repression by Wy-1464S, fenofibrate, and bezafibrate. 
Using a deletion constructs combined with site directed mutagenesis produced relative 
results. As previously seen the -2 kb human KPNAS proximal promoter construct 
was inhibited to about 50% when compared to vehicle control after treatment 1 pM 
Wy-1464S, 50 pM fenofibrate, and 50 pM bezafibrate. However, the inhibition was 
no longer observed in a deletion construct removing the -1.7 kb PPRE. This result 
suggests that the putative PPRE mediates the inhibition observed in response to 
PPARa ligands. However, such approach to identify functional transcription 
regulation may be further augmented since the number of other putative response 
element were also deleted in this construct, hence a site directed mutagenesis 
approach was also employed to further confirm. Mutagenesis of the PPARa binding 
site within -2 kb human KPNAS proximal promoter was done to delete the most 
highly conserved bases and produce a mutant PPRE recognition site. The results 
suggests that mutation in PPARa response element completely abolished the PPARa- 
mediated respression of human KPNAS gene transcription, indicating that PPRE 
region within human KPNA proximal promoter is needed for full activity of human 
KPNAS regulation.
Moreover, an interaction between PPARa and PPRE site was also confirmed 
by EMSA: the results indicated that nuclear protein extract from Huh-7 cells formed 
two complexes with a PPRE probe in vitro. One of them demonstrated similar 
mobility with the complex of the Aco PPRE whereas another one shows faster
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mobility than the complex of the Aco PPRE. This probably indicates that the PPAR 
complexes of human KPNAS-PPRE are unique and more complex than Aco-PPRE 
either in transcriptional composition or charge of complex which remains to be 
elucidated. Displacement of wild type human KPNAS-PPRE by mutant human 
KPNAS-PPRE effectively diminished the binding of nuclear protein and in vitro 
synthesized PPARa. Taken together, our results demonstrate that the inhibition of 
hKPNAS promoter is mediated by PPRE in response to Wy-1464S, fenofibrate, and 
bezafibrate.
4.6.2 Inhibition of human KPNAS expression by H2O2 in Huh-7 cells
Since an increase in oxidative stress is a side effect of treatment with 
peroxisome proliferators such as the PPARa ligands used in this study, I next assessed 
the role of oxidants and antioxidants in regulating human KPNAS. Re-examining the 
in silico search identified a putative oxidative stress response element (Nrf2 binding 
site) within the -2 kb hKPNAS proximal promoter region. Nrf2 has been widely 
demonstrated as a transcription factor involved in regulating the expression of 
antioxidant and phase II drug metabolising enzymes, and is central to cellular 
response to oxidative stress (Klaassen and Reisman 2010). H2O2 is a by-product of 
normal cell aerobic metabolism and is generated by a variety of cellular processes in 
both normal and pathological states (Messner and Imlay 2002). I have used this 
compound as an inducer of oxidative stress along with the anti-oxidants, vitamin C 
and vitamin E in the wild type and mutant Nrf2-RE -2 kb promoter constructs. This 
mutant construct was used to confirm the functionality of the putative Nrf2 binding 
site.
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In the present study H2O2 elicited a dose-dependent inhibition of the SEAP 
reporter gene activity in the wild type -2 kb human KPNAS with the maximum 
inhibition observed at a concentration 10 pM, after which it became saturated. 
Interestingly, these effects were substantially reduced by about 50% in the mt Nrf2- 
RE reporter plasmid at a concentration of 10 pM H2O2 with no further decrease in 
repression at a higher dose. It is important to note that although H2O2 had an effect on 
cell death at concentrations 10 pM and greater, the inhibition effect presented here 
came from live cells since SEAP reporter gene activity was corrected for cell death 
before being expressed as a % of the (untreated) control. The present study 
demonstrates that Nrf2 might play an important role in human KPNAS suppression by 
H2O2 because the inhibition effect was reduced in Nrf2 mutant pSEAP2 plasmid 
construct. Even though, this effect is not totally diminished; this may be due to the -2 
kb promoter region not containing all response elements necessary to hKPNAS 
expression by H2O2 . Further studies need to be carried out to elucidate this 
mechanism of inhibition. Whereas other studies have suggested the inhibition effects 
of H2O2 on other components of nuclear protein transport, such as the disturbance of 
Ran concentration gradient, elevating cytoplasmic GTPase levels in Hela cell (Kodiha 
et al. 2004), these studies demonstrate the inhibition effect of H2O2 on nuclear protein 
transport at transcriptional level. These results therefore support the idea that 
oxidative stress affects different components of the nuclear transport system.
The effect of the anti-oxidants vitamin C and vitamin E was examined to 
investigate whether they can attenuate the repression of human KPNAS gene 
regulation. Surprisingly, pre-treatment of -2 human KPNAS construct with vitamins 
C and E led to an increase of the H202-mediated repression of KPNAS reporter gene 
expression at low doses when compared to respective H2 O2 treated group in the
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absence of vitamins. The reason for this is not clear, however other factors might be 
involved in this regulation since vitamin C and vitamin E alone had no effect on 
human KPNAS regulation. In contrast, at higher H2O2 vitamin C or E pre-treatment 
served to protect cells from the H202-mediated repression of KPNAS reporter gene 
expression. One explanation for this reduce inhibition effect by these vitamins is that 
vitamins C and E act as a free radical scavenger by reacting directly with oxidizing 
intermediates and by regulating the expression of protective enzyme results in 
prevention of H202-induced cell death (Gonzalez et al. 2007; Valko et al. 2007) and 
finally increase hKPNAS expression when compared to H202-treated group. 
Therefore, vitamins C and E pre-treatment attenuate hKPNAS inhibition by H2O2 
mostly related to cytoprotective effect of vitamins C and E rather than the effect of 
these vitamins on hKPNAS expression.
4.7 Summary
These results were consistent with an in silico analysis that revealed putative 
PPRE regulatory elements located at position between -1875 to -I85S. The PPRE is 
functional in the hKPNAS proximal promoter and has an inhibitory effect on KPNAS 
expression in response to the PPAR agonists, Wy-I464S, fenofibrate, and bezafibrate. 
Furthermore, this data not only indicates the involvement of nuclear protein transport 
and oxidative stress but also suggests that an alteration of nuclear protein import 
expression by H2O2 or PPARa agonists has the potential to affect cell function by 
altering nuclear translocation of various proteins, such as transcription factors which 
finally effect many biological processes in hepatocytes.
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5. REGULATION OF HUMAN KPNAS EXPRESSION BY MULTIPLE  
VDRE ELEMENTS AND ITS BIOLOGICAL CONSEQUENCES 
5.1 Introduction
In the previous chapters, I used in silico analysis to identify four putative VDR 
binding sites in human KPNAS proximal promoter, followed by reporter gene 
analysis to demonstrate that la , 25(OH)2D3 can alter hKPNAS expression in Huh-7 
cells (Chapter S). As these data were consistent with the involvement of VDR in the 
regulation of KPNAS gene expression, promoter deletion constructs, site directed 
mutagenesis and electromobility shift assay were used to further examine this 
phenomenon, with results detailed in this chapter. A deletion series was generated 
from the original -2 kb reporter gene construct used in chapter S, sequentially deleting 
putative VDREs. In addition, each VDRE was ablated via site directed mutagenesis 
within the hKPNAS proximal promoter. SEAP reporter gene activity was assayed in 
each of these daughter constructs to examine the effect of both the deletions and point 
mutations on la , 25(OH)2D3-mediated regulation of hKPNAS gene expression. 
Finally, electromobility shift assays (EMSA) were performed to test the binding of 
nuclear protein extract to each of the putative VDREs.
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5.2 The effect o f putative VDRE deletion constructs on human KPNAS
expression
5.2.1 Generation of promoter deletion construct
Figure 5-1 details the four deletion constructs made from the full-length 
KPNAS reporter gene, detailing how each deletion construct impacts upon putative 
VDRE inclusion into the final reporter gene.
PPM*
-2 kb
VCR-ld03 VDR.I300
-1.2 Lb
•500 bp
-1 9 0  b*
PSEAP
PSEAP
Figure 5-1. A series deletion construct of human KPNAS proximal promoter. Each 
deletion fragment was generated by PCR and cloned into pSEAP2-basic reporter 
vector resulting in four deletion constructs which differ in size and the number of 
VDREs. The size of each deletion fragment is indicated. Boxes representing putative 
nuclear receptor binding sites are shown: red for PPRE and blue for VDREs.
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The pSEAP2-hKPNA3 plasmid containing the -2 kb hKPNAS proximal 
promoter examined in chapter S was sequentially deleted to remove each putative 
VDR binding site beginning from the 5’ (distal) end using PCR. The resulting four 
PCR products were separated on a 1% agarose gel (Figure 5-2A, B), demonstrating 
PCR products of the expected size in each case: for VDRE-1402 and VDRE-ISOO 
deletion fragments of 1.4, and 1.S2 kb , respectively are shown in Figure 5-2A while 
for VDRE-7S9 and VDRE-2S7 the expected fragments were 750 and 270 kb, as 
shown in Figure 5-2B.
All promoter deletion fragments were subsequently digested and inserted into 
the pSEAP2-basic vector as described in section 2.2.S. Correct construction of the 
desired daughter constructs were confirmed first by diagnostic restriction digest, using 
restriction enzymes that cut both the vector and insert asymmetrically (Figure 5-SA- 
D), and then by sequencing to ensure that no mutations had been incorporated during 
the cloning process.
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Figure 5-2. Gel electrophoresis of a serial deletion of the human KPNA3 proximal 
promoter region. PCR products of VDRE-1402 and VDRE-1300 deletion fragments 
are shown in A which shows the expected 1.4 (lane 1) and 1.32 kb (lane 2) bands 
respectively. The expected PCR products of deletion VDRE-739 and VDRE-237 
fragments are 750 (lane 3) and 270 kb (lane 4) respectively (B). M=molecular weight 
markers (values are size of bands in kilobases)
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Figure 5-3. Diagnostic digest of deletion plasmid construets. A) The -1.35 kb 
plasmid was digested with Bgl W/Sph I (lane 1; predieted fragment sizes 4.9 kb, and
1.1 kb), Nco I (lane 2; predicted fragment sizes 3.9 kb, 1.3 kb, and 760 bp), Bgl l/Sph 
I (lane 3; predicted fragment sizes 4.4 kb and 1.6 kb) and Acc65 l/Bgl II (lane 4; 
predicted fragment sizes 5.05 kb and 1.35 kb). B) The -1.2 kb plasmid was digested 
with Bgl ll/Sph I (lane 1; predicted fragment sizes 4.7 kb, and 1.1 kb), Nco I (lane 2; 
predicted fragment sizes 3.7 kb, 1.3 kb, and 760 bp), Bgl \l/Sph I (lane 3; predieted 
fragment sizes 4.4 kb and 1.4 kb) and Acc65 MBgl II (lane 4; predicted fragment sizes
4.7 kb and 1.1 kb). C) The -600 bp plasmid was digested with Avr II (lane 1 ; predieted 
fragment sizes 3.4 kb and 1.2 kb) and Bgl WINco I (lane 2; predicted fragment sizes
4.2 kb, 739 bp and 303 bp). D) The -190 bp plasmid was digested with Bgl \MNco I 
(lane 1; predicted fragment sizes 3.8 kb, 760 bp, and 303 bp) and Hind WMBamH I 
(lane2; predicted fragment sizes 3 kb, 1.57 kb, and 235 bp). M=molecular weight 
markers (values are size of bands in kilobases).
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5.2.2 Reporter gene analysis of deletion constructs in response to la ,
25(0H)2D3 in Huh-7 cells.
Previous results showed that human KPNA3 promoter activity was increased 
by la , 2 5 (0 H)2D3 in a dose-dependent manner at lower concentrations, reaching a 
peak at 10 nM. Above this concentration, la , 25(OH)2D3 exerted a repressive effect, 
with maximal repression at the highest dose examined, 300 nM. To examine the 
potential molecular mechanisms for this mixed effect, each of the daughter constructs 
described above were transiently transfected into Huh-7 cells and exposed to 10 nM 
and 100 nM la , 25(OH)2D3 for 48 hours. SEAP reporter gene assay was then 
performed and results are shown in Figure 5-4.
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Figure 5-4. Promoter activity of -2 kb, -1.35 kb, -1.2 kb, -600 bp, or -190 bp deletion 
constructs in response to 10 (A) and 100 (B) nM la, 25(0H)2D]. pSEAP2-hKPNA3 
deletion constructs (25 ng) were co-transfected with pEF6/vs-HisVDR expression 
plasmid (25 ng) into Huh-7 cells. After 24 hours, the pre-dose media was collected 
and the cells were treated with 0.1% ethanol (vehicle control) or 10 nM or lOOnM la, 
25(0H)2D]. The post-dose media was collected after 48 hours and the level of 
expression was evaluated by measuring the luminescence from SEAP reporter gene 
products. Data was normalized with the pre-dose and expressed as % of the vehicle 
control for each plasmid. Data was analyzed by two-way ANOVA with Bonferroni 
post-hoc test and is presented as average + SEM (error bars), ** P<0.01, ***P<0.001, 
N=5.
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As seen previously, 10 nM la , 25(OH)2Ü3 elicited a significant increase in 
human KPNA3 promoter activity (1.6 fold compared to vehicle) in Huh-7 cells 
transfected with the -2 kb pSEAP2 reporter construct (Figure 5-4A). Moreover, the 
induction effect was also observed in Huh-7 cells transfected with the next largest 
1.35 kb deletion construct after administration of 10 nM la , 25(OH)2D3. In contrast, 
no significant difference in SEAP activity was observed in Huh-7 cells transfected 
with the smaller -1.2 kb, -600 bp or -190 bp deletion constructs when compared to its 
vehicle control. This suggests that the putative VDRE-1402 is not involved in the 
positive regulation of human KPNA3 promoter activity, whereas VDRE-1300, at 
least, is involved in the up-regulation human KPNA3 expression mediating the action 
of la , 25(0H)2D3 at 10 nM. However, from this experiment it was not possible to 
draw any firm conclusions as to the role of the putative VDREs at positions -739 and - 
237 kb since any consequences of their deletion was masked by the removal of 
VDRE-1300.
In contrast to the results obtained using 10 nM la , 25(OH)2D3, hKPNA3 
expression was drastically inhibited (by 90%) in response to 100 nM la , 25(OH)2D3 
compared to vehicle treated Huh-7 cells transfected with the -2 kb pSEAP2 reporter 
construct, as previously reported (Figure 5-4B). Use of any of the daughter deletion 
constructs completely eliminated this inhibitory response to 100 nM la , 25(OH)2D3 
(Figure 5-4B), suggesting that the most distal VDRE, VDRE-1402, is necessary for 
this repressive effect. Once again, the other putative VDRE sites (VDRE-1300, 
VDRE-739, and VDRE -237), cannot be equivocally discarded as important for the 
repressive effect, and need to be further examined, since all other clones also lack 
VDRE-1402.
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5.3 The effect of site directed mutagenesis of VDREs on human KPNA3
expression
5.3.1 Generation of putative VDRE mutant constructs
In order to further determine the precise position of putative nuclear receptor 
binding elements, site specific mutation of the four VDRE binding sequences were 
accomplished by PCR-based method as described in section 2.5.1.3. The mutated 
sequences are shown in Table 5-1.
Table 5-1. Mutated base of VDRE binding elements
Putative NR 
Binding sites
Sequence 
Capitals: core sequence
VDRE-1402 tcacaaCTCGaggaggtcgagacca
VDRE-1300 tgaagaCTCGagaaaggacaatctt
VDRE -739 gtgggagtgctacacCTCGagtgtct
VDRE - 237 tatcaggaggaCTCGagtgggcctt
*The uppercase in the sequence represent core element of binding site. The mutated 
bases are in bold.
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As described for the PPRE in section 4.3, the first PCR reactions were 
performed to generate distal and proximal PCR products which overlap at the mutated 
region, which also contained an introduce restriction site (Xho I). PCR products of 
the correct size were identified on a 1% agarose gel (Figure 5-5A), purified, digested 
with Xho I, and ligated together with DNA ligase; this resultant fragment was used as 
a template for the second PCR reaction to generate the full-length -2 kb KPNA3 
promoter fragment containing an ablated VDRE (Figure 5-5B).
The digested -2 kb PCR products, each containing one mutated VDRE, were 
sub-cloned into the pSEAP2-basic vector. The correct plasmid was confirmed and 
screened by diagnostic digest using restriction enzymes that cut both the vector and 
insert asymmetrically; the expected digestion products are shown in Figure 5-6. 
Finally, the recombinant plasmids were further confirmed by sequencing to assure 
that the required mutation had been incorporated and that no additional unwanted 
mutations had arisen during the cloning process.
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Figure 5-5. Gel electrophoresis of VDREs mutagenesis in -2 kb hKPNAS proximal 
promoter region. A) shows the expected proximal and distal PCR products of VDRE- 
237 (lane 1; predicted fragment size 500 bp and lane 2; predicted fragment size E8 
kb), VDRE-739 (lane 3; predicted fragment size 1.04 kb and lane 4; predicted 
fragment size 1.56 kb), VDRE-1300 (lane 5; predicted fragment size 1.55 and lane 6; 
predicted fragment size 1.38 kb), and VDRE-1402 (lane 7; predicted fragment size 
1.65 kb and lane 8; predicted fragment size 1.29 kb), respectively. B) shows the 
expected -2 kb full length KPNA3 promoter containing mutant VDRE-237, -739, - 
1300, and -1402 were digested with restriction enzymes, Acc65 1 and Bgl II and are 
seen in lanes 1, 2, 3, and 4, respectively (predicted fragment size 2 kb). M=molecular 
weight markers (values are size of bands in kilobase).
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Figure 5-6. Diagnostic digest of SDM plasmid constructs. A) The VDRE-237 
mutant construct was digested with EcoR I (lane 1 ; predicted fragment sizes 4.9 kb 
and 1.8 kb), Xho VScal I (lane 2; predicted fragment sizes 4.4 kb and 2.3 bp), and Kpn 
MHpa I (lane 3; predicted fragment sizes 3.7 kb and 3 kb). The VDRE-1402 mutant 
construct was digested with EcoR I (lane 4; predicted fragment sizes 4.9 kb and 1.8 
kb), and Kpn MHpa I (lane 5; predicted fragment sizes 3.7 kb and 3 kb). B) The 
VDRE-739 mutant construct was digested with EcoR I (lane 1; predicted fragment 
sizes 4.9 kb and 1.8 kb), Xho MXba 1 (lane 2; predicted fragment sizes 3.7 kb and 3 
bp), and Kpn MHpa 1 (lane 3; predicted fragment sizes 3.7 kb and 3 kb). The VDRE- 
1300 mutant construct was digested with EcoR 1 (lane 4; predicted fragment sizes 4.9 
kb and 1.8 kh),Xho 1/Xba 1 (lane 5; predicted fragment sizes 4.1 kb and 2.6 bp), and 
Kpn MHpa 1 (lane 6; predicted fragment sizes 3.7 kb and 3 kb). M=molecular weight 
markers (values are size of bands in kilobase).
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5.3.2 Reporter gene analysis of human KPNAS VDRE SDM plasmid
constructs in response to la , 25(OH)2D3 in Huh-7 ceils.
As discussed earlier, whereas the use of a deletion construct series provides 
initial evidence for the functionality of the putative VDREs within the proximal 
promoter, it does not allow full analysis of the input of each of the four sites in any 
regulation. Therefore, specific mutation of each site was used to fully examine the 
functionality of each putative VDRE located within -2 kb hKPNAS proximal 
promoter using mutagenesis. To test the functionality of each VDRE, the wild type 
human KPNAS promoter was compared to the VDRE mutants described above. Huh- 
7 cells transfected with each plasmid were treated with 10 nM or 100 nM la, 
25(OH)2Ds, or with a vehicle control, for 48 h and the results are presented in Figure 
5-7A-B.
Although the mutation of VDRE-1402 sequences still enabled the human 
KPNAS promoter to be significantly induced 10 nM la , 25(OH)2Ds, mutations in 
VDRE-1300, VDRE-739, and VDRE-237 fully abolished the response when 
compared to the vehicle-treated group (Figure 5-7A). Thus, these results demonstrate 
that the activity of 10 nM la, 25(OH)2D3 to activate KPNAS gene expression is 
mediated through all three of these more proximal VDREs, with each being obligate 
for the response to occur.
In contrast to the data produced by treatment with 10 nM la, 25(OH)2D3, each 
VDRE mutant construct completely abolished the inhibitory response to higher (100 
nM) doses of la, 25(OH)2D3 (Figure 5-7B). Indeed, mutation of the VDRE-1402 not 
only prevents the repressive activity of lOOnM la , 25(OH)2D3, but supports an 
induction instead. Again, this result supports my analysis of the promoter deletion
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plasmids described in section 5.2.2 and further suggests that all four of the KPNAS 
VDRE sites are essential in suppression of human KPNAS gene in response to 100 
nM la, 25(0H)2D3. Taken collectively, the human KPNAS proximal promoter is 
indeed functionally complex and contains both positive and negative VDRE binding 
elements in a dose dependent regulation.
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Figure 5-7. Promoter activity of four mutant VDRE reporter gene constructs (mt 
VDREs) in response 10 (A) and 100 Nm (B) la, 25(OH)2D3. Each mt VDRE-human 
KPNAS reporter construct (25 ng) was co-transfected with pEF6-VDR expression 
plasmid (25 ng) into Huh-7 cells. After 24 hours, the pre-dose media was collected 
and the cells were treated with 0.1% ethanol (vehicle control) or 10 nM or lOOnM la, 
25(0H)2D3. The post-dose media was collected 48 hours later and the level of 
promoter activity was evaluated by measuring the luminescence from SEAP reporter 
gene products. Data was normalized against the pre-dose reading and expressed as % 
of the vehicle control for each plasmid. Data were analyzed by two-way ANOVA 
with Bonferroni post-hoc test and represent as average + SEM (error bars), *E<0.05, 
**f<O.OE ***f<0.001,N=5.
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5.4 Characterization of protein-DNA interaction of the human KPNAS 
putative VDREs
To support the previous findings of my deletion and mutagenesis studies, 
EMSA was undertaken to investigate whether a direct interaction occurs between 
VDR and the putative VDRE sites in human KPNAS proximal promoter. Double 
stranded oligonucleotides corresponding to each putative VDRE (wt-VDRE) within 
human KPNAS proximal promoter, plus mutant VDREs with nucleotide changes 
corresponding to those introduced in the site directed mutagenesis experiment 
described above (mt-VDRE) were used for these studies. In addition, a control 
oligonucleotide corresponding to the previously described VDRE of human 
osteocalcin gene (OC-VDRE, Uchida et al. 1997) was also used for comparison. 
These oligonucleotides were labelled with biotin at the 3' end of the sense strand and 
used as probes to look for evidence of protein binding.
The assay indicated that factors present in the crude nuclear extracts prepared 
from Huh-7 cells bound to all VDRE sites (Figure 5-7A-D, lane 2 compared to lane 
1), and that this binding could be removed by competition with a excess unlabelled 
DNA, demonstrating specificity of binding (Figure 5-7A-D, lanes 3-6 compared to 
lane 2). The complexes formed with VDRE-1402, VDRE-1300, and VDRE-739 
showed similar mobility to that observed with the positive control sequence, OC- 
VDRE (Figure 5-7A-C, lane 7 respectively), implying that these complexes resulted 
from VDR protein binding. By contrast, VDRE-237 formed two complexes with the 
nuclear protein extract, with one demonstrating slower mobility than the OC-VDRE 
complex (Figure 5-7D). Thus, this complex might represent other proteins bound to 
VDRE-237, or a different composition of transcription complex.
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Taken together, these results show that all of the putative VDREs within the 
human KPNA3 promoter are able to bind speeifically to protein (complexes) of 
similar molecular weight as that which binds to the osteocalcin VDRE. This supports 
the previous finding from reporter gene assay that multiple VDRE sites are necessary 
for the human KPNA3 gene regulation (section 5.2 and 5.3).
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Figure 5-8 VDR binding to the hKPNA3 VDRE. EMSA was performed using 
nuclear protein extracted from Huh-7 cells transfected with a VDR expression 
plasmid. The wild type hKPNA3 VDRE-1402 (A), VDRE-1300 (B), VDRE-739 (C), 
and VDRE-237 (D) probes were incubated in the absence (lane 1) or presence (lanes
2-6) of nuclear extract while OC-VDRE (lane 7) provided a positive control. In lanes
3-6 unlabelled oligonucleotide competitors (wt-VDRE) was also added to the binding 
reaction at a concentration equal to 10, 30, 50, and 100 fold molar excess that of 
probe. The protein DNA complexes were resolved by 6% non-denaturing 
polyacrylamide gel: the free probe and the putative VDR complexes are indicated.
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To further examine the interaction between the KPN A3 VDREs and VDR, and 
to validate the previous reporter gene studies that employed site directed mutagenesis, 
I analysed the mutant VDRE by EMSA. As shown in Figure 5-8, mutation of VDRE- 
1402, -1300, and -739 oligonucleotide probe failed to bind to nuclear extract from 
naive (i.e. untransfected) Huh7 cells (lane 2), extract from Huh7 cells transfected with 
a VDR over-expression plasmid (pEF6/vs-VDR) (lane 3) and VDR synthesized in 
vitro by TNT reaction (lane 4). Interestingly, mutation of VDRE-237 probe only 
blocked the formation of the complex that had similar mobility to OC-VDRE complex 
(Figure 5-8D), while the lower mobility complex was still able to form. This might 
suggest that the slower mobility complex seen with the wild type VDRE-237 probe is 
probably a false positive result.
Overall, this data demonstrates that the VDREs present at -1402, -1300, -739 
and -237 within the human KPN A3 proximal promoter are all able to bind to VDR in 
a sequence specific manner. In addition, EMSA with probes carried the mutations 
used in my site directed mutagenesis experiments, demonstrated that these mutations 
were effective in ablating protein binding.
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Figure 5-9 Ablation of the hKPNAS VDRE sites abolished VDR binding. EMSA 
was performed using nuclear protein extracted from naive Huh-7 cells or from Huh-7 
cells transfected with a VDR expression plasmid (pEF6/vs-VDR) or with VDR 
synthesized in vitro by TNT reaction. The mutant human KPN A3 VDRE (mt- 
VDRE1402 (A), VDRE-1300 (B), VDRE-739 (C), and VDRE-237 (D) 
oligonucleotide probes were incubated in the absence (lane 1) or presence (lanes 2-4) 
of protein extract. The OC-VDRE (lane 6) provided a positive control for protein 
binding. The protein-DNA complexes were resolved on a 6% non-denaturing 
polyacylamide gel: the free probe and the putative VDR complexes are indicated.
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5.5 Increased nuclear localisation of VDR by human KPNA3 over­
expression
The work described above clearly demonstrates that the nuclear receptor VDR 
is an important transcription factor in the regulation of human KPNA3 gene 
expression after la , 25(OH)2D3 administration. Following on from this, I wanted to 
ascertain the biological consequences of alterations in the level of KPN A3, and in 
particular was interested in its possible impact on the localisation of VDR itself.
Recently, the involvement of VDR and a karyopherin protein has been 
reported by Miyauchi et al (2005). They demonstrated that the nuclear translocation 
of VDR is mediated by importin 4 which is a member of the p-karyopherins. 
However; the specific role of the a-karyopherins on nuelear transport of VDR has not 
been examined. Therefore, this study was undertaken to investigated the effect of 
human KPN A3 over-expression on nuclear translocation of VDR after la , 25(OH)2Ds 
treatment.
5.5.1 Human KPN A3 over-expression
Human KPNA3 over-expression following transfection of Huh-7 cells with a 
KPNA3 expression plasmid was confirmed by western blot analysis (Figure 5-9). In 
naïve cells, the intracellular level of KPNA3 was relatively low. Transfection with 
pTriEx 1.1 -hKPNA3 at 50 and 100 ng/well did not significantly increase KPNA3 
levels when compared to the control. In contrast, densitometry analysis showed an 
increase in KPNA3 protein levels of two and seven fold after transfection with 500 ng 
and 1000 ng of pTriExl. 1 -hKPNA3 plasmids for 24 hr, respectively (Figure 5-9); it
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should be noted, however, that transfection with 1000 ng of pTriEx 1.1-hKPNAS also 
resulted in some cell toxicity (data not shown).
Taken together, this study confirmed that pTriExl. 1 -hKPNA3 was effectively 
expressed in cell culture conditions and 500 ng of this plasmid was chosen for further 
studies to determine localization of VDR.
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Figure 5-10 Detection of KPN A3 over-expression. Huh-7 cells were seeded in a 6- 
well plate at 3x10^ cells/well and 24 h later were transiently transfected with 50, 100, 
500, and 1000 ng of pTriEx 1.1 -hKPNA3. After 24 hr, total protein extract was 
prepared from the cells and 50 pg were analyzed by Western blot using primary goat 
anti-KPNA3 (1:1000 dilution) antibody follow by secondary horseradish peroxidise- 
conjugated anti-goat IgG (1:10000 dilution) (A, top panel). The approximate 
moleeular mass of the KPNA3 protein is 56 kDa. The same membrane was cut and 
probed with anti p-actin antibody as a loading control (A, bottom panel). Proteins 
extraeted from cells transfected with pTriExl.l vector with no inserted coding region 
were run for comparison (lane 0). B) The bands were quantified by densitometry and 
are presented as fold over-expression compared to cells transfected with empty 
pTriExl .1 vector (lane 0).
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5.5.1 VDR translocation in to the nucleus by human KPNA3 over­
expression
The localisation of KPNA3 and VDR was characterized in Huh-7 hepatoma 
cells by immunocytochemistry and confocal microscopy. The cells were transiently 
co-transfected with pEGFP-VDR (N-terminal enhanced green fluorescent protein 
(EGFP) tagged VDR expression plasmid) and pTriExl. 1 -hKPNA3 or empty 
pTriExLl vector for 24 hr. Next, cells were incubated with or without la , 
25(0H)2D3 at concentration 10 and 100 nM for 48 hrs, and then the cells were fixed 
and stained: an anti-KPNA3 antibody was used, along with a fluorescent secondary 
antibody (Alexa Flour 588 conjugated anti-goat) to determine the localisation of 
KPNA3 within the cells by immunofluorescence whereas propidium iodide was used 
as a counterstain to identify the nucleus.
The three fluorophores used (GFP, Alexa 588 and PI) were each detected by 
confoeal microscope using appropriate filters as described in Materials and 
Methods. Figure 5-11 shows representative images in which the top left quadrant (A) 
shows EGFP-VDR fluorescence, (B) shows KPNA3 staining with Alexa 588, (C) 
shows nuclear staining with propidium iodide and (D) shows the overlay of all three 
images. Whereas all cells showed staining with PI and anti-KPNA3 (which 
recognises both the exogenously supplied protein from the pTriEx-KPNA3 expression 
plasmid and endogenous KPNA3), only those cells which were successfully 
transfected showed green fluorescence generated by EGFP-KPNA3; typically these 
cells represented 5-10% of the total number of cells.
In cells which have not been exposed to la, 25(OH)2Ds, KPNA3 is mainly 
localized in the nucleus whereas VDR is distributed throughout the cell (Figure 5-11, 
top left panel); quantitative image analysis showed localisation of VDR in the
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cytoplasm to be 34% and in the nucleus 66% (Figure 5-12). Co-transfection with the 
KPNA3 over-expression plasmid resulted in cells with an almost exclusively nuclear 
localisation of VDR (95%) in the absence of ligand (top right panel). These results 
indicate that KPNA3 induces nuclear aecumulation of VDR regardless of the presence 
of its ligand.
Incubation with either la , 25(OH)2D3 (10 and 100 nM) clearly increased 
accumulation of VDR in the nucleus of Huh-7 cells (middle and bottom left panels). 
Quantitative image analysis further confirmed significant increase of VDR 
accumulation in the nucleus of vector control Huh-7 cells in the presence of 10 nM 
and 100 nM la , 25(OH)2D3 (Figure 5-11). In comparison, as KPNA3 over-expression 
(right panel) results in VDR becoming almost completely nuclear in the absenee of 
ligand (top right panel), addition of la , 25(OH)2D3 did not have any significant 
impact on this localisation (middle and bottom right panel). This may indicate that 
over-expressed KPNA3 prevents further VDR accumulation in the nucleus in the 
presence of ligand which could result in alteration of VDR target gene regulation.
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Figure 5-11 Nuelear accumulation of VDR by KPNA3 over-expression. Localization of 
VDR in Huh-7 cells was examined by fluorescence microscopy. The cells were transiently 
eo-transfeeted with 100 ng of pEGFP-VDR and 500 ng of pTriExl.l-KPNA3 (right panels) 
or empty pTriExl.l vector (left panels). After 24 hr, the cells were treated with 0.1% ethanol 
(vehicle control; top panels) or la, 25(OH)2D3 at concentration 10 nM (middle) or 100 nM 
(bottom panels) for 48 hr. The cells were then fixed and stained with anti-KPNA3 antibody 
followed by Alexa Flour 588 conjugated secondary antibody, and nuclei were counterstained 
with propidium iodide (PI). In each panel, quadrant (A) shows green fluorescence from 
EGFP-VDR expression, quadrant (B) shows both endogenous and exogenous KPNA3 
expression by immunofluorescence, quadrant (C) shows PI nuelear staining and (D) shows 
the merged image in order to demonstrate localisation of EGFP-VDR within the nucleus or 
cytoplasm.
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Figure 5-12 Quantitative image analysis of VDR localisation in the nucleus of Huh-7 
cells. The experiment protocol above was used. Quantitative image analysis was 
performed using laser scanning microscope SLM 510 software and expressed as % of 
total VDR in a cell. Two independent experiments were performed. Data were 
analyzed by two-way ANOVA with Bonferroni post-hoc test and represent as average 
+ SEM (error bars), *** P<0.001, n=20. KPNA3 enhances VDR accumulation in the 
nucleus of KPNA3 over-expressing cells when compared to vector control Huh-7 
cells in the absenee of ligand.
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5.6 Discussion
The VDR not only plays a major role in calcium and phosphate homeostasis 
and bone metabolism, but also regulates the expression of drug metabolizing enzymes 
and enzymes involved in bile acid detoxification (Trottier et al. 2006; Khan et al.
2009). The VDR is not usually considered to be one of the major nuclear receptors in 
the liver, and is found expressed at low level in the human liver (Gascon-Barre et al. 
2003). However, experimental evidence demonstrated that the natural VDR ligand, 
la , 25(OH)2Ds has selected activity in the liver: It has been reported that la ,
25(0H)2D3 controls DNA polymerase activity, as well as cytoplasmic and nuclear 
protein kinases, leading to an accelerated regeneration process in rat liver (Whitfield 
et al. 2001). In addition la , 25(OH)2D3 has also been reported to regulate several 
genes in the liver including the major cytochrome P450 involved in xenobiotic 
metabolism, CYP3A4 (Thummel et al. 2001; Khan et al. 2009), as well as genes 
involved in metabolism of hepatotoxic bile acids and their metabolites (CYP7A1 and 
CYP27A) (Theodoropoulos et al. 2003; Han et al. 2010). Moreover, this study is the 
first demonstration that la , 25(OH)2D3 also play a important role in regulation of a 
nuclear transport gene which might affect many biological process in the liver cell.
5.6.1 Multiple VDRE-dependent human KPNA3 regulation by la , 25 
(0H2)D3
The finding that the -2 kb of KPNA3 proximal promoter was responsive to la , 
25(0H)2D3 in transfection studies (chapter 3) encouraged me to determine which of 
the 4 putative VDRE sites in this region contributes to the regulation of KPNA3 in 
human liver cells using serial promoter deletion and site directed mutagenesis 
approaches. These two methods yielded complementary results: deletion and point
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mutation of each VDRE revealed that the VDREs located at -1300, -739, and -237 bp 
are required for the rise in SEAP reporter activity at low (10 nM) doses of la, 
25(0H)2D3, whereas ablation of the VDRE located at -1402 still enabled induction of 
KPNA3 promoter activity to similar levels to that seen in the wild type -2 kb human 
KPNA3 proximal promoter. This might suggest that all three of the downstream sites 
are required, as mutation of any one completely ablates the response to low dose la, 
25(0H)2D3. Such a scenario, requiring binding of multiple VDR molecules to a 
single promoter to elicit transcription would suggests that these sites function co­
operatively, with the recruitment of coregulatory proteins from one binding complex 
potentially aiding further binding at other sites, which further enforces the 
transcriptional response. Interestingly, treatment with higher doses of la , 25(OH)2D3 
showed a different mechanism of human KPNA3 gene regulation: at 100 nM la, 
25(0H)2D3 is able to inhibit the expression of KPNA3 in the wild type promoter 
construct. However, deletion or mutation of any of the VDREs located at -1402, - 
1300, -739, and -237 abrogated all response to 100 nM la, 25(0H)2D3 when compared 
to vehicle control; again this suggests cooperativity since all four VDREs are required 
to see any response.
In agreement with these observations, EMSA further confirmed the 
functionality of the VDREs within the KPNA3 promoter, revealing interactions 
between all four VDREs and nuclear protein extracted from Huh-7 cells. 
Furthermore, mutation of each VDRE diminished or completely ablated protein 
binding, verifying the effectiveness of SDM. These results suggest that VDR is 
directly binding to VDRE elements in order to regulate human KPNA3 gene 
transcription. In addition, the EMSA competition experiments showed the varied 
ligand binding affinity of each VDRE site, this further support that a VDRE cluster in
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the human KPNA3 proximal promoter may act co-operatively to regulate human 
KPNA3 gene. The proposed mechanism of this KPNA3 regulation is described in 
Chapter 6, section 6.3.
Taken together, the results of my promoter mutagenesis and EMSA studies 
demonstrate that la , 25(OH)2D3 modulates human KPNA3 gene regulation through at 
least four VDRE regions, which appear to act co-operatively to regulate expression. 
This is consistent with other reports that have showed the presence of multiple 
functional VDRE sites in the promoters of a number of genes (Thompson et al. 2002; 
Sinkkonen et al. 2005; Turunen et al. 2007; Deblois et al. 2008; Matilainen et al.
2010). These findings raise an interesting question as to why the VDRE sites appear 
to contribute to the ability of la, 25(OH)2D3 to regulate both induction and inhibition 
of hKPNA3 promoter. Such a differential action might indicate that regulation of 
hKPNA3 expression by la , 25(OH)2D3 is tightly controlled, because any downstream 
impact on VDR nuclear localisation would also affect other transcription factors also 
imported by KPNA3, and hence their target gene sets. Thus, any alteration in KPNA3 
expression levels might have important implications for generalised cell processes.
5.6.2 The ligand-independent nuclear localisation of VDR by human 
KPNA3
Immunocytochemical studies of Huh-7 cells demonstrated that VDR is 
distributed in a diffuse pattern over the cytoplasm and nucleus in the absence of la , 
25(0H)2D3 administration. This result is in agreement with the study of VDR 
distribution in Caco-2 cells, reported by Klopot et al (2007). However, it should be 
noted that the intracellular localization of VDR exhibits cell and tissue-specific 
differences; VDR is mainly localized in cytoplasm in some cells such as COS-7 and
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Ros 17/2.8 (Racz and Barsony 1999; Klopot et al. 2007), whereas it resides 
predominantly in the nucleus of human brain cells (Eyles et al. 2005). The reason 
underlying this differential localisation is not clear, but may reflect either 
technological (i.e. histochemical staining versus over-expression) or biological (i.e. 
presence of endogenous ligands, presence of coregulatory proteins) variability.
Interestingly, human KPNA3 over-expression in Huh-7 cells causes the steady 
state localisation of VDR to move until it is predominantly nuclear, even in the 
absence of la , 25(0H)2D3. This data demonstrated that KPNA3 is effectively 
promoting nuclear accumulation of VDR in a ligand-independent manner. The 
nuclear translocation of VDR in the absence of ligand has been reported in several 
studies: for example Miyauehi et al (2005) reported that VDR is imported into 
nucleus by importin4 as a ligand-independent mechanism in COS-7 and HeLa cells. 
However, this is the first report to suggest that human KPNA3 plays a role in VDR 
translocation into the nucleus in Huh-7 cell. There are two possibilities for the altered 
sub-cellular distribution of VDR by KPNA3 over-expression, 1) enhanced nuclear 
import of VDR by KPNA3, 2) decreased nuelear exported by CRM-1 (Prufer et al. 
2002) or the export adaptor, calreticulin (Black et al. 2001), which may result in the 
regulation of other VDR target genes, thus ensuring an appropriate biological 
response.
Upon la, 25(0H)2D3 treatment, VDR accumulates in the nucleus of naive 
Huh-7 cells. In comparison, addition of la , 25(OH)2D3 dose not have any significant 
impact on this localisation in KPNA3 over-expressed cells; in these cells VDR is 
already predominantly nuclear in the absenee of ligand and therefore no futher nuclear 
accumulation could be observed. However, this result dose not discount the 
possibility that KPNA3 could be involved in VDR translocation into nucleus in the
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presence of ligand since KPNA3 is expressed in a significant amount in naive Huh-7 
cells (S.Yimthaing, preliminary data). Two mechanisms for the translocation of 
liganded VDR into the nucleus have been proposed to date; first, including the direct 
interaction between nuclear transport protein and VDR (Yasmin et al. 2005) and, 
second, the activation of an intracellular signalling pathway (Gocek et al. 2007). 
Since KPNA are nuclear transport proteins that directly bind to their cargos and 
mediate translocation into nucleus my data supports the first mechanism in Huh-7 
cells. However, further nuclear transport assays will be necessary to unequivocally 
demonstrate the direct interaction between KPNA3 and VDR.
5.7 Summary
In silico screening of the human KPNA3 promoter region revealed four 
putative VDREs regulatory elements located at -1400, -1300, -763, and -261 as DR3, 
DR3, DR5, and DR3, respectively. The results presented demonstrate that all four 
VDREs are functional and have both negative and positive regulatory functions on 
human KPNA3 expression in response to la, 25(OH)2D3. Furthermore, KPNA3 
plays a role in the ligand-independent nuclear accumulation of VDR in Huh-7 cells. 
These findings strongly suggests that VDR is a nuclear receptor that regulates human 
KPNA3 gene expression which ultimately effects VDR translocation into the nucleus.
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6 DISCUSSION
6.1 Introduction
The karyopherin a family encodes soluble proteins that mediate the transport 
of macromolecules into the nucleus, and as such are central to a number of basic 
cellular processes. In addition to their nuclear import functionality, KPNA proteins 
have also been reported to be involved in other essential cellular function, impacting 
on cellular proliferation, regulation of protein degradation and mitotic onset (Tabb et 
al. 2000; Gruss et al. 2001). Furthermore, KPNA may be involved in apoptosis, and 
has been implicated in a number of pathologieal processes; for example, the KPNA3 
protein has been reported to be involved aetiology of schizophrenia, alzheimer’s 
disease, and cancer, as well as infection by some of the hantaviruses, influenza A and 
HIV (Yasuhara et al. 1997; Kim et al. 2000; Wang et al. 2004). Taken together, these 
data suggest that the regulation of KPNA gene expression, and its capacity to mediate 
nuclear import, may have important consequences on a number of important 
biological functions. It is, hence, important to further investigate the molecular 
mechanisms underlying this regulation.
To date, no information is available on human KPNA3 gene regulation at the 
transcriptional level or its biological consequences; however there have been 
indications that pharmacological agents and in particular nuclear receptor ligands may 
play a role (Kohler et al. 2002; Plant et al. 2006). Therefore, the current work focused 
on transcriptional regulation of human KPNA3 gene by nuclear receptors in a human 
hepatoma cell line; this is of interest because the liver is a primary site of nuclear 
receptor expression where the transcriptional regulation of many gene batteries is 
regulated in response to NR ligands (Boyer 2005). KPNAs not only have the
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potential to be transcriptionally regulated by nuclear receptors, but as key components 
of the nuclear transport machinery they also have the potential to regulate nuclear 
receptor function by altering subcellular localisation; thus to complement my analysis 
of the KPNAS promoter I also examined the effect of KPNAS levels on the nuclear 
translocation of a well characterized molecule, VDR.
6.2 Regulation of hKPNAS gene by PPARa
In silico analysis of the KPNAS promoter regions (2 kb immediately upstream 
of the transcription start site) revealed a number of putative NR binding sites, 
including a PPRE DRl site at position -1875 to -1853. In the present study, it was 
found that activated PPARa binds to this site and inhibits the hKPNAS promoter 
activity in Huh-7 cells. Using reporter gene analysis and site directed mutagenesis, I 
have shown that the response of the KPNAS promoter to PPARa ligands (Wy-I4643, 
fenofibrate, and bezafibrate) depends upon the presence of PPRE -1849, whilst the 
results of my EMSA experiments demonstrated the binding of a protein complex of 
similar size to that formed on the ACOX PPRE, a previously characterised PPRE, 
and through direct binding of in vitro synthesized PPARa to the PPRE at position - 
1875 to -1853. Based on these finding, 1 propose that Wy-14643, fenofibrate, and 
bezafibrate bind to the ligand binding domain of PPARa, which causes an increased 
binding to the specific DNA response element, PPRE, in the target gene promoters. 
Such enhanced binding can elicit either transcriptional activation, as seen in the 
ACOX gene for example (Varanasi et al. 1996), or suppression of gene transcription, 
as observed here. While 1 have suggested the direct mechanism of human KPNA3 
gene suppression by showing an direct interaction between PPARa and PPRE element 
and deleting the PPRE in the KPNA3 promoter ablates the inhibition of the promoter
171
by PPARa ligands. An indirect inhibition mechanism of CYP7A1 gene by PPARa 
and fibrates has also been previously reported. (Marrapodi and Chiang 2000). PPARa 
and fibrates inhibit CYP7A1 gene by down regulating HNF4a which in turn results in 
CYP7A1 inhibition via a DRl site. The effect of fibrate on inhibition of mRNA 
expression has previously been reported in aromatase cytochrome P450 expression in 
ovary of mouse (Toda et al. 2003).
The biological rationale for the negative regulation of human KPNA3 
expression seen with PPARa ligands could be as a result of the oxidative stress 
associated with liver exposure to peroxisome proliferators. This hypothesis is based 
on the observation that PPARa agonists markedly induced hydrogen peroxide- 
generating enzyme such as CYP4A, resulting in increased levels of H2 O2 leading to 
oxidative damage (Seo et al. 2004), which may finally result in inhibition of mRNA 
expression. In parallel to this finding, 1 also examined the effect of H2 O2 as an 
oxidative stress inducing agents on the regulation of human KPN A3. 1 demonstrated 
that H2O2 also inhibits human KPNA3 expression in a dose-dependent manner, and 
that this effect was mediated through a putative Nrf2 in the human KPNA3 proximal 
promoter. Therefore, this result could support a mechanism of human KPNA3 
repression by oxidative stress as described above.
This study demonstrates that PPARa ligands inhibit hKPNA3 expression, 
which may in turn affect the translocation of a number of proteins involved in the 
response to peroxisome proliferators. It remains unclear whether the nuclear 
translocation of PPARa is itself mediated by KPNA proteins in general or KPNA3 
specifically; nevertheless, several studies show the involvement of KPNA with 
nuclear translocation of regulatory factors in response to peroxisome proliferators.
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For example, fibrates decrease the nuclear translocation of several pro-survival factors 
such as NF-A5-p50 which is a cargo for KPNA2 and 3 (Kleemann et al. 2003; 
Fagerlund et al. 2005; Otis et al. 2006). The mechanism of this action could be due to 
the inhibition of hKPNA3 gene expression by fibrates resulting in a decrease in 
hKPNA3 protein level and results in a reduction in NF-^B-p50 translocation into the 
nucleus. Therefore, decreased expression of KPNA3 in response to fibrates could be 
an underlying mechanism related to the inflammatory effects of NF-Â:5 in 
hepatocytes. Further work needs to be carried out to establish the effect of hKPNA3 
on nuclear translocation of PPARa and its related proteins as well as to clarify the 
exact mechanism of this action.
It has been reported that the PPARa ligand Wy-14643 can induce the nuclear 
translocation of another nuclear receptor, the constitutive androstane receptor (CAR), 
in mouse liver cells, but that this does not result in any increase in transcriptional 
expression of CAR target genes (Guo et al. 2007). It is widely accepted that CAR is 
sequestered in the cytoplasm of hepatocytes, in a complex with accessory proteins 
such as the CAR cytoplasmic retention protein (CCRP) and heat shock protein 90 
(Yoshinari et al. 2003; Koike et al. 2005); hence, nuclear translocation is a key 
determinant of its ability to activate target gene expression. Recent studies in primary 
hepatocytes have shown that the nuclear import mechanism of CAR is regulated by 
the karyopherin beta family (Kanno et al. 2010).
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Figure 6-1. Postulated mechanism model for inhibition of human KPNAS gene 
expression by PPARa agonists. This model shows both direct and indirect inhibition 
mechanisms. The direct mechanism of human KPNAS gene suppression by showing 
an direct interaction between PPARa and PPRE element where as an indirect 
mechanism of human KPNAS repression by producing oxidative stress in response to 
peroxisome proliferators, resulting in decreased mRNA levels. The repression of 
human KPNAS expression may act in a negative-feedback effect and affect nuclear 
translocation of a number of proteins in response to peroxisome proliferators resulting 
in effecting the expression of relevant target genes which finally affect many 
biological processes in hepatocyte.
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6.3 Regulation of hKPNAS gene by VDR
In addition to identifying one functional PPRE within the KPNAS proximal 
promoter, in silico analysis also revealed four putative VDREs. Reporter gene 
analysis confirmed that la , 25(OH)2Ds regulates the expression of hKPNAS in Huh? 
cells, and EMSA showed binding of nuclear proteins to all four of the putative 
VDREs. Dual effects on gene expression was observed in a dose-dependent manner; 
at low concentrations (10 nM), la , 25(OH)2D3 induced expression of KPNAS by 60% 
and this appeared to be mediated through three of the four VDREs (at position -ISOO, 
-7S9, and -2S7); at higher concentrations (100 nM) la , 25(0H)2D] exerts an 
inhibitory effect with expression reduced by 94% of the control, and this appears to 
require all four VDRE regions for functionality. The multiple VDRE elements in the 
KPNAS proximal promoter show co-operative action in response to la , 25(OH)2D3, 
since deletion or mutation of any single VDRE eliminates the original effect on 
promoter activity. Furthermore, maximal levels of promoter activity were only 
achieved when all required elements were intact, indicating that a function synergism 
occurs among the VDRE elements; such a paradigm has been previously reported 
with VDRE and other response elements (Kerry et al. 1996; Yasmin et al. 2005).
The mechanism of multi-VDRE elements in the positive regulation of the 
CYP 24 gene and negative regulation of the CYP27B1 gene by la , 25(OH)2D3 has 
been previously reported by Matilainen et al (2010) and Turunen et al (2007), 
respectively. These mechanisms could be used to explain the co-operative action of 
VDREs in hKPNAS proximal promoter. A proposed model that may explain the role 
of these multiple VDREs in the regulation of transcription KPNAS regulation is 
shown in Figure 6-2. Briefly, the induction of KPNAS by low doses of la , 
25(0H)2D3 could be due to the co-operative interaction of each VDRE region
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(position -1300, -739, and -237) associated with co-activator transcriptional factors 
such as SRC-1 (Xu 2005) and finally bind to basal transcription machinery including 
RNA polymerase II resulting in transcription activation of KPNAS gene. In contrast, 
exposure of cells to higher doses of la , 25(OH)2D3 (>100nM) could result in the 
recruitment of potentially different transcriptional complexes at each VDRE site 
(position -1402, -1300, -739, and -237), by recruiting transcriptional factor repressor 
proteins such as NcoRI (Chen and Evans 1995) or SMRT (Horlein et al. 1995), 
allowing all four VDREs to produce a suppression in KPNAS gene regulation. The 
repression model proposed in this study is different from that previously described for 
CYP27B1; in the latter case DNA-independent interaction between VDR and VDR 
interacting repressor (VDIR) is important (Turunen et al. 2007), whereas in the 
current scenario, EMSA has demonstrated a direct interaction between VDR and all 
four VDRE sites for both progressive and repressive modes of action.
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Figure 6-2. A proposed model representing the role of VDREs in transcription 
regulation of KPNA3 gene
77
Nuclear translocation of VDR is an essential step for its activation of target 
genes. Several reports show different localisation of VDR: for example VDR is 
mainly localized in cytoplasm in some cells such as COS-7 and Ros 17/2.8 (Racz et 
al. 1999; Klopot et al. 2007) whereas it resides predominantly in the nucleus of human 
brain cells (Eyles et al. 2005). However, VDR was evenly distributed in Huh-7 cells. 
These results correlate with the recent report by Klopot et al (2007) who demonstrated 
that VDR is evenly distributed between the cytoplasm and the nucleus in Caco-2 cells, 
and shows translocation to the nucleus after ligand activation. The mechanism 
mediating this nuclear translocation has been reported to involve the karyopherin 
family, and indeed this appears to be the case for VDR. Within the present study I 
have demonstrated that over-expression of hKPNA3 induces the translocation of VDR 
into the nucleus without the requirement for additional ligand. This is strongly 
supportive of the notion that KPNA3 mediates VDR translocation between the 
cytoplasm and nucleus. However, it is also possible that there could be an indirect 
effect of the over-expression of KPNA3, potentially overloading other components of 
the import/export pathway causing a change in distribution. We have not yet 
investigated the effect of reducing hKPNA3 expression on nuclear translocation of 
VDR because of time constraints, but this would be a logical next step. If KPNA3 is 
proven to be an obligate partner of nucleo-cytoplasmic shuttling of VDR then it could 
also represent a check point control for VDR target gene expression relating to cell 
proliferation (inhibit proliferation of breast cancer), immunosuppressive effect, 
apoptosis and detoxification of xenobiotics and drugs (Thompson et al. 2002; 
Margolis et al. 2010).
Combining all of the data presented herein, I propose a model that may 
explain the role of hKPNA3 gene regulation by la , 25(OH)2Ds and its biological
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consequences, as shown in Figure 6-3. Briefly, the activation of hKPNA3 expression 
by 10 nM la, 25(OH)2D3 would result in increasing nuclear accumulation of VDR 
and stimulate VDR responsive genes to enact the appropriate physiological responses. 
In contrast, at higher dose, 100 nM of la , 25(OH)2Ds, there was a marked decrease in 
hKPNA3 expression, thus inhibiting the translocation of VDR into the nucleus, and 
that this would result in a reduced activation of VDR target gene expression by 
ligand. Such a differential effect may allow an attenuation of VDR-mediated 
transcriptional responses to higher concentrations of agonist, preventing 
overstimulation that could lead to pathogenesis.
The regulation of hKPNA3 gene expression observed herein will not only 
effect VDR translocation, but also the effect of other transcription factors that are also 
translocated into the nucleus by KPN A3. In agreement with our study, Agarwal et al 
have recently reported that 100 nM la, 25(OH)2D3 decreases the expression of 
KPNA3 in human white blood cells after in vivo administration of vitamin D for I 
year in a vitamin D-deficient subject (Agrawal et al. 2010). The authors suggest that 
this action may responsible for immunosuppressive effect of vitamin D because 
KPNA3 mediates the nuclear translocation of NF-kB, which is a major inflammatory 
mediator (Fagerlund et al. 2005; Kim et al. 2006) , although they present no data to 
support this supposition. These two studies are therefore consistent with the 
observation of a decrease in KPNA3 expression by higher level exposures to la, 
2 5 (0 H)2D3 , while the work here also identifies the regulatory elements by which this 
action is mediated. This mechanism of action draws attention to anti-inflammatory 
and immunoregulatory effect of la , 25(OH)2D3 in the liver.
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Figure 6-3. Postulated model for mechanism of regulation of human KPNA3 gene 
expression by VDR agonists, la , 25(OH)2D3. Nuclear import of VDR is mediated by 
KPNA3 in response to la , 25(OH)2D3. The activation of hKPNA3 gene expression 
may result in enhance nuclear import of other transcriptional factors while repression 
of human KPNA3 expression may act in a negative-feedback effect and prevent 
nuclear translocation of VDR which may result in control over-expression of VDR 
target genes.
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Interestingly, it has been reported that la , 25(0H)2Dg induces the expression 
of both the VDR and PPARa nuclear receptors, thereby suggesting a crosstalk 
between VDR- and PPARa-signalling pathways (Sertznig et al. 2009). However, the 
complete mechanism of this action has not been fully elucidated, but the current work 
may provide some insights. In the present study, PPARa and VDR both directly 
regulate hKPNAS gene expression, and this may provide a focal point in the 
regulatory signal network involving these two nuclear receptors, and thus a point of 
cross-talk.
All together the regulation of the expression of hKPNA3 by PPARa and VDR 
is very complex and not only depends on nuclear receptor ligands but also the type of 
nuclear receptor response element, especially VDRE. Moreover, other factors need to 
take into account, such as co-activators and co-repressors, in order to clarify the 
mechanism of hKPNA3 gene regulation. It is also important to note that this study, 
however, was limited to studies carried out in vitro using a human hepatoma cell line, 
Huh-7. The nature of the hKPNA3 regulation in a different cell type needs to be 
addressed individually due to the complex mode of action of nuclear receptor. Such 
work would thus allow the identification of core- and tissue-specific regulatory 
aspects of KPNA3-mediated modulation of nuclear receptor signalling networks.
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6.4 Summary
To date most research has been focused on karyopherin function. Another 
important issue, which was explored in this study, is karyopherin regulation, which 
we believe will also play a key role in the regulation of many biological processes in 
cell. This is the first demonstration of a role for nuclear receptors, VDR and PPARa 
in regulation of hKPNAS gene expression in response to their ligands, and the first 
report to indicate that human KPNA3 is involved in nuclear translocation of VDR into 
the nucleus in Huh-7 cells. These data might represent an underlying mechanism of 
various cellular functions including cell proliferation, immune response, 
xenobiotics/drugs metabolism, lipid metabolism, oxidative stress and apoptosis as 
well as human diseases.
6.5 Future work
There are six KPNA proteins, which are highly conserved across species, 
indicating a significant physiological role of this family. Therefore, it is special 
interest to studies the regulation of other KPNA genes. Since KPNA3 has been 
reported to link with many diseases, defining the co-regulators of the KPNA3 gene 
will not only provide better understanding of transcriptional regulation but also may 
provide pharmacologic targets. Moreover, further investigations are required to 
evaluate the biological relevance of hKPNA3 gene regulation that may result from the 
effects of other transcriptional factors transported by KPNA3 as well; for example, 
this study demonstrates the effect of KPNA3 on VDR accumulation in the nucleus, 
then further study need to be carried out to determine the effect of KPNA3 on VDR- 
responsive genes and in vitro nuclear transport assay will be necessary to demonstrate 
the direct interaction between KPNA3 and VDR.
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